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Abstract
The objective of this thesis is the examination of variations in the human heat shock
protein gene 60 (chaperonin60, hsp60) between SIDS cases and controls. The SIDS
(Sudden Infant Death) cases showed typical characteristics of the Sudden Infant Death
Syndrome (SIDS). The controls were age– and sex–matched children from paternity
testing and children who died of causes other than SIDS. The Sudden Infant Death
Syndrome is a multifactorial process. A genetic defect is thus assumed to be necessary,
but not sufficient for the genesis of SIDS.
No difference between SIDS cases and controls in the DNA sequence of the exon 5
of the hsp60 gene could be detected. However, the SIDS cases showed a statistically
significant higher number of deletions than the controls in the intron 5 adjacent to
exon 5. The deletions in the intron 5 disrupt no known regulatory sequences (donor,
acceptor, branch site). Yet, intron 5 belongs to the rare GC–AG intron class, the latter
are assumed to be highly regulated. Thus, the deletions may have an impact on other
regulatory sites. The increased number of mutations confirms the findings in previous
publications on DNA variations in SIDS cases. Overall, more mutations are found in
the DNA of SIDS cases than in the DNA of controls.
During the research on the human hsp60 gene, another gene of the Chaperonin
(HSP60) family was found. It shows a high similarity in length and sequence (97.5
%) to the mRNA of the hsp60 gene. Its genomic sequence does not contain introns,
compared to the regular hsp60 gene it is thus much shorter. It was named hsp60s (s
for short). Due to both the similarity of the hsp60s gene and the hsp60 mRNA, and a
mitochondrial leader peptide sequence at the N–terminal end of the putative Hsp60s
protein, it could be concluded that it can be an inducible variant of the hsp60 gene.
After fully sequencing it, two open reading frames instead of the single one of hsp60
were found. A readthrough to the stop codon of the first open reading frame (ORF)
would lead to a continuous ORF, ending at the stop codon of the second ORF. Such
stop codon readthroughs occur in the human genome, but only on rare occasions. An
expression analysis (reverse transcriptase PCR on RNA from blood) produced no pos-
itive results. Based on these findings, it can be concluded that the hsp60s gene is a
pseudogene of the human chaperonin60 gene. However, it may still be possible that
hsp60s is only expressed under stress (our expression analysis was carried out under
non–stress conditions) and/or in tissues other than blood.
The techniques developed for this work can be practically applied to forensics: The
amplification and direct sequencing of genomic DNA from corpses is becoming more
and more important. It was demonstrated in the present thesis that these techniques
work reliable for lengths up to 400 bases in 15 year old blood samples and might also
be applicable to even older samples.
Keywords: Chaperonin60, Hsp60s, Heat Shock Proteins, Stress Proteins, Heat Stress, Hyper-
thermia, Sudden Infant Death Syndrome.
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Kurzfassung
In der vorliegenden Arbeit sollten Teile des Gens des humanen Hitzeschockprotein 60
(chaperonin60, hsp60) auf Variationen bei Fällen des plötzlichen Säuglingstodes und
einer Kontrollgruppe untersucht werden. Die Fälle wiesen typische Merkmale des
plötzlichen Säuglingstodes (engl. SIDS = Sudden Infant Death Syndrome) auf. Die
Kontrollen waren Kinder gleichen Alters und Geschlechts aus Vaterschaftstests und
Kinder, die nicht am plötzlichen Säuglingstod verstorben sind.
Es wurden keine Unterschiede in der DNA–Sequenz des Exon 5 im humanen hsp60
Gen bei SIDS–Fällen und Kontrollen gefunden. Die SIDS (Sudden Infant Death
Syndrome)–Fälle wiesen aber statistisch signifikant eine höhere Anzahl von Deletio-
nen im Intron 5 des hsp60 Gens auf, als die Kontrollen. Dies deckt sich mit anderen
molekulargenetischen Arbeiten, in denen die SIDS–Fälle ebenfalls stets eine erhöhte
Anzahl an Mutationen aufweisen. Da der plötzliche Säuglingstod ein multifaktorielles
Geschehen ist, liegt die Vermutung nahe, dass eine genetische Komponente existiert,
die notwendig, aber nicht ausreichend für die Genese des plötzlichen Säuglingstodes ist.
Intron 5 gehört zur seltenen Klasse der GC–AG Introns, für die umfangreiche Steuer-
funktionen vermutet werden. Möglicherweise sind eine oder mehrere solcher Funk-
tionen durch die Deletionen gestört.
Im Zuge der Forschung am humanen hsp60 Gen wurde ein weiteres Gen der
Chaperoninfamilie (HSP60 Familie) entdeckt. Es ist in Länge und Sequenz der Boten–
RNA des hsp60 Gens zu 97,5 % ähnlich. Die genomische Sequenz zeigt aber keine
Introns. Im Vergleich mit dem regulären hsp60 Gen (16986 bp) ist es sehr kurz (2176
bp), daher wird es hsp60s (s = short, eng. kurz) benannt. Zunächst wurde aufgrund
der Ähnlichkeit mit hsp60 und der mitochondrialen Signalsequenz am N–terminus
des putativen Proteins eine induzierbare Variante des regulären hsp60 Gens vermutet.
Eine vollständige Sequenzierung zeigte jedoch anstelle eines durchgehenden, zwei
kürzere offene Leseraster. Ein Überlesen des ersten Stopcodons, im menschlichen
Genom möglich, hätte jedoch ein durchgehendes Leseraster zur Folge. Eine Expres-
sionsanalyse (reverse Transkriptase PCR an RNA aus Blut) zeigte kein positives Ergeb-
nis. Nach den vorliegenden Informationen ist es wahrscheinlich, dass es sich bei
hsp60s um ein Pseudogen handelt. Es ist aber nicht auszuschließen, dass es entweder
nur unter Stress (die Expressionsanalyse fand unter non–Stress Bedingungen statt)
und/oder in anderen Geweben als Blut exprimiert wird.
Die Techniken der vorliegenden Arbeit können in der forensischen Forschung ange-
wandt werden. Die Amplifikation und direkte Sequenzierung von genomischer DNA
aus Leichenblut gewinnt immer mehr an Bedeutung. Es wird gezeigt, dass in Be-
reichen bis 400 Basen ein solches Verfahren bei bis zu 15 Jahre alten Blutproben möglich
ist (eventuell auch bei noch älteren Proben).
Schlagwörter: Chaperonin60, Hsp60s, Hitzeschockproteine, Stressproteine, Hitzestress, Hy-
perthermie, Plötzlicher Säuglingstod.
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1 Introduction
In this chapter, the fundamentals of the research area of the project are established. It
starts with an overview of heat shock and stress proteins, their function as molecular
chaperones and protein folding. Furthermore, the stress response and the phenomenon of
stress tolerance are being described. Because a mutation analysis was performed on one
of its members, the HSP60 family is described in detail. Finally, the current knowledge
on Sudden Infant Death Syndrome is documented, and the main question of the thesis is
presented.
1.1 Terminology and Notations
Since no uniform naming system for stress and heat shock protein genes and stress and
heat shock proteins exists, the conventions according to the Cell Stress Society International
will be used in this work (Cell Stress & Chaperones 2000). Gene names are written entirely
in lower case letters, e.g., hsp60. Protein names start with a capital letter, e.g., Hsp60.
Protein family names are written entirely in capital letters, e.g., HSP60. The inducible
and constitutively expressed members should be distinguished, if possible. For example
the inducible member of the HSP70 family is named Hsp70, the constitutively expressed
(sometimes called cognate) member is named Hsc70.
1.2 Heat Shock Proteins/Stress Proteins
The ability to cope with heat by expressing a certain type of proteins is a key function
of cells. This ability was first described by Ferrucio Ritossa in 1962 (Ritossa 1962) in a
short paper titled ”A New Puffing Pattern Induced by Temperature Shock and DNP in
Drosophila.” Unintentionally, he described a process in Drosophila that is essential also
for human survival: Heat Shock Response. In 1974, the proteins were named heat shock
proteins by Tissiéres et al. (Tissiéres et al 1974; Pockley 2003). Later on, the name was
changed to the more general description stress proteins, because heat shock and other
proteins protect the cells against various kinds of stress.
Other environmental stress factors include cold, heavy metals, oxygen free radicals,
ethanol, caloric restriction and the absence of O2. Some ”clinical” stress factors (medical
conditions) are for example acute hypertension, anoxia, circulatory shock, endotoxins,
hemorrhagic shock, ischemia/reperfusion and hyperthermia. Living stress factors in-
clude a broad range of bacteria, viruses and parasites (Pockley 2003; Verbeke et al 2001;
De Maio 1999; Fink 1999; Hartl 1996; De Maio 1995; Minowada and Welch 1995; Becker
and Craig 1994; Morimoto et al 1994a; Sztankay et al 1993; Welch 1993a; Welch 1993b).
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Stress proteins are ubiquitous. They exist in every compartment of a cell and in every
organism. This ubiquity is well documented. The following examples give an overview
of the stress proteins’ involvement in physiological processes and diseases.
• Stress proteins are involved in aging and thermotolerance (Verbeke et al 2001).
• Many neurodegenerative diseases show inclusion bodies associated with ubiquitin
and the proteasome: Alzheimer’s, Parkinson’s, Huntingdon’s (Sherman and Gold-
berg 2001).
• Stress proteins also play a role in cardiovascular biology (Benjamin and McMillan
1998).
• Members of the HSP70 family are presumed to be involved in the apoptosis path-
way (Beere and Green 2001).
• Gp96, also a member of the HSP70 family, derived from tumors was used in an
experimental clinical trial as a cancer vaccine (Srivastava and Amato 2001). The
purified Gp96 from a certain cancer was able to elicit a protective immunity specific
to that cancer.
• Stress proteins play a distinct role in autoimmune diseases (Van Noort and Amor
1998).
Stress proteins in general are highly conserved in the evolution. They are named for
their approximate molecular weight, e.g., Hsp60 (60 kD). Six large stress protein fami-
lies are currently known: Small HSPs, HSP40, HSP60, HSP70, HSP90 and HSP110. An
overview is given in Table 1.1 that summarizes results from the following publications:
Pockley 2003; Verbeke et al 2001; De Maio 1999; Fink 1999. For some of the stress proteins,
location, function and expression profiles are known. The HSP60 family and the HSP10
family will be discussed separately in Section 1.6. An overview can be found in Table 1.2.
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Family, Members Intracellular Function Expression
location
Normal Stress
Ubiquitin Cytosol Tag protein for degradation + ++
HSP10, see Table 1.2
Small HSP
αB–crystallin Cytoplasm Cytoskeletal stabilisation
Hsp27 Cytoplasm, Actin Dynamics + ++
Nucleus
Hsp32 Cytoplasm Haem catabolism; antioxidant of properties + ++
(Haem Oxygenase)
Hsp35 (G3PDH) Cytosol + ++
HSP40
Hsp40 Cytoplasm, Regulates the activity of Hsp70; Binds non–native + ++
Nucleus proteins
Hsp47 ER Processing of pro–collagen; Processing and/or
secretion of collagen
DnaJ E. Coli partner of DnaK + ++
HSP60, see Table 1.2
HSP70
Hsp70 Inducible Cytoplasm, Bind to extended polypeptides; prevent aggregation – +++
Nucleus of unfolded peptides; dissociate some
oligomers; ATP binding; ATPase activity;
downregulates HSF1 activity
Hsp70hom Cytoplasm, as Hsp70; testis–specific – +++
Inducible Nucleus
Hsc70 constitutive, Cytoplasm Bind to extended polypeptides; prevent aggregation ++
cognate Peroxisome of unfolded peptides; dissociate some
oligomers; ATP binding; ATPase activity
Grp78/BiP ER as Hsc70 ++ +++*
mtHsp70/Grp75 Mitochondria as Hsc70 + ++
DnaK E. Coli partner of DnaJ – +++
HSP90
Hsp90 (α and β) Cytoplasm, Bind to other proteins; regulate protein activity; ++ +++
Nucleus prevent aggregation of refolded peptide;
correct assembly and folding of newly
synthesised protein; assists in the maintenance
of the HSF1 monomeric state in non–stressful
conditions
Grp94/gp96/Hsp100 ER Bind to other proteins; regulate protein activity; + ++*
prevent aggregation of refolded peptide;
correct assembly and folding of newly
synthesised protein
HSP110
Hsp110 (human) Nucleolus, Thermal tolerance + ++
Nucleus
Cytoplasm
Apg–1 (mouse) Cytoplasm Protein refolding
Hsp105 Cytoplasm
Hsp104 Cytosol + +++
Grp100 ER, Golgi + ++*
Normal = normal expression level, Stress = upregulated during stress, * = non–heat induced, empty box = no information available,
– = no expression, +, ++, +++ = weak, moderate, strong expression
Table 1.1: Classification of Heat Shock Proteins; Small HSPs, HSP40, HSP70, HSP90,
HSP110
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1.3 Molecular Chaperones and Protein Folding
In 1972, Christian Anfinsen received the nobel prize in chemistry for his work on protein
folding. Anfinsen denatured and refolded ribonuclease in vitro from an inactive state
back to a 100 % active enzyme (Anfinsen 1973). He postulated that ”all information nec-
essary to achieve the native conformation of a protein is contained in its amino acid sequence”.
Contrary to Anfinsen stands the so–called Levinthal Paradox, named by Levinthal in 1968
(Levinthal 1968; Yon 2002). Levinthal proposed, that for a polypeptide chain of hundred
amino acids, assuming only two possible conformations for each residue, there are 1030
possible conformations. Estimating the required time for converting the conformations
into another as 10−11 seconds, it would take 1011 years generating all conformations! In
the actual cell, far more protein folding is performed in minutes or seconds, indicating
the existence of additional mechanisms of protein folding.
Many stress proteins are molecular chaperones. The name was originally used by
Laskey et al. in 1978 (Laskey et al 1978) as a description of nucleoplasmin, a protein
involved in the building of nucleosomes in Xenopus eggs. Later on, in 1987, Ellis used
the term molecular chaperone for all proteins involved in folding and assembly of other
proteins and protein complexes (Ellis 1987). The definition of Ellis is still valid. Molec-
ular chaperones are highly conserved in evolution. Similar to enzymes, they are a part
of the reaction, but not a part of the later protein target. The targets of molecular chap-
erones are newly synthesized proteins, mutated proteins (mutations in a gene may lead
to misfolding of the appendant protein) and damaged proteins (due to endogenous or
exogenous stress factors like heat). Molecular chaperones are a very important part of the
house–keeping machinery of the cell.
Many newly synthesized proteins need their help in developing the correct three–
dimensional structure. According to Yon (Yon 2002) the Anfinsen postulate is not violated
during this process: Molecular chaperones associate with nascent, stress–destabilized and
translocated proteins, preventing improper folding and aggregation. The ability of the
newly synthesised proteins to achieve native conformation is not impeded. It must not
be forgotten, that a significant proportion of the volume in a cell is physically occupied,
limiting the space for protein folding. Compared to in vitro experiments, the cell in vivo
is a crowded environment, with an effective protein concentration of up to 300 mg/ml,
in addition to macromolecules, organelles and a cytosceleton (Ellis 2001, Frydman 2001).
Chaperones minimize the space required for successful protein folding.
Molecular chaperones, combined with proteases, work as a posttranslational quality
control system in the cell, minimizing the amount of misfolded and degraded polypep-
tides during protein synthesis (Wickner et al 1999).
The best known chaperones belong to the HSP40, HSP60, HSP70 and HSP90 families.
Hsp40 and Hsc70 bind to nascent polypeptides emerging from the ribosome. Hsp60 pro-
vides a protected environment for folding. Hsp90 is a component of the machinery as-
sembling multiproteins (Frydman 2001). The HSP60 family will be discussed in detail in
Section 1.6.
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1.4 The Stress Response
The stress response is an ancient and highly conserved mechanism. It guarantees the
survival of cells during various stress situations, e.g., heat, cold and exposure to chemicals
(Section 1.2). In this thesis, the focus will be on heat as a stress factor, due to its importance
in the genesis of the Sudden Infant Death Syndrome. Stress generates molecular damage
in compartments and cells. One characteristic trait following all stress reactions is the
accumulation of abnormally folded proteins. This is a universal trigger for the stress
response.
As an example of stress response, the heat shock response in mammals (humans) will
be discussed in this Section with a simplified overview being shown in Figure 1.1 ( based
on Latchman 2001 and Morimoto 1998). The heat stressed cell reacts to the abnormally
folded proteins with the production of heat shock proteins. This process requires the
transcription (synthesis of mRNA on a DNA template) of heat shock protein genes, fol-
lowed by their translation (synthesis of protein on the mRNA template). The heat stress
response starts with the trimerization of the heat shock transcription factor 1 (HSF1). This
factor is essential for the RNA polymerases (enzyme for mRNA synthesis) binding to the
heat shock gene. HSF1 exists as a monomer in the cell. Upon heat shock it assembles
into a homotrimer, that binds to the heat shock response element (HSE). The latter is a
characteristic short sequence in the promoter (the region of DNA involved in binding of
RNA polymerase to initiate transcription) of a heat shock gene. After synthesis of the
heat shock gene mRNA, the latter is translated into the heat shock protein. The protein
now displays its protective properties in the cell, e.g., refolding of proteins.
Stress (e.g., heat)
−→ Damaged proteins
−→ Trimerization of heat shock transcription factor 1 (HSF1).
−→ HSF1–Homotrimer binds to the heat shock (response) element
(HSE, promoter region).
−→ Heat shock gene is activated, expression of the heat shock protein gene.
−→ Protein synthesis.
−→ Protective properties become effective:
e.g., enhanced protein folding,
refolding of proteins,
degradation of abnormal proteins,
inhibition of apoptosis,
inducing apoptosis,
protection of the cytoskeleton.
−→ Negative regulation cascade starts, if enough protein has been produced
(depending on protein type).
Figure 1.1: The Stress (Heat Shock) Response (based on Latchman 2001 and Morimoto
1998)
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In mammals three heat shock transcription factors (HSFs) are known: HSF 1, 2 and
4. In avians an additional factor HSF3 exists. All HSFs are highly conserved in the evo-
lution. They are modular constructions and show distinct domains: an amino–terminal
helix–turn–winged–helix DNA binding domain (DBD), regulatory domains, one or more
coiled–coil trimerization domains, nuclear localization domains and a carboxy–terminal
transcriptional trans–activation domain (Ahn and Thiele 2003; Pirkkala et al 2001; Mori-
moto1998; Wu 1995; Wu et al 1994; Morimoto et al 1994b).
HSF1 is a stress–inducible factor. Heat stress and H2O2 activate HSF1, both in vivo
and in vitro. The cystein residues C35 and C105 in HSF1 build redox–regulated disul-
fide bonds during this process (Ahn and Thiele 2003). Under non–stress (basal) con-
ditions, it exists as a monomer, a form incapable of DNA binding. HSF1 is integrated
in a complex control system in the cell; including the Hsp90 multichaperone system,
mitogen–activated (MAP) kinases and extracellular signal–related kinase (ERK 1; Has-
day and Singh 2000).
HSF2 and HSF4 exist in at least two isoforms A and B, arising from alternative splicing
of the genes. HSF2 and HSF4 work in combination with HSF1 (He et al 2003; Zhang et al
2001). Also, HSF2 is negatively regulated by the stress factor heat. Under the influence of
heat stress, it is deactivated (Mathew et al 2001). The isoform HSF4a is a repressor of heat
shock transcription for hsp27 and hsp90 (Zhang et al 2001; Frejtag et al 2001; Tanabe et al
1999).
The HSE is the heat shock (response) element, the promoter element for binding of
the heat shock transcription factors. The consensus sequence is 5’nGAAn’3. Typical heat
shock elements consist of 3 to 5 repeats, e.g., 5’nGAAn nTTCn nGAAn’3. The location
of the element in the promoter is variable and ranges from forty to hundreds of bases
upstream the starting point of the gene (Fernandes et al 1994; Morimoto et al 1994b).
1.5 Stress Tolerance/Thermotolerance
Heat and other stress tremendously affect the living organism, down to the cellular level.
For example, the cytoskeleton is disrupted due to collapsing microfilaments. The num-
ber of mitochondria decreases, the respiratory chain inside the mitochondria is disturbed.
Polysomes disappear rapidly and the splicing machinery is disturbed or stopped. How-
ever, the heat shock proteins continue to be transcribed, translated and processed.
A special phenomenon known as thermotolerance occurs when light heat stress is in-
duced prior to severe heat stress. A cell pretreated with a light heat shock is coping much
better with a following severe heat treatment. The mild heat treatment induces the pro-
duction of heat shock proteins, equipping the cell with a faster repair mechanism for the
damaged proteins. In some cases (yeast, bacteria), even lethal stress can be countered fol-
lowing a mild heat shock. The general term applying to different kinds of stress is stress
tolerance (Parsell and Lindquist 1994).
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1.6 HSP60, Chaperonin
The HSP60 heat shock protein family is also known as the Chaperonin family. This fam-
ily is of special interest to this thesis, because of the possible involvement of a family
member (Hsp60) in the genesis of Sudden Infant Death Syndrome. The term Chaper-
onin was introduced by R. John Ellis in 1990 referring to non–heat–induced Heat Shock
Protein 60 (Hsp60; Ellis 1990; Fink1999). As with all stress proteins and molecular chap-
erones, members of the Chaperonin family are highly conserved in the evolution. They
exist in every organism and every cell compartment. The only exception are some para-
sites, microsporidia (Katinka et al 2001) and mycoplasma (Glass et al 2000; Ranford and
Henderson 2002). Chaperonins usually work in combination with a smaller protein, the
co–Chaperonin.
In Homo sapiens and other mammals the terms Hsp60, Chaperonin and Chaperonin60
are used synonymously. Some publications also use the abbreviation Cpn60 instead of
Hsp60 for certain members of the type I subfamily of Chaperonins. Preferentially, Cpn60
names the members of the HSP60 family active in chloroplasts.
1.6.1 The HSP60 family: Subfamilies and Members
The first sequencing of the mRNA of the human hsp60 was done in 1989 by Jindal et al.
(Jindal et al 1989). Later, the sequence was confirmed by Venner et al. in 1990 (Venner et
al 1990). The current sequence in the GenBank Database is based on Venner et al. (Venner
et al 1993; GenBank Accession Number M34664). The term GenBank Accession Number
will be abbreviated as GAN in this treatise. The first expression of the human protein in E.
Coli and the development of monoclonal antibodies was performed by Singh and Gupta
in 1992 (Singh and Gupta 1992). In 1996, Pochon and Mach gave the first description of
the human hsp60 gene regarding its exon/intron structure (Pochon and Mach 1996). The
final sequencing of the human hsp60 gene, revealing the complete exon/intron structure,
was done by Hansen et al. in 2003 (Hansen et al 2003b; publication, the sequence was
submitted to GenBank in 1999 with a GAN AJ250915 (Hansen et al 2003a)). Hansen et al.
also demonstrated, that human hsp60 is localised with its partner hsp10 (co–chaperonin)
on chromosome 2 (2q33.1); in a ”head to head” (starting point to starting point) direc-
tion, sharing the bidirectional promoter. The hsp60 gene contains 12 exons, of whom the
first one is non–coding. This configuration is the same in the hsp60/hsp10 genes in rat
(Rattus norvegicus; Ryan et al 1997a); pufferfish (Fugu rubripes), zebrafish (Danio rerio),
the nematode Caenorhabditis elegans (Martin et al 2002); and the mouse (Mus muscu-
lus), indicated in a ”Homologene” search in the GenBank (GENBANK 2004), no direct
publication available.
The equivalent gene in Escherichia Coli is groEL (protein GroEL), its partner is groES
(protein GroES). The genes are located similarly to to the abovementioned eukaryotic
genes in the E. Coli groE operon (Zeilstraryalls 1991). In plant chloroplasts, the genes are
named cpn60 (protein Cpn60) and cpn10 (protein Cpn60).
The Chaperonins can be divided into two subfamilies: type I Chaperonins, also known
as the GroEL/Hsp60–subfamily and type II Chaperonins, also known as the TCP–1 (t–
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Family, Members Intracellular Function Expression
location
Normal Stress
HSP10 (Co–Chaperonins)
Hsp10 Mitochondria assists Hsp60 + ++
GroES E. Coli assists GroEL + ++
Cpn10 Chloroplasts assists Cpn60 + ++
HSP60 (Chaperonins)
Hsp60 Mitochondria Bind to partly folded polypeptides
and assist correct folding;
assembly of multimeric complexes
GroEL E. Coli as Hsp60 + +
Cpn60 Chloroplasts as Hsp60 + +
Thermophilic Archaea as Hsp60
Factor 55
TriC/CCT Cytoplasm as Hsp60
Normal = normal expression level, Stress = upregulated during stress, * = non–heat induced, empty box = no information available,
– = no expression, +, ++, +++ = weak, moderate, strong expression
Table 1.2: The HSP60 family, Chaperonins and Co–Chaperonins
complex polypeptide 1) ring complex subfamily. Type I Chaperonins are present in
prokaryotes (eubacteria) and organelles (mitochondria and chloroplasts). Type II Chaper-
onins are present in archaebacteria and in the eukaryotic cytosol. They are known under
two different names: TriC = TCP–1 ring complex and CCT = Chaperonin Containing
TCP–1 (Levy–Rimler et al 2002; Fink 1999). An overview of the Chaperonins and their
co–Chaperonins is shown in Table 1.2.
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1.6.2 The HSP60 family: Proteins, Structure and Function
All members of the HSP60 family (type I and II) have a similar structure: They are ring–
shaped oligomeric protein complexes with a large central cavity, working either as a sin-
gle or double ring. Nonnative protein structures bind in the central cavity, which is some-
times referred to as the Anfinsen Cage or folding cage. This cage represents a compartment
with a defined environment and certain steric conditions and restrictions. The informa-
tion on the molecular weight (60 kD) represents the weight of the monomeric protein. The
members of the HSP60 family work as multimers. Graphical descriptions for the type I
family are shown in Figures 1.2 (Slavotinek and Biesecker 2001) and 1.3 (Bukau and Hor-
wich 1998). The latter shows a side and top view of a type I Chaperonin with a protein
inside. The gap shown between the two heptamers indicates the double ring structure,
but does not represent an unpassable vertical separation.
The type II subfamily (TCP–1) multimers are heteromeric and consist in the single ring
form as an octamer or nonamer (8 or 9 60kD subunits). In contrast to the single gene
encoding of the homomeric subunits, the heteromeric subunits are encoded by different
unique genes. The CCT in the eukaryotic cytosol plays a fundamental role in the folding
of cytoskeletal proteins (Carrascosa et al 2001; Slavotinek and Biesecker 2001; Fink 1999;
Kubota et al 1994; Willison and Kubota 1994).
In thermophilic and hyperthermophilic archaea, the TCP–1 complexes are called ther-
mosomes. They play a crucial role in constantly heat–stressed environments with tem-
peratures above 100◦C. This indicates that a great amount of metabolic energy is needed
to maintain protein stability with constant folding and refolding occurring. Unlike the
members of the type I subfamily, the thermosome of the Thermosoma species seems to
have a built–in lid for covering the folding cavity (Sterner and Liebl 2001).
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Figure 1.2: Chaperonin60: Structure and Function (Slavotinek and Biesecker 2001)
Figure 1.3: Chaperonin60: Side and Top View (Bukau and Horwich 1998)
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The multimers of the type I subfamily (GroEL/Hsp60) are homomeric and exist in the
single ring form in a heptamer (7 60kD subunits). The typical structure in the cell is the
double ring form of 14 identical 60kD subunits in two heptameric rings. The rings are
stacked on top of each other in an inverted orientation. This is a barrel–shaped structure,
sometimes referred to as the ”double donut” (named by Bukau and Horwich in 1998
(Bukau and Horwich 1998)), see Figure 1.3. The co–Chaperonins (Hsp10, GroES) consist
of 7 subunits forming a single ring. The small partners build the caps sitting on either
side of the double ring structure of the Hsp60/GroES. The activity of type I Chaperonins
is modulated by the binding and hydrolysis of ATP. X–ray cristallography and electron
microscopy of the GroEL/GroES complex are complete (Xu et al 1997).
Most studies on structure, function and the mechanism of protein folding in type I
Chaperonins examine the GroEL/GroES system of E. coli. Each ring consists of three
domains: the equatorial, the intermediate and the apical. The apical, forming the mouth
of the central cavity undergoes major conformational changes on binding of ATP and the
co–Chaperonin GroES, which lead to substantial changes in the hydrophobic nature of
the cavity. In addition to their folding tasks, the type I Chaperonins assemble oligomeric
proteins. For GroEL/GroES evidence for the mechanism is present (Wynn et al 2000). The
folding mechanism in the type I Chaperonin can be described as follows:
1. Capture
The protein enters the proximal Chaperonin ring. It is a in a special conformation
and energy state called a folding intermediate and thus prone to aggregation. Typi-
cal molecular distinguishing marks for this state are exposed hydrophobic surfaces.
The Chaperonins bind these hydrophobic surfaces to prevent them from incorrect
interaction and aggregation.
2. Encapsulation
The binding of the co–Chaperonin enlarges the central cavity by inducing a confor-
mational change in the proximal Chaperonin ring. The environment in the central
cavity is changed from a hydrophobic to a hydrophilic one. This environment forces
a change in the conformation of the substrate. The folding then occurs in the central
cavity under ATP hydrolysis.
3. ATP hydrolysis and ring conditioning
This is a timing device, controlling the lifetime of the encapsulated state.
4. Ligand release and domain relaxation
After folding, the ATP hydrolysis of the distal Chaperonin ring drives the release of
the ligands, protein, co–Chaperonin and ADP.
If a protein begins to misfold after synthesis, Hsp60 is even able to unfold it partially.
From this newly corrected energy state, the protein can reach its native conforma-
tion more easily.
It is still unclear if a certain protein undergoes a single or multiple cycles of folding in
the type I Chaperonins. Both alternatives appear to be possible. Also, the energy states
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of a protein and their influence on folding are under discussion (Walter 2002; Thirumalai
and Lorimer 2001; Grantcharova et al 2001; Lewin 2000; Fink 1999; Bukau and Horwich
1998; Frydman et al 1994).
A graphical description is shown in Figure 1.4. For simplicity, only the proximal or cis
ring of the GroEL tetradecamer is shown. The original figure appeared in Thirumalai and
Lorimer 2001.
GroEL/Hsp60
GroES/Hsp10
SP = substrate protein; T = tightly bound, the state in which the substrate protein is most tightly bound; R = relaxed bound, the state
in which the substrate protein is less tightly bound; τH = time with hydrophobic interaction between SP and Chaperonin; τP = time
with hydrophilic interaction between SP and Chaperonin
Figure 1.4: Chaperonin60: Mechanism of Protein Folding (based on Thirumalai and
Lorimer 2001)
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1.6.3 The Human Chaperonin60
The human Chaperonin Hsp60 is located in the mitochondria, where it exists most likely
in a dynamic equilibrium between monomers, single ring heptamers and double ring
tetradecamers. A high concentration of Hsp60 and the presence of ATP and Hsp10 (the
most likely condition in a cell) favors the formation of the tetradecameric structure.
Many proteins located in the mitochondrial matrix are encoded in the nucleus, not in
the mitochondrial DNA. They are thus translated in the ribosomes of the cytoplasm. It
is not possible for a folded protein to pass the mitochondrial membrane, only a linear
unfolded structure can pass. For recognition, the proteins carry a leader peptide, that
is later cleaved at their amino terminal end. This leader or signal peptide marks a pro-
tein for transport into mitochondria. E.g., in Hsp60, the leader consists of the first 26
amino acids. In a typical eukaryotic cell, about 10 % of all proteins are targeted at the
mitochondria. A complex system exists that directs the protein into the appropriate inner
section of the mitochondria (outer membrane, intermembrane space, inner membrane
and matrix). Hsp60 is located in the innermost compartment, the mitochondrial matrix.
In combination with the mitochondrial Hsp70 (mt–Hsp70), the Hsp60 machinery is the
most important chaperone machinery in the mitochondria. In the human mitochondria,
the chaperoning of new proteins is a more vital function of Chaperonin60 than its stress
response (Levy–Rimler et al 2001; Fink 1999; Ryan et al 1997b). Additionally, evidence ex-
ists that Hsp60 is exported from the mitochondria into extramitochondrial settings such
as the cell surface, peroxisomes and the ER (Soltys and Gupta 1999).
1.6.4 Involvement of Hsp60 in physiological processes
Chaperonins are essential for cellular functions and processes:
• The deletion of the genes in yeast (Saccharomyces cerevisiae: hsp60/hsp10) and
bacteria (E. Coli: groEL/groES) are lethal for the organisms (Levy–Rimler et al
2002).
• In humans, many diseases with Hsp60/Hsp10 involvement are known. Hereditary
spastic paraplegia spg13 is associated with a mutation in the hsp60 gene: The amino
acid 72 valine is changed to isoleucine (mutation V72I; Hansen et al 2002).
• A patient with congenital lactic acidaemia caused by insuffiency of mitochondrial
enzymes, suffered from a Hsp60 deficiency and died shortly after (Ranford and
Henderson 2002).
• Recombinant Human Hsp60 interacts with the prion protein PrPc (Edenhofer et al
1996). Chaperonins may be involved in the conversion process from the wild type
prion PrPc to the disease type prion PrPsc. The latter is the pathogenic isoform, asso-
ciated with scrapie (sc), where the disease type prion was first noticed (Gauczynski
et al 2001).
The human immune system preferentially targets the members of Type I subfamily
(GroEL/Hsp60) in pathogens such as bacteria, viruses, protozoa and worms. They are
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members of the so–called common antigen group. In humans, immune responses to the
Hsp60 of several microorganisms are known:
• Tuberculosis (Mycobacterium tuberculosis)
• Leprosy (Mycobacterium leprae)
• Trachoma (Chlamydia trachomatis)
• Lyme Disease (Borrelia burgdorferi)
• Q–fever (Coxiella burnetti)
• Legionnaires’ Disease (Legionella pneumophila)
• Brucellosis (Brucella abortus)
• Whooping Cough (Bordetella pertussis)
• Gastric Ulcer, Gastritis (Helicobacter pylori)
• Yersiniosis (Yersinia enterocolitica)
• Syphilis (Treponema pallidum)
• Listeriosis (Listeria monocytogenes)
Some of the infections can even be diagnosed based on the presence of antibodies
against Hsp60. The downside of a potent immune reaction to microbial Chaperonins
are autoimmune diseases and immunodeficiency diseases. GroEL for example, the best
studied Chaperonin from E. coli, affects both the innate and the acquired immune system
of humans and other mammals.
An infectional invasion stresses both, the pathogen and the infected host. Both re-
act with an upregulated expression of stress proteins, including Chaperonins (Zügel and
Kaufmann 1999; Fracella and Rensing 1995).
Heat shock proteins are involved in the allograft rejection process after transplantation.
However, the precise influence of these proteins is unknown. A fine balance may exist
between protective and damaging effects (Pockley 2001).
The Chaperonins are highly conserved in the evolution and thus very similar. It is
hence possible, that an immune system attacks both its own and the foreign Chaperonins.
This process is called molecular mimicry: the immune system, e.g., T cells and antibodies,
is not able to discriminate sharply between different sources of antigens, e.g., amino acid
sequences of Chaperonins (Van Noort and Amor 1998). Often, the antibodies bind to the
target tissues and cause an autoaggressive response. Examples for autoimmune diseases
and other diseases in humans in which Hsp60 plays a role are summarized in Table 1.3
(Falkowska–Podstawka and Wernicki 2003; Ranford and Henderson 2002; Neuer et al
2000; Ranford et al 2000; Zügel and Kaufmann 1999; Edenhofer et al 1996; Fracella and
Rensing 1995).
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In connection with the immune system, Chaperonins are also involved in cellular com-
munication. Different Chaperonins can bind to different cell–surface receptors. They
may be intercellular stress signals, secreted into the extracellular fluid in times of stress
(Maguire et al 2002; Ranford et al 2000; Soltys and Gupta 1999).
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Autoimmune Diseases
Insulin–dependent Diabetes mellitus (IDDM)
Adjuvant Arthritis (AA)
Pristan–induced Arthritis
Reactive Arthritis
Response of αβ T cells from synovial fluid to human Hsp60, to stressed host cells,
and to mononuclear cells isolated from inflamed joints.
Juvenile Arthritis
Anti–Hsp60 antibodies found.
Rheumatoid Arthritis (RA)
Increased levels of Hsp60–specific antibodies in serum; response of crossreactive αβ T cells
from inflamed sites to mycobacterial Hsp60 and human Hsp60
Morbus Bechterew
Multiple Sclerosis (MS)
Detection of Hsp70–reactive and Hsp60–reactive αβ T cells in spinal fluid of MS patients.
Systemic Lupus Erythematosus (SLE)
Chronic Gastritis
Colocalization of γβ T cells with Hsp60 expression of imflammatory gastritis epithelium.
Behcets Disease
Hsp60–specific antibodies in serum from patients; T cell response to self Hsp60.
Arteriosclerosis
Systemic Sclerosis
Increased levels of Hsp60–specific antibodies (mycobacterial) in serum.
Atherosclerosis
Increased levels of Hsp60–specific antibodies in serum;
presence of Chaperonin60 in atherosclerotic lesions;
lysis of macrophages expressing Hsp60 from patients by antibodies against self hsp60.
Psoriasis
Increased levels of Hsp60–specific antibodies (mycobacterial) in serum.
Kawasaki Disease
Increased levels of Hsp60–specific antibodies in serum; both against mycobacterial and human.
Inflammatory Bowel Diseases
Crohn’s Disease
Increased levels of Hsp60–specific antibodies in serum
Ulcerative Colitis
Increased levels of Hsp60–specific antibodies in serum
Borderline Hypertension
Increased levels of Hsp60–specific antibodies in serum
Prion Diseases
Hsp60 interacts with the prion protein
Immune mediated pregnancy failure
Suggested mechanism: strong immune response to self Hsp60 after persistent infection
with Chlamydia trachomatis disturbing the embryo development
Table 1.3: Hsp60, Involvement in Diseases
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1.7 Sudden Infant Death Syndrome (SIDS)
The Sudden Infant Death Syndrome (SIDS) is still an enigma. Even in our current times
only theories exist on its genesis. One of the earliest mentions of this phenomenon is
described at about 4000 B. C. in the cultures of the orient. The branch of legal medicine is
engaged in this topic since 1895 (Riße 2002).
SIDS (the code in the International Classification of Diseases (ICD) is 798.0 (Sudden
Infant Death Syndrome), ICD 9th Edition, and R 95, ICD 10th edition) is one of the most
frequent causes of death in Germany and other Western countries (Switzerland, Nether-
lands, France, Great Britain, Ireland, Denmark, Norway, Finland, USA, Australia, New
Zealand) in children up to 1 year. The annual rate of SIDS infant mortality in these coun-
tries over the last twenty years lies between 0.4 and 1.7 per 1000 live births (Hunt and
Hauck 2004; Jorch 2000).
SIDS remains a diagnosis of exclusion. Only after ruling out other possible causes of
death, is the diagnosis ”Sudden Infant Death” given. The definition of Beckwith (Beck-
with 2003) is the most substantial: ”The sudden and unexpected death of an infant younger
than 1 year and usually beyond the immediate perinatal period, which remains unexplained af-
ter a thorough case investigation, including performance of a complete autopsy and review of the
circumstances of death and of the clinical history. Onset of the lethal episode was presumably
during sleep (ie, the infant was not known to be awake). Minor inflammatory infiltrates or other
abnormalities insufficient to explain the death are acceptable.”
Hunt and Hauck (Hunt and Hauck 2004), Riße (Riße 2002), Hunt (Hunt 2001) and Roll
(Roll 2000) also emphasise a thorough postmortem examination to eliminate other causes
of death such as congenital anomalies, deadly infections and traumatic child abuse (fili-
cide). An older definition described by Beckwith is still in use (Beckwith1970; Beckwith
2003): ”The sudden death of any infant or young child, which is unexpected by history,
and in which a thorough postmortem examination fails to demonstrate an adequate cause
of death.” Also commonly used, especially in the United States of America, is the defini-
tion by Willinger (Willinger 1991), Valdes–Dapena (Valdes–Dapena 1992) and Beckwith
(Beckwith 1993; Kurz 2000a): ”The sudden unexpected death of an infant under one year
of age, which remains unexplained after a thorough case investigation, including perfor-
mance of a complete autopsy, examination of death scene, and review of clinical history.”
Despite the complexity and problems of diagnosis, certain characteristics are known.
This includes risk factors, autopsy findings (pathological features), findings at the death
scene and epidemiological features. These are typical characteristics found solely or more
likely in SIDS victims compared to controls. A complete overview of these characteristics
is shown in Section 1.7.1. A subset of the characteristics will be designated SIDS criteria
and is of greater interest in this doctoral thesis (see Section 1.7.1 and Section 1.7.3).
Based on their pathological findings, SIDS cases are categorised. In this thesis, the
pathological categories (1–4) of the SIDS cases were classified according to the German
Study on Sudden Infant Death (GeSID; Findeisen et al. 2003), see Figure 1.5.
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Category 1 includes all children without pathological findings from autopsy and ad-
ditional investigations.
Category 2 (minor pathological findings):
• minor infections of the respiratory tract
– rhinitis, otitis media, pharyngitis tracheitis
– bronchitis, mild/intermediate forms of peribronchitis
– mild/intermediate forms of bronchiolitis and of interstitial pneumonia;
• tonsilitis
• mild abnormalities and congenital disorders
– mild forms of hepatitis/hepatosis
– enteritis without exsiccosis
– mild forms of nephritis/nephrosis
– local infections with cytomegalovirus
– mild forms of metabolic disorders without symptoms
Category 3 (major pathological findings):
• metabolic disorders
• interstitial pneumonia with bacterial superinfection
• severe bronchiolitis
• enteritis with exsiccosis
• peri–/myocarditis, especially of the borderline type
• mild forms of meningo–encephalitis
Category 4 (includes all non SIDS cases, children with a clear cause of death): e.g.,
• bronchopneumonia
• interstitial pneumonia with carditis
• severe meningo–encephalitis
• major congenital disorders
• generalised infection
• myocarditis with sarcolysis
Figure 1.5: Pathological Categories of Sudden Infant Death Cases
1.7.1 SIDS Characteristics
SIDS characteristics can be divided in two sets. The first contains autopsy results (patho-
logical features) including histological analyses. The second includes all other charac-
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teristics, with most of them being determined epidemiologically (this also applies to the
findings at the death scene). By now, many of the characteristics that are associated with
an increased risk of SIDS are known. In many countries, SIDS prevention programs were
introduced to give parents advice on how to minimize the risks (Hunt and Hauck 2004),
Deutsche Akademie für Kinderheilkunde und Jugendmedizin (Poets and Jorch 2000),
American Academy of Pediatrics, Task Force on Infant Sleep Position and Sudden Infant
Death Syndrome (1999) .
Characteristic autopsy results are :
• Inthrathoracic petechiae (mostly subepicardial, subpleural and beneath the thymus)
• Pulmonary edema
• White or bloody foamy secrete/fluid around the nose, also in mouth, pharynx, lar-
ynx, trachea and bronchus, indicating a pulmonary edema
• Certain brainstem abnormalities
• Liquid blood in the right heart
• Cyanosis of lips and nailbeds
• Anemic abdominal organs
• Empty bladder
• Infections of the upper respiratory tract
• Lymphatic system with big lymph node in thymus, neck and intestines
(Hunt and Hauck 2004; Byard 2003; Kleemann and Rognum 2000; Kleemann 2000;
Kleemann 1996; Berry 1992).
General characteristics associated with a higher risk of Sudden Infant Death are an
age between 2 and 4 months and male sex. Also a ”winter peak” exists (highest SIDS
incidence during the winter months). The high rate of infections in victims of Sudden
Infant Death shortly before they died is often associated with the cold season (Byard
2003; Kurz 2000c; Jorch 2000; Vege and Rognum 1999; Blackwell 1999; Blackwell and
Weir 1999; Helweg–Larsen et al 1999; Forsyth 1999; Douglas et al 1998; Mage and Donner
1997; Kleemann 1996; Kleemann 1991).
Social characteristics include:
• Ethnicity (for example a higher risk in African–Americans than in Caucasian Amer-
icans or Asians)
• Socioeconomic status (a lower status and income indicates a higher risk)
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• Age of the parents (younger parents undergo a higher risk than older parents)
• Educational level of the parents, especially the mother (mothers with a lower edu-
cational level undergo a higher risk)
(Pollack and Frohna 2002; Einspieler 2000; Blackwell 1999; Kleemann 1996; Willinger
1995).
Pregnancy, birth and neonatal care are also important in determining a possible risk
of Sudden Infant Death:
• Twin births and multiple births undergo a higher risk
• Children born prematurely or those who have a low birth weight undergo a higher
risk
• Short interpregnancy intervals and high birth order undergo a higher risk
Poor prenatal care is associated with a higher risk.
In the postnatal care the greatest risk factors are:
• Absence of breast feeding
• Co–sleeping (bedsharing)
• Maternal drug use
• Sleeping outside parents bedroom (lesser factor)
Smoking is one of the highest known risk factors. Parental/maternal smoking and ex-
posure to cigarette smoke (during and after pregnancy) leads to greater vulnerability
against infections, breathing problems during sleep, and disturbs the general develop-
ment of a child. It also increases the carbon dioxide threshold necessary for arousal (Byard
2003; Cohen et al 2002; Köstl and Kerbl 2000; Einspieler 2000; Kurz 2000c; Blackwell 1999;
Raza et al 1999; Kleemann 1996; Schlaud et al 1996; Willinger 1995; Poets et al 1994).
Prone sleeping is often considered along with smoking as the highest risk factor at all.
Children sleeping prone undergo a significantly higher risk of Sudden Infant Death than
children sleeping supine. The back–to–sleep campaign (advice for parents to put their
children to sleep supine, if not medically contraindicated) in some countries, e.g., USA,
Great Britain, in the early Nineties (1991–1995) reduced the SIDS incidence tremendously.
No uniform theory exists, why prone sleeping increases the risk of SIDS. A possibility is
a greater vulnerability to infections or heat stress. Others indicate a reduction in physio-
logical control related to respiratory, cardiovascular and autonomic control mechanisms.
The latter is important for arousal during sleep. A delayed arousal or no arousal at all
may have deadly consequences. A delayed arousal is especially dangerous, if the child
becomes hypoxic, in consequence of having an infection of the upper airways (Byard
2003; Galland et al 2002; Pollack and Frohna 2002; Einspieler 2000; Gibson 2000; Black-
well 1999; Schlaud et al 1999; Douglas et al 1998; Kleemann et al 1998; Willinger 1995;
Hardy Havens and Zink 1994; Kleemann 1991).
1.7.2 SIDS and Heat Stress
Due to a possible connection between Sudden Infant Death and heat stress (heat stress
and/or a deficiency in the heat stress response because of mutated heat shock proteins),
this risk factor is of special interest in this thesis.
Human beings have a very complex thermoregulation. A human is homeotherm, the
internal temperature is kept constant. Thus, the heat storage in the body must be zero,
heat gain and heat loss are balanced. Body temperature is a function of three variables:
internal heat production, external environmental temperature and thermal insulation de-
termining the exchange of thermal energy between the body and its environment. In an
infant, heat production depends, for example, on muscular activity and metabolism. Heat
loss is regulated, for example, via sweating and an outstretched body position.
Following Guntheroth and Spiers (Guntheroth and Spiers 2001) a differentiation is
made between thermal stress and hyperthermia. Thermal stress describes a threat to
the organism’s thermal regulation, that is mild enough to permit the core temperature to
remain within normal limits. Hyperthermia describes a condition with an increased core
temperature, such as a fever.
During sleep, the heat exchange with the environment can be accomplished in four
different ways: Conduction (exchange between two surfaces, e.g., skin and mattress),
radiation (exchange between body and walls due to infrared electromagnetic energy),
convection (exchange between skin and air) and evaporation (exchange due to the con-
version of liquid into a gas phase – sweating). Heat exchange in neonates is more rapid
and overall greater than in adults. Thus an increased risk exists for a neonate to suffer
from hyperthermia or hypothermia. The most important aspect of this characteristic is,
that neonates cannot maintain a thermoregulatory response during long exposures (Bach
et al 2002).
As mentioned before, many SIDS victims die between 2 and 4 months of age. At this
age, the thermal balance of a child is shifted in favour of heat conservation (Bach et al
2002). This fact also points to heat stress as an important environment and/or internal
factor in Sudden Infant Death. Typical environmental factors are overheated rooms and a
larger thermal insulation due to winter clothes and bedding (remember the ”winter peak”
– seasonality of SIDS); a typical internal factor is an infection, see Section 1.7.1.
Bach et al. (Bach et al 2002) theorize that homeostatic challenges (coping with heat
stress) could require a protective arousal of the child. If this mechanism is faulty due to
a delayed maturation of the arcuate nucleus, a brain–stem area implicated in the hyper-
capnic ventilatory response, chemosensitivity and blood pressure responses, the arousal
may be not possible. Empiric research documented certain risk factors that are consistent
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with thermal (heat) stress:
• Prone sleeping
• Child’s head covered
• Soft mattress and pillows in child’s bed
• Sheepskin in child’s bed
• Swaddling the baby in combination with prone sleeping
• Excessive sweating of the children
• Overheated rooms
• Children having infections with fever
• Seasonal distribution of deaths
• Excess bedclothes – children wearing to much clothing in bed
• Passive cigarette smoking
(Guntheroth and Spiers 2001; Einspieler 2000; Kurz 2000c; Kleemann et al 1998;
Sawczenko and Fleming 1996; Kleemann et al 1996; Kleemann1996; Ponsonby et al 1992;
Fleming et al 1992; Stanton 1984).
These factors document that, despite any other potential trigger for Sudden Infant
Death Syndrome, heat stress plays an important role. Nelson et al. (Nelson et al 2002)
worked with a neonatal rat model and performed an interesting experiment, that com-
bined the two risk factors heat stress and infection. They induced hyperthermia in neona-
tal rats and mimicked an infection with the chemical Muramyl Dipeptide (MDP). These
risk factors lead to an increased production of specific interleukins (IL–1β, IL–6) that
were also documented in SIDS victims (Rognum 2000). Furthermore, the mortality rate
of the neonatal rats confronted with the infection–equivalent MDP and heat stress was
increased.
Elabbassi et al. (Elabbassi et al 2001) argue, that body position and the risk of ther-
mal stress induced by increased body heat storage are two independent risk factors for
Sudden Infant Death. Their assumptions are based on an experiment with a thermal man-
nequin for testing the effects of clothing and body position (prone vs. supine). However,
the model is without adaptive thermoregulatory processes, which are essential to human
heat regulation. This reduces the adaptability in comparison with human beings.
Hahn et al. (Hahn et al 1991) examined the combined impact of heat and nicotine in
cell culture (chinese hamster cells of the ovary). Nicotine alone does not induce the stress
response, but nicotine in combination with heat induces the heat shock proteins Hsp28
and Hsp70 via binding of heat shock transcription factors to the heat shock element.
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1.7.3 SIDS Criteria
The following characteristics are termed SIDS criteria. In context of this thesis, they are
the most common characteristics and/or risk factors for Sudden Infant Death Syndrome.
These criteria are:
• Preterm birth (risk factor)
• Body position and body temperature in death scene (risk factors prone sleeping and
heat stress)
• Nicotine abuse by mother (risk factor smoking)
• Petechiae in pleura, epicard and thymus (characteristic autopsy results)
• Oedemata, foam and hemorrhage in the respiratory tract (characteristic autopsy re-
sults)
1.7.4 SIDS and Gene Variations
Until recently, research on Sudden Infant Death Syndrome was conducted mainly based
on autopsy results (including histological findings) and epidemiological factors/risk fac-
tors. In the last ten years more and more molecular biology findings have made a valuable
contribution to the known facts. It is very important to realize though, that even now all
known genetic variations are insufficient to explain the genesis of Sudden Infant Death.
No genetic trait or mutation has been identified as the sole trigger or actual reason for
Sudden Infant Death.
The possibility of an x–chromosomal factor that would be a necessary but not sufficient
factor for causing Sudden Infant Death Syndrome was theorized by Mage and Donner
(Mage and Donner 1997). This theory was based on the significantly higher male SIDS
fraction compared to the male birth fraction. Mage and Donner investigated 67378 SIDS
cases from 36 global data sets and applied the Hardy–Weinberg genetic principle. Even
today, no such factor has been identified.
Weese–Mayer et al. (Weese–Mayer et al 2003) theorize an influence of serotonin on
Sudden Infant Death Syndrome because of its functions: Serotonin is involved in the reg-
ulation of breathing, the cardiovascular system, temperature control and the sleep–wake
cycle. Narita et al. (Narita et al 2001) and Weese–Mayer et al. researched a polymorphism
in the promoter region of the serotonin transporter gene (5–HTT; serotonin = 5–HT, 5–
hydroxytryptamine). The polymorphism is a VNTR (variable number of tandem repeats)
and has been shown to differentially modulate gene expression. Three human alleles are
known: S, short, 14 repeats of the 20–23 base pair repeat unit; L, long, 16 repeats; XL,
extra long, 18–20 repeats. SIDS victims have a statistically significant higher frequency of
the long alleles (genotype L/L) compared to gender/ethnicity matched controls. Another
VNTR is located in intron 2 of the 5–HTT gene, which so far has not been noticeable in
Sudden Infant Death Syndrome.
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In a pilot study, Gordon et al. (Gordon et al 2002) found a polymorphism in the
interferon–γ gene (IFN). This polymorphism, called genotype 3/3, was significantly
higher in SIDS families (40 %) than in control families (15.4 %).
In a recent study, Puffenberger et al. discovered a disorder named SIDDT (Sudden
Infant Death with dysgenesis of the testes syndrome, OMIM Accession Number 608800;
Puffenberger et al 2004). This disorder was found in 21 individuals of the Belleville Amish
Community. 4 of the 21 SIDS cases showed a specific gene variant in both copies of a gene:
A frameshift mutation 457–458insG at codon 153 in the TSPYL1 gene (testis–specific Y–
like gene), which was identified by sequence analysis. The mutation leads to a truncation
of translation at codon 169.
Defects of the mitochondrial β–oxidation (fatty acid metabolism), for example MCAD
deficiency (medium chain acyl–CoA dehydrogenation), and glucose metabolism have
long been mistaken as a genetic component in Sudden Infant Death Syndrome. Actu-
ally, these defects are diseases of the metabolism and do not belong into the genesis of
Sudden Infant Death. For a review of these diseases, see Vockley and Whiteman 2002.
Some theories link the Sudden Infant Death Syndrome to a prolongation of the
QT interval and to mutations in sodium channel and potassium channel genes, e.g.,
sodium channel alpha–subunit gene SCN5A (Wedekind et al 2001; Schwartz et al 1998).
Wedekind et al. (Wedekind et al 2001) published a case report linking a missense mu-
tation (A1330P) in the sodium channel alpha–subunit gene (SCN5A) to a Sudden Infant
Death. The QT interval is a part of the electrocardiogram: It represents the time between
the start of ventricular depolarization and the end of ventricular repolarization. It is use-
ful as a measure of the duration of repolarization. Fatal arrhythmias from occult long QT
syndrome may be responsible for some SIDS cases. Patients who suffer from long QT
syndrome with sodium channel gene (SCN5A) defects show an increased frequency of
cardiac events during sleep. It is suggested that mutations in cardiac ion channels may
provide a lethal arrhythmogenic substrate in some infants at risk for SIDS.
Mutations in the mitochondrial genome were found by Opdal et al. (Opdal et al 1998)
and Hofmann et al. (Hofmann et al 1997). Both documented differences between the mi-
tochondrial DNA of SIDS cases and controls. Opdal et al. described a tendency towards
a higher substitution rate in the displacement–loop (D–loop, the non–coding part of the
mitochondrial genome containing the promoter regions) of the SIDS cases compared to
controls.
Rahim et al. (Rahim et al 1996) described fragment length polymorphisms in the human
heat shock protein genes hsp60, hsp70 and hsp90. For the genes hsp70 and hsp90, no
difference was found between SIDS cases and controls. The gene hsp60 showed a MspI–
polymorphism that exists highly significant less often in SIDS cases than in controls.
Bross et al. (Bross et al 2001) described DNA variations in the human heat shock pro-
tein gene hsp60. Two of them are in the coding region and alter the amino acid code.
The change G537A (glycine to alanine) is present in similar frequency in SIDS cases and
controls. The change N158S (asparagine to serine) was observed in one SIDS case and no
controls and Bross et al. assumed a possible rare disease allel of the hsp60 gene.
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1.8 Research focus
Due to the large number of differences in characteristics which occur in SIDS cases, a high
probability exists, that the Sudden Infant Death Syndrome is multifactorial:
1. Factor One is an infant in a vulnerable state of development. The highest SIDS in-
cidence is between 2 and 4 months, up to 6 months. During that time, for example,
the immune system of the child changes from the fetal immune system provided
by the mother to its own. The autonomous regulation in sleep (respiration, ther-
moregulation, circulation) is not entirely stable (Forsyth 1999; Vege and Rognum
1999; Blackwell and Weir 1999).
2. Factor Two is an exogenous stress factor. Almost all of the SIDS victims had vi-
ral or bacterial infections shortly before their deaths. These infections often cause
high fever and considerable heat stress. Other exogenous factors are prone sleeping,
problems with respiration due to nicotine influence and overheating.
3. Factor Three is an endogenous factor. One possibility is a physiological defect such
as magnesium deficiency (Durlach et al 2002). Another possibility is a genetic vari-
ant or defect.
In context of this thesis, the multifactorial genesis was examined with the following
hypothesis:
1. Factor One is a vulnerable infant, because of its developmental stage.
2. Factor Two is an exogenous factor: heat stress.
3. Factor Three is an endogenous factor: A possible genetic variation in a heat shock
protein/gene, hsp60.
Thus, the fundamental question is: Is there any difference at the DNA level between
children, who died of Sudden Infant Death Syndrome and children, who are either
healthy or died of other causes? In context of this work, a more specific form of that
question is asked as:
Is there a difference in the DNA of the human chaperonin gene hsp60
between SIDS victims and other children?
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2 Materials and Methods
The discussion in Chapter 1 now leads to the experimental body of this thesis. DNA was
obtained both from SIDS cases and control children to perform a mutation analysis of the
partial human chaperonin60 gene, employing the techniques PCR and direct sequencing.
2.1 Materials
2.1.1 SIDS cases
91 SIDS cases from the years 1987–2001, 56 male and 35 female infants, were examined.
Their ages ranged from 13 to 341 days (1–12 months). The cause of death in each of the
cases was diagnosed as Sudden Infant Death, if, after a thorough postmortem examina-
tion, no other cause of death could be detected. All autopsies were performed in the
Institute of Legal Medicine, Medical School Hanover, Germany. Hence, the Institute for
Legal Medicine, Medical School Hanover, Germany, will be abbreviated as RM/MHH.
The analysis of the autopsy protocols was performed in cooperation with the physicians
Ingo Reimann and Yvonne Schulz, RM/MHH. For the analysis of the variations in the
hsp60 gene, the DNA of the SIDS cases was isolated from blood samples obtained during
autopsies at the RM/MHH.
All 91 cases discussed here belong to the pathological categories of SIDS cases 1 to 3
(see Section 1.7). Typical SIDS criteria (characteristic findings in autopsy and at death
scene, well known risk factors) were documented, if mentioned in the autopsy protocols
(see Section 1.7.3).
2.1.2 Controls
It is very difficult to obtain control children for studies on Sudden Infant Death. As SIDS
is the leading cause of death of children under one year in Western countries (Hunt and
Hauck 2004; Jorch 2000), only a comparatively small number of children died of causes
other than SIDS. As an alternative, the head of the DNA laboratory of the RM/MHH
specified a control group matched in age and sex to the SIDS cases as the basis for this
research project.
In this thesis 108 controls from the years 1994–1999, 59 male and 49 female children,
were examined. Their ages ranged from 103 to 361 days (3–12 months). Most of the
controls (N=104) are children who were subject to paternity testing at the RM/MHH. Very
few (N=4) died of other causes and underwent autopsy at the RM/MHH. They belong to
category 4 according to the German Study on Sudden Infant Death (GeSID; Findeisen et
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al 2003; see Section 1.7). For the analysis of the variations in the hsp60 gene, the DNA of
the controls was isolated from blood samples of the children.
2.1.3 Databases
Various databases were accessed for this research:
Gene sequences were retrieved from the GenBank/EMBL/DDBJ Database (GEN-
BANK 2004). GenBank Accession Numbers are abbreviated GAN.
Genomes As resources for information on entire genomes the GenBank/EMBL/DDBJ
Database (GENBANK 2004) and the Genome Database (GDB 2004) were used. For
information on the human mitochondrial genome the Mitomap Database was used
(MITOMAP 2004).
Genetic disorders As a resource for information on human genes and genetic disorders
the OMIM Database was used (OMIM 2000).
Protein sequences were retrieved from the Swiss–Prot Database (SWISSPROT 2004)
and the TrEMBL Database (TrEMBL 2004). Swiss–Prot Accession Numbers are ab-
breviated SPAN.
Transcription factors As a resource for transcription factors and other factors regard-
ing the gene regulation on the level of transcription, the Transfac Professional 7.4.1
Database (Matys et al 2003) was used, courtesy of Biobase Biological Databases
GmbH Wolfenbüttel, Germany. TRANSFAC is a database on eukaryotic transcrip-
tion factors, their genomic binding sites and DNA–binding profiles.
2.1.4 DNA for PCR and sequencing of hsp60s
For the PCR and the sequencing of the newly discovered member of the HSP60 family
hsp60s, DNA was isolated from blood samples of three adult test persons (two female
and one male).
2.1.5 RNA for RT–PCR and sequencing of hsp60s
For the RT–PCR and the sequencing of the newly discovered member of the HSP60 fam-
ily hsp60s, RNA was isolated from blood samples of one test person (one of the female
human adults, whose DNA was used for PCR and sequencing of the hsp60s gene), see
last Section.
2.1.6 hsp60 – Human Chaperonin60 gene
The sequence of hsp60 was retrieved from the GenBank Database, GAN AJ250915
(Hansen et al 2003a). The corresponding paper is from Hansen et al. (Hansen et al 2003b).
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The original sequence of the hsp60 mRNA was described by Venner et al. (Venner et al
1990), GAN M34664 (Venner et al. 1993). There is a difference between the mRNA from
Hansen et al. and the mRNA from Venner et al.: In position 67 of the protein, Hansen et
al. described the amino acid serine, Venner et al. described a glycine. In the RNA, it reads
an A in position 259 from Hansen et al., corresponding to a G in position 223 from Venner
et al. This difference may be a SNP (single nucleotide polymorphism). For this thesis, its
occurrence is not relevant.
2.2 Methods
All of the original protocols and programs were customized to adjust them for the exper-
iments of the research project.
2.2.1 Laboratory Equipment and Reagents
Equipment:
• Centrifuges. Centrifugation steps with 15–ml sterile test tubes were carried out at a
Haereus Sepatech Megafuge 1.0 R (abbreviated HS). An Eppendorf 5415 D bench–
top centrifuge (abbreviated EP) was used for micro test tubes, 1.5 and 2.0 ml, its
maximum speed is 13.200 rpm.
• Rotator. For extracting DNA fragments, from agarose gel, a rotator was used
(REAX2 Rotator, REAG 2050, Heidolph Company, Germany).
• Interval Shaker. For resolving a DNA pellet, an interval shaker was used (LKB
Wallace 1292 Rack Shaker).
• Plastic materials for DNA experiments were disposables: 1.5–ml and 2.0–ml mi-
cro test tubes were supplied by Eppendorf AG, Germany. 15–ml test tubes were
supplied by Sarstedt AG, Germany.
• Plastic materials for RNA experiments. For RNA experiments, the plastic mate-
rials used were disposables and RNAsefree. The pipet tips (epTIPS Filter) and the
micro test tubes 1.5 and 2.0 ml (Biopur Safe–Lock) were supplied by Eppendorf AG,
Germany. The 15–ml sterile test tubes were supplied by Sarstedt AG, Germany.
• PCR Engine and plastic material. PCR and RT–PCR reactions were performed in
0.2 ml PCR tubes (supplied by Biozym Scientific GmbH, Germany) on a PTC–200
Peltier Thermal Cycler DNA Engine (MJ Research).
• PCR Purification. The purification reactions for either PCR or RT–PCR were per-
formed with the QIAquick PCR Purification Kit (supplied by Qiagen GmbH, Ger-
many). The only exception is the PCR of hsp60s. These fragments were extracted
by preparation of agarose gels with the Easypure DNA Purification Kit (supplied
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by Biozym Scientific GmbH, Germany). PCR products of different sizes in addi-
tion to hsp60s were generated in the PCR reaction. These would have interfered
with the following sequencing reaction, thus the need to isolate hsp60s from these
contaminants.
• Primers were manufactured by Applied Biosystems/Applera Deutschland GmbH,
Germany and MWG–Biotech AG, Germany.
If not specified otherwise, the following reagents were used in the experiments:
• 96% Ethanol.This ethanol absolute was used in all DNA experiments (supplied by
J. T. Baker).
• 96% Ethanol, ethanol absolute, molecular biology grade. This RNAse–free ethanol
was used in all RNA experiments (supplied by Applichem GmbH, Germany).
• HPLC–analyzed H2O. This HPLC–grade water was used, in all but RNA experi-
ments (supplied by J. T. Baker).
• H2O, molecular biology grade. This RNAse–free water was used in the RNA exper-
iments (supplied by Applichem GmbH, Germany).
• β–Mercapthoethanol, molecular biology grade. This reagent was used for RNA
isolation (supplied by SIGMA–ALDRICH Chemie GmbH, Germany).
• dNTPs (deoxy nucleotide triphosphate). Since the kits do not contain a sufficient
number of dNTPs, additional dNTPs (GeneAmp 10 mM dNTP Mix with dTTP)
were supplied by Applied Biosystems/Applera Deutschland GmbH, Germany.
2.2.2 Isolation of DNA – SIDS samples and Controls
The DNA of the controls was isolated from leukocytes in buffy coat samples for Factor
XIIIA protein isolation (Section 2.2.2.1). These samples were originally prepared for pa-
ternity testing at the RM/MHH. For DNA isolation, either a Qiagen QiAmp Mini Kit
(blood protocol) or a Qiagen Blood Mini Kit was used (same protocol as for QiAmp Mini
Kit, see Section 2.2.2.2). The RNAse A used in the isolation procedure was also provided
by Qiagen. The Qiagen protocols were customized, using longer incubation time with
application of buffer AL. The amount of DNA isolated was determined photometrically
(Section 2.2.4).
The DNA of the SIDS cases was isolated from whole blood (either heart or femoral vein
blood), which was taken during the autopsies. The same protocol as for the controls was
used (see Section 2.2.2.2). Instead of the buffy coats, whole blood was used in the first
step.
The DNA for the PCR and the sequencing of the hsp60s gene was also isolated from
whole blood (basilic vein blood), which was taken from the test persons at the RM/MHH.
The same protocol as for the SIDS cases and controls was used, starting with whole blood,
see Section 2.2.2.2.
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2.2.2.1 Preparation of Buffy Coats, Factor XIIIA isolation
1. Centrifuge whole blood samples (EDTA–blood) of at least 4 ml volume for 1 minute at 500
x g (1750 rpm) without brake on the HS centrifuge.
2. Centrifuge recovered platelet–rich plasma (PRP, upper phase) once again for 10 minutes at
2000 x g (3500 rpm) on the HS centrifuge.
3. Discard supernatant retaining only approximately 2 droplets.
4. Swirl pellet up homogenously.
5. Freeze at −18◦ C to initiate ”rhexis” of thrombocyte membrane for setting free intracellular
Factor XIIIA protein.
2.2.2.2 Isolation of DNA
1. Pipet 200 µl buffy coat or whole blood into a 1.5–ml microcentrifuge tube.
2. For RNA–free genomic DNA add 4 µl RNase A stock solution (100) mg/ml to sample, before
adding Buffer AL. Vortex and centrifuge briefly. Incubate at room temperature for 5 min.
3. Add 20 µl Qiagen Proteinase K to sample, ensure proper mixing by vortexing.
4. Warm Buffer AL at 56◦ C for 5 minutes.
5. Add 200 µl Buffer AL to the sample. For efficient lysis, proper mixing is needed. Mix by
pulse–vortexing for 15 sec. Centrifuge briefly. Do not add Qiagen Protease or Proteinase
directly to Buffer AL.
6. Incubate at 56◦ C for at least 12–15 hours.
7. Centrifuge briefly to remove drops from the lid.
8. Add 200 µl ethanol (96–100%), mix by pulse–vortexing for 15 sec, centrifuge briefly to re-
move drops from the lid.
9. Carefully apply the mixture from step 8 to the QIAmp spin column (in a 2–ml collection
tube) without wetting the rim, close the cap, and centrifuge at 6000 x g (8000 rpm) for 1
min. Place the QIAmp spin column in a clean 2–ml collection tube and discard the tube
containing the filtrate.
10. Carefully open the QIAmp spin column and add 500 µl Buffer AW 1 without wetting the
rim. Close the cap and centrifuge at 6000 x g (8000 rpm) for 1 min. Place the QIAmp spin
column in a clean 2–ml collection tube and discard the tube containing the filtrate.
11. Carefully open the QIAmp spin column and add 500 µl Buffer AW 2 without wetting the
rim. Close the cap and centrifuge at 13.200 rpm for 3 min.
12. Place the QIAmp spin column in a new 2–ml collection tube (or use 1.5–ml tube) and discard
the collection tube with the filtrate. Centrifuge at 13.200 rpm for 1 min.
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13. Place the QIamp spin column in a new sterile 1.5–ml tube (not included in kit) and discard
the collection tube containing the filtrate. Dry off the open spin column at 56◦ C for max.
3 min to evaporate remaining EtOH. Add 100 µl Buffer AE and then 100 µl sterile HPLC
water or mix buffer AE and water before. Incubate at room temperature for 5 min, and then
centrifuge at 6000 x g (8000 rpm) for 1 min.
14. The purified DNA can be used immediately or stored at -20◦C for later use.
2.2.3 Isolation of RNA – hsp60s
The RNA for the expression analysis of hsp60s was isolated using the Qiagen QIAmp
RNA Blood Mini Kit from fresh whole blood (basilic vein blood), see following Section.
EDTA was used as an anticoagulant. The blood was processed immediately after taking
the blood sample. The Qiagen protocols were customized: The amount of blood used in
the isolation was increased to 2.0 ml instead of 1.5 ml. The centrifugation speed for the
steps with the HS centrifuge was increased to 800 x g compared to 400 x g in the original
Qiagen protocol. Step 1 to step 5 must be performed on ice. Beginning with step 6, the
isolation is performed at room temperature.
1. Mix 1 volume of whole human blood with 5 volumes of buffer EL in a 15–ml sterile test
tube: 2.0 ml blood + 10 ml Buffer EL. Pipet the blood into the tube filled with buffer EL. The
volume of the mixture should not exceed three quarters of the tube to allow efficient mixing.
2. Incubate for 10–15 minutes on ice. Mix by vortexing briefly 2 times during incubation. The
cloudy suspension becomes translucent during incubation, indicating lysis of erythrocytes.
If necessary, incubation time can be extended to 20 min.
3. Centrifuge at 800 x g (HS) for 10 min at 4◦C. Leukocytes will form a pellet after centrifuga-
tion. Ensure supernatant is completely removed. Trace amounts of erythrocytes, which give
the pellet a red tint, will be eliminated in the following washing step. If erythrocyte lysis is
incomplete, the white pellet may not be visible and large amounts of erythrocytes will form
a red pellet. If this happens, incubate for an additional 5–10 min on ice after addition of
Buffer EL at step 4.
4. Add Buffer EL to the cell pellet (use 2 volumes of Buffer EL per volume of whole blood
employed in step 1): 4 ml Buffer EL. Resuspend cells by vortexing briefly.
5. Centrifuge at 800 x g (HS) for 10 min at 4◦C, and completely remove and discard super-
natant. Incomplete removal of the supernatant will interfere with lysis and subsequent
binding of RNA to the QIAmp spin column, resulting in lower yield.
6. Add 600 µl buffer RLT to pelleted leukocytes. The buffer must be freshly made: 10 µl β–
Mercaptoethanol (β–ME) + 1 ml RLT. Then, the buffer RLT is stable for 1 month at room
temperature (15–25 ◦C) after addition of β–ME.
7. Pipet lysate directly into a QIAshredder spin column sitting in a 2–ml collection tube and
centrifuge for 2 min at 13.200 rpm (EP) to homogenize. Discard QIAshredder spin column
and save homogenized lysate. To avoid aerosol formation, adjust pipet to≥ 750 µl to ensure
that the lysate can be added to the QIAshredder spin column in a single step. If too many
31
cells have been used, the lysate will be too viscous to pipet after homogenization. In this
case divide the sample into two aliquots and adjust the volumes of each aliquot to 600 µl
with Buffer RLT. Continue with the procedure in step 7. The β–ME waste is hazardous
material and must be disposed of separately.
8. Add 1 volume (600 µl) of 70 % ethanol to the homogenized lysate and mix by pipetting. Do
not centrifuge. A precipitate may form after the addition of ethanol. This will not affect the
QIAmp procedure.
9. Carefully pipet sample, including any precipitate which may have formed, into a new QI-
Amp spin column sitting in a 2–ml collection tube (provided) without moistening the rim.
Centrifuge for 15 sec at ≥ 8000 x g (≥ 10000 rpm). Maximum loading volume is 700 µl. If
the volume of the sample exceeds 700 µl, successively load aliquots onto the QIAamp spin
column and centrifuge as above. Discard flow–through and collection tube.
10. Transfer the QIAmp spin column into a new 2–ml collection tube. Apply 350 µl Buffer RW1
to the QIAmp spin column and centrifuge for 15 sec at ≥ 8000 x g (≥ 10000 rpm). Discard
flow–through and collection tube.
11. Add 10 µl DNAse I stock solution (DNAse I is from the RNasefree DNase Set, supplied
by Qiagen) to 70 µl Buffer RDD. Mix by gently inverting the tube. DNAse I is especially
sensitive to physical denaturation. Mixing should only be carried out by gently inverting
the tube. Do not vortex.
a) Prepare DNAse I stock solution before using the RNAse–Free DNAse Set for the first
time. Dissolve the solid DNAse I (1500 Kunitz units) in 550 µl of the RNAse–free
water provided. Take care that no DNAse I is lost when opening the vial. Mix gently
by inverting the tube. Do not vortex.
b) Do not vortex the reconstituted enzyme. DNAse I is especially sensitive to physical
denaturation. Mixing should only be carried out by gently inverting the tube.
c) For long term storage, remove the stock solution from the glass vial, divide it into
single–use aliquots, and store at -20◦C for up to 9 months. Thawed aliquots can be
stored at 2–8◦C for up to 6 weeks. Do not refreeze after thawing.
12. Pipet the DNAse I incubation mix (80 µl) directly onto the spin column membrane, and
incubate for 15 min. at 20–30◦C. Note: Make sure to pipet the DNase I incubation mix
directly onto the spin–column membrane. DNAse digestion will be incomplete if part of
the mix sticks to the walls or the O–ring of the spin column.
13. Pipet 350 µl Buffer RW1 into the spin column and centrifuge for 15 sec at ≥ 8000 x g (≥
10000 rpm). Discard flow–through and collection tube.
14. Place the spin column in a new 2–ml collection tube. Pipet 500 µl of Buffer RPE into the spin
column, and centrifuge for 15 sec at ≥ 8000 x g (≥ 10000 rpm). Discard flow–through and
collection tube. Note: Ensure ethanol is added to Buffer RPE before use.
15. Pipet 500 µl of Buffer RPE into the spin column, and centrifuge for 2 min at 13.200 rpm to
dry the silica gel membrane. It is important to dry the silica–gel membrane, since residual
alcohol may interfere with subsequent reactions. This 2 min spin ensures that no ethanol is
carried over during elution. Following the spin, remove the spin column from the collection
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tube carefully so the column does not contact the flow–through as this will result in a carry–
over of ethanol.
16. Transfer spin column to a new 1.5–ml collection tube, and pipet 30–50 µl of RNAse–free
water directly onto the silica–gel membrane. Centrifuge for 1 min at ≥ 8000 x g (≥ 10000
rpm) to elute.
17. Repeat step 16 if the expected RNA yield is >30 µg. If a second elution step is performed,
elute into the same collection tube using another 30–50 µl of RNAse–free water. With the
QIAmp RNA Blood Mini Kit, a second elution is recommended if more than 0.5 ml of whole
blood (or >2x106 leukocytes) have been processed.
The amount of RNA was determined photometrically. The procedure is described in
the next Section.
2.2.4 Quantification and purity of nucleic acids
The quantification of both DNA and RNA was carried out on a Pharmacia Biotech Ul-
trospec 2000 UV/Visible Spectrophotometer. For DNA, a quartz glass cuvette was used
(Hellma Type No. 105.202–QS, layer thickness 10mm). A 1:10 dilution was used for mea-
suring the DNA concentration (10 µl DNA–solution and 90 µl HPLC–H2O).
For RNA, sterile, disposable plastic cuvettes were used (Eppendorf Uvette with Uni-
versal Adapter). A 1:5 dilution was used for measuring the RNA concentration (20 µl
RNA–solution and 80 µl RNAse–free H2O). All measurements were carried out against
HPLC–H2O as reference.
Calf thymus DNA (Gibco BRL Life Technologies, stock solution 10mg/ml) of a known
concentration (20 ng/µl) was used for calibration of the photometer. The concentration
of the DNA– and RNA–solutions was measured using absorbance at 260 nm. A solution
of DNA with an optical density of 1.0 has a concentration of 50 µg/ml, for RNA it is 40
µg/ml.
The purity of DNA– and RNA–solutions is determined by calculating the ratio of
absorbance at 260 nm to absorbance at 280 nm. Pure DNA has an absorbance ratio
A260/A280 of 1.8, pure RNA has one of 2.0.
Concentration of DNA [ng/µl] = absorption at λ260 *50 ng/µl *10
Concentration of RNA [ng/µl] = absorption at λ260 *40 ng/µl *5
Absorbance ratio (Purity) = A260A280
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2.2.5 Polymerase Chain Reaction (PCR) and Reverse Transcriptase
Polymerase Chain Reaction (RT–PCR)
The Polymerase Chain Reaction (PCR) is used for the amplification of DNA fragments.
This method was originally developed by Mullis et al. in 1986 (Mullis et al 1986). The
Reverse Transcriptase Polymerase Chain Reaction (RT–PCR) is used for the amplification
of RNA fragments. It is a two step reaction. First, the reverse transcriptase transcribes
the RNA into a cDNA, then the normal PCR starts. Reverse transcriptases were at first
isolated from retroviruses. Their genome consists of single–stranded RNA, which needs
to be converted into DNA for integrating the virus genome into the genome of a cell
(Lewin 2000).
All primers used in the PCR and RT–PCR experiments were self constructed, except
the GAPDH primers for testing the RNA quality. The software used for this procedure
was Primer3 (Rozen and Skaletsky 2000). Furthermore, all PCR and RT–PCR protocols
and programs for this thesis, following the appropriate guidelines in the manuals, were
customized. For PCR, the ProofStart DNA Polymerase (supplied by Qiagen GmbH, Ger-
many; Qiagen Proofstart DNA Polymerase 2002) and the GeneAmp XLPCR Kit (supplied
by Applied Biosystems/Applera Deutschland GmbH, Germany; XLPCR Kit 1997) were
used. For RT–PCR the Qiagen OneStep RT–PCR Kit (Qiagen GmbH, Germany; Qiagen
OneStep RT–PCR Kit 2002) was used. The customization affected the reagent concentra-
tions in the reactions, the time and temperature of the different reaction steps, and the
number of cycles.
2.2.5.1 Purification of PCR products and RT–PCR products
This purification method is designed to purify single– or doublestranded PCR products
ranging from 100 bp to 10 kb from primers, nucleotides, polymerases and salts, using
QIAquick spin columns in a microcentrifuge. All centrifugation steps were performed at
13.200 rpm. The method was customized: The elution buffer was diluted 1:8 with water.
1. Add 5 volumes of Buffer PB to the PCR reaction and mix. It is not necessary to remove
mineral oil or kerosene. For 25 (50, 100) µl reaction use 125 (250, 500) µl PB.
2. Place the QIAquick spin column in a 2.0–ml micro test tube.
3. To bind DNA, apply the sample to the QIAquick column and centrifuge for 1 min.
4. Discard the flow–through. Place the QIAquick column carefully into a new 2.0–ml tube.
5. To wash, add 600 µl Buffer PE to the column and centrifuge for 30–60 sec.
6. Discard the flow–through. Place the QIAquick column into a new tube and centrifuge the
column for an additional minute.
7. Place the QIAquick column into a sterile 1.5 ml micro test tube.
8. Open the column lid and let the remaining EtOH evaporate for 3 min at 56◦C.
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9. To elute the DNA, add 50 µl Buffer EB (10mM Tris–Cl, pH 8.5, diluted 1:8 with water, for
1 ml: 125 µl EB + 875 µl H2O) to the center of the QIAquick column, incubate for 5 min
at room temperature, and centrifuge for 1 min. Alternatively, for increased DNA concen-
tration: Add 30 µl Buffer EB to the center of the QIAquick column, incubate for 1–5 min
at room temperature, and then centrifuge. Ensure that the elution buffer (EB) is dispensed
directly onto the QIAquick membrane for complete elution of bound DNA. The average
eluate volume for 50 (30) µl Elution Buffer is 48 (28) µl.
For analyzing DNA yield and purity in the eluate, use 10 µl DNA–solution and 90 µl
H2O.
2.2.5.2 Purification of PCR products – Agarose Gels
The protocol was customized by adding an extra step for extracting more DNA.
1. Cut the DNA band out of the gel and apply it to a 15–ml test tube. Weigh the gel piece to
measure the volume (100 mg = 100 µl). The volumes of the solutions MELT and SALT are
dependent on the volume of the gel band.
2. Dissolving of the agarose (TBE gels).
a) First add 0.5 volume MELT solution (pink) and then 4.5 volume SALT solution (yellow)
to the gel fragments.
b) Incubate for 10 min at 55◦C. Mix by gentle vortexing. Repeat 3 to 4 times if necessary.
The agarose must be fully dissolved. Vortexing is dependent on fragment size.
3. Binding of the DNA:
a) Vortex the BIND solution (red) thoroughly.
b) Take 5 µl plus 1 µl per µg of expected DNA amount Matrix (BIND). Use a yellow pipet
tip.
c) Mix for 15 min at room temperature in the rotator, speed level 3.
d) Centrifuge briefly (maximum 5 sec). Take away the supernatant and keep it.
4. Washing:
a) Resolve the pellet in 1 ml fresh washing solution (240 µl Concentrate, 4.76 ml Water,
5.00 ml EtOH). Shake gently. The pellet must be fully resolved. Transfer the solution
into a micro test tube (1.5 ml). Incubate for 15 to 30 min at room temperature without
mixing.
b) Centrifuge briefly (for maximal 5 sec) and discard supernatant. Use a blue pipet tip.
c) Centrifuge briefly (for maximal 5 sec) and discard supernatant. Use a yellow pipet tip.
d) Dry the pellet at 56◦C for 10 min; or until all solution has evaporated.
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5. Elution:
a) Resolve the pellet in 100 µl HPLC–H2O. Incubate for 10 min at room temperature on
an interval shaker.
b) Centrifuge for 1 min in the EP at 13.200 rpm. Take away the supernatant carefully into
a sterile new 1.5–ml micro test tube, take no more than 60 µl.
c) Additional step for extracting more DNA: resolve the pellet again in 40 µl HPLC–H2O,
incubate for 10 min on the interval shaker, and centrifuge for 10 min in the EP at 13.200
rpm. Then take 50 µl from the supernatant.
For analyzing DNA yield and purity, use 10 µl DNA–solution and 90 µl HPLC–H2O.
2.2.6 PCR of partial human hsp60 gene
For the amplification of the partial hsp60 gene, exon 5 with 5’ and 3’ boundaries, the
Qiagen ProofStart DNA Polymerase (with ProofStart PCR Buffer, Q–Solution, MgSO4;
Qiagen GmbH Germany) was used. The parameters for the ProofStart DNA Polymerase
reactions were obtained from the manual of Qiagen (Qiagen ProofStart DNA Polymerase
2002). The quantity of the starting template was calculated as follows: The size of the hu-
man genomic DNA is 3.3 · 109 base pairs; this number corresponds to 4.7 · 10−7 pmol/µg
and 2.8 · 105 Molecules/µg (2.8 · 104 Molecules/ng) for single copy genes. Thus, the num-
ber of copies of the starting template is 1 · 103 to 5 · 104. This refers to 3.6–179 ng of human
genomic DNA. The individual primer concentration used was 1 µM (50 pmol per 50 µl
reaction). The dNTP concentration used was 1.5 µl for a 50 µl reaction (final concentration
300 µM).
2.2.6.1 Primers for the PCR of partial human hsp60 gene
The primers for the amplification of the partial hsp60 gene were constructed based on
the sequence of the human hsp60 genomic DNA and are shown in table 2.1. The letter L
stands for left (forward primer), the letter R stands for right (reverse primer). The original
annealing temperature (TA) is 5 ◦C lower than the melting temperature (TM), but may be
adjusted in the PCR optimization process.
Primer Sequence, 5′ −→ 3′ TM % GC length
XXLHSEXON5IL GGT AAG GGA ACT GAC TGA GG 56.25◦C 55.00 20
XXLHSEXON5IR GAT GGA TTC ATT TCA TGC AG 56.47◦C 40.00 20
XXLHSEXON5IIR GAT CAT CAG ATA ACT CAA AC 46.57◦C 35.00 20
XXLHSEXON5IIIR CTA TAC ATG TGC TGA GAC TAC 47.30◦C 42.86 21
TM = melting temperature; %GC = amount of GC nucleotides; length = number of nucleotides
Table 2.1: hsp60, Exon 5 with Boundaries: PCR Primers
The primer pair XXLHSEXON5IL and XXLHSEXON5IR was used for the partial am-
plification of hsp60 from human genomic DNA. The primer XXLHSEXON5IIR was used
36
as an additional sequencing primer. The primer XXLHSEXON5IIIR was used only for
testing purposes during PCR optimization, but not for the actual experiments.
The partial sequence of the human chaperonin gene 60 exon 5 with 5′ and 3′ boundaries
is shown in Table 2.2. The exon 5 is marked in boldface. Primer sequences are underlined,
their direction is marked. The expected fragment has a length of 380 base pairs (GAN
AJ250915: base position 8701–9040). The exon 5 ranges from base position 8748–8843
with a size of 96 bp; the upstream adjacent intron 4 ranges from base position 8207–8747
with a size of 541 bp and the downstream adjacent intron 5 ranges from base position
8844–9251 with a size of 408 bp.
8641 CCCCTGGATG GAAGTATCAA TTTGGAAGTT ACTAGGAAAA GGTAAGGGAA CTGACTGAGG
>8681–8700> >XXLHSEXON5IL>
8701 ACACTAGGCT TACCTTTTAA TTTCGAAGAG TAACTGGATT ATTTCAGGTT GCTACGATTT
8761 CTGCAAACGG AGACAAAGAA ATTGGCAATA TCATCTCTGA TGCAATGAAA AAAGTTGGAA
8821 GAAAGGGTGT CATCACAGTA AAGGCAAGTG TGTTTGTATT TTTAAAGATA ATTTTGAGTT
8748–8843 exon 5
8881 ATCTTATGAT CAAAA GTTTG AGTTATCTGA TGATCAAAAC TGAATTTTTC AAACAGAAAA
<8896–8915< <XXLHSEXON5IIR<
8941 ATTCTGTTTT AAAAACAGTG CTTTTTTTAT TCCTTCATAT GTAGTCTCAG CACATGTATA
<8981–9001< <XXLHSEXON5IIIR<
9001 GAATAAAGTA CTTACTGTGT TTTATGTGAA TTAGCCTTTG CTGCATGAAA TGAATCCATC
<9041–9060< <XXLHSEXON5IR<
boldface = exon 5; underlined = primer
Table 2.2: hsp60: Exon 5 with boundaries (AJ250915, base position 8641–9060); Position of
PCR Primers
2.2.6.2 Protocols and Programs for the PCR of partial human hsp60 gene
The protocol and program are shown in Tables 2.3 and 2.4. The reagents were mixed at
room temperature.
Template DNA 100–200 ng
Primer forward XXLHSEXON5IL 50 pmol
Primer reverse XXLHSEXON5IR 50 pmol
10x ProofStart Buffer 5 µl
10mM dNTP Mix 1.5 µl
Q–Solution 5x 10 µl
Proofstart Polymerase 2.5 Units
Water ad 50 µl
Table 2.3: hsp60, Exon5 with Boundaries: PCR Protocol with Q–Solution, 50 µl
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1. 5 min 95◦C Activation Proofstart DNA Polymerase
2. 1 min 94◦C Denaturation
3. 1 min 57◦C Annealing
4. 1 min 72◦C Extension
5. Goto 2 41 times Cycles
6. 10 min 72◦C Final Extension
7. Forever 4◦C Hold
Table 2.4: hsp60, Exon5 with Boundaries: PCR Program XXLHS5V2
2.2.7 PCR of hsp60s
Initially, the PCR of hsp60s occurred unintentionally. The primer pair XLLEFT/XLRIGHT
was originally constructed to amplify the coding part of the genomic hsp60 gene (exons
2–12 with introns, size 13248 base pairs). Thus, all PCR parameters were chosen for a
single copy gene in the human genome, the size parameters were adjusted to 13248 base
pairs. However, instead of the desired hsp60 fragment, a previously unknown gene was
discovered. It was named hsp60s (GAN AF380943; Teske et al 2001). The complete anal-
ysis of hsp60s is described in Section 3.3.
For the amplification of the hsp60s gene, the GeneAmp XLPCR Kit (Applied Biosys-
tems/Applera GmbH Deutschland) was used. Thus, all primer names start with XL. The
parameters for the XLPCR reactions were adapted according to the manual of Applied
Biosystems/Applera GmbH Deutschland (XLPCR Kit 1997).
2.2.7.1 Primers for the PCR of hsp60s
The primers for the amplification of the hsp60s gene were constructed based on the se-
quence of the human hsp60 mRNA and the sequence of the human hsp60 genomic DNA
(Table 2.5). The suffix LEFT stands for the forward primer, the suffix RIGHT stands for the
reverse primer. The original annealing temperature (TA) is 5 ◦C lower than the melting
temperature (TM), but may be adjusted in the PCR optimization process.
Primer Sequence, 5′ −→ 3′ TM % GC length
XLLEFT GAC GAC CTG TCT CGC CG 61.65◦C 70.59 17
XLLEFTII CTC GCC GAG CCA CGC CT 68.55◦C 76.47 17
XLLEFTIII TCT CGC CGA GCC ACG CCT 70.19◦C 72.22 18
XLRIGHT ACA CAA AGG TTG TCA CAT AAT TGG 60.08◦C 37.50 24
XLRIGHTII GCC TTG GGC TTC CTG TC 59.28◦C 64.71 17
XLRIGHTIII TAA CTT CTC ATC TGG TGG TGG CAA 65.04◦C 45.83 24
XLRIGHTIV ACT GCT TAA CTT CTC ATC TGG TGG TGG CAA 71.67◦C 46.67 30
TM = melting temperature; %GC = amount of GC nucleotides; length = number of nucleotides
Table 2.5: hsp60s: PCR Primer
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The primer pair XLLEFT/XLRIGHT was used for the amplification of hsp60s from hu-
man genomic DNA. The other primers were used only for testing purposes during PCR
optimization. The partial sequence of the human chaperonin60 gene with the primer
XLLEFT is shown in Table 2.6; the illustration for XLRIGHT is shown in Table 2.7. The
exons are marked with boldface. Primer sequences are underlined, their direction is
marked. The expected fragment has a length of 13248 base pairs (GAN AJ250915, base
position 3669–16917).
3361 CCCGGAAATG ACGCGATTTG ACCCTTGAGC CGTAGGGAGC GCGGCATTTT CTGGAAAGTT
3408–3428 putative heat
3421 CTGGAACCGA GCGAGGCCCG GGAACTAGAC TAAGCCGGCC GGAGAGGGCT GAGCGCGCTA
shock element
3481 GCACACCCTG CGCGGGTAGG GAGGGGCGGG GCTCGCGCGC AGGGTGTGCA GATTGCAGGG
3504–3510 SP1 element
3541 CCCGGGCTGA CGGGAAGTGG GTGGGAGCTG CCTGCACACG CGGTGCCGCG GGGCGGGAGT
3591–3597 SP1 element
3601 AGAGGCGGAG GGAGGGGACA CGGGCTCATT GCGGTGTGCG CCCTGCACTC TGTCCCTCAC
C3654: start p10gene C3655: start p60gene/mRNA
3661 TCGCCGCC GA CGACCTGTCT CGCCGAGCGC ACGCCTTGCC GCCGCCCCGC AGGTACGCGG
>3669–3685> >XLLEFT> 3655–3712 exon 1
boldface = exons; underlined = primer
Table 2.6: hsp60: AJ250915, base position 3361–3720; Position of Primer XLLEFT
16261 CATATTTTAC TAAGGGAAAA CTAATTAATT AAATTTTTTT CTAGGTTGTG AGAACTGCTT
16873–16917 exon 12
16321 TATTGGATGC TGCTGGTGTG GCCTCTCTGT TAACTACAGC AGAAGTTGTA GTCACAGAAA
16381 TTCCTAAAGA AGAGAAGGAC CCTGGAATGG GTGCAATGGG TGGAATGGGA GGTGGTATGG
16441 GAGGTGGCAT GTTCTAACTC CTAGACTAGT GCTTTACCTT TATTAATGAA CTGTGACAGG
A16457 end p60cds
16501 AAGCCCAAGG CAGTGTTCCT CACCAATAAC TTCAGAGAAG TCAGTTGGAG AAAATGAAGA
16561 AAAAGGCTGG CTGAAAATCA CTATAACCAT CAGTTACTGG TTTCAGTTGA CAAAATATAT
16621 AATGGTTTAC TGCTGTCATT GTCCATGCCT ACAGATAATT TATTTTGTAT TTTTGAATAA
16681 AAAACATTTG TACATTCCTG ATACTGGGTA CAAGAGCCAT GTACCAGTGT ACTGCTTTCA
16741 ACTTAAATCA CTGAGGCATT TTTACTACTA TTCTGTTAAA ATCAGGATTT TAGTGCTTGC
16861 GTAGAGAAGT AT CCAATTAT GTGACAACCT TTGTGTAATA AAAATTTGTT TAAAGTTAAT
<16873–16896< <XLRIGHT< T16917 end p60gene/mRNA
boldface = exons; underlined = primer
Table 2.7: hsp60: AJ250915, base position 16261–16720; Position of Primer XLRIGHT
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2.2.7.2 Protocols and Programs for the PCR of hsp60s
The protocol and program are shown in Tables 2.8 and 2.9. The reagents were assem-
bled on ice. The PCR fragments were extracted from a 0.4% agarose gel (Seakem Gold
Agarose, 1X TBE–Buffer, Section 2.2.5.2). The fragments obtained were used as a template
for a second amplification (”template from template” method) with the same protocol and
program as the first time. The purification after the second amplification was performed
with the QIAquick PCR Purification Kit (Section 2.2.5.1). The purified fragments from the
second processing were used for direct sequencing.
Template DNA 25–50 ng
Primer forward XLLEFT 15 pmol
Primer reverse XLRIGHT 15 pmol
3.3x XL Buffer 15.2 µl
10 mM dNTP Mix 6.0 µl
25 mM Mg(Oac)2 3 µl
Proofstart Polymerase 1.5 Units
Water ad 50 µl
Table 2.8: hsp60s: PCR Protocol, 50 µl
1. 10 min 4◦C Cooling down the reaction, ”Manual Hot Start”
2. 45 sec 94◦C Denaturation
3. 15 sec 94◦C Denaturation
4. 30 sec 55◦C Annealing
5. 8.5 min 67.5◦C Extension
6. Goto 2 29 times Cycles
7. 10 min 72◦C Final Extension
8. Forever 4◦C Hold
Table 2.9: hsp60s: PCR Program AT1
2.2.8 PCR of different fragment sizes for direct sequencing with DNA
from SIDS victims
The DNA isolated from blood or tissues of corpses is often degraded due to cell degra-
dation after death. This causes problems: Only comparatively short fragments (a few
hundred bases) that can be amplified and sequenced are left intact. Thus, a PCR/direct
sequencing approach on this DNA is costly and time–consuming. To improve the re-
search regarding the Sudden Infant Death Syndrome, the applicability of this methods
was extended to longer fragments (up to 2200 bases). As a test subject for short frag-
ments, the partial human hsp60 gene (about 400 bases, see Section 2.2.6), was used. For
longer fragments, the human hsp60s gene (about 2200 bases, see Section 2.2.7) was used.
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2.2.9 RT–PCR (PCR with Reverse Transcriptase) of hsp60s
For the amplification of the hsp60s gene from RNA the Qiagen OneStep RT–PCR Kit
(Qiagen GmbH, Germany) was used. This Kit provides an enzyme mix of two reverse
transcriptases (Omniscript and Sensiscript) and a HotStarTaq DNA Polymerase (Qiagen
OneStep RT–PCR Kit 2002). The reverse transcriptases perform at a reaction temperature
of 50◦C. Then the temperature is increased to 95◦C to activate the HotStarTaq Polymerase.
This step deactivates the reverse transcriptases. The parameters for the RT–PCR reactions
were obtained from the Qiagen OneStep RT–PCR Kit Handbook (Qiagen OneStep RT–
PCR Kit 2002): The mRNA is classified based on abundance. For GAPDH, 7 · 106− 7 · 107
(7–70 Million) copies are estimated in 100 ng RNA. This leads to 25–30 cycles in the RT–
PCR reaction. For hsp60s, 7 · 104− 7 · 106 (70.000–7 Millioned) copies are estimated in 100
ng RNA, leading to 25–35 cycles. The water used in all RT–PCR reactions was RNAse-
free water included in the Qiagen OneStep RT–PCR Kit. As a RNAse inhibitor during
the RT–PCR reactions, rRNAsin(R) RNase Inhibitor (Recombinant RNAsin Ribonuclease
Inhibitor) supplied by Promega GmbH, Germany was used.
2.2.9.1 Primer for RT–PCR of hsp60s
For testing the quality of the RNA, a human GAPDH primer pair (R&D Systems GmbH,
No. RDP–30–025) was used. This primer pair amplifies a 576 base pair cDNA observed
from pseudogenes of the human genome, GAN M33197 (Tokunaga et al 1994). The results
were verified on an agarose gel (1%, NuSieveGTG Agarose/ TBE–Buffer).
The primer for the amplification of the hsp60s cDNA are shown in Table 2.12. They
were constructed based on the sequence of the human hsp60s genomic DNA, the se-
quence of a human chromosome 5 clone (GAN AC091873; DOE Joint Genome Institute
and Stanford Human Genome Center 2002), the sequence of the human hsp60 mRNA and
the sequence of the human hsp60 genomic DNA. The name Start stands for the forward
primer, the name Stop stands for the reverse primer. The original annealing temperature
(TA) is 5◦C lower than the melting temperature (TM), but may be adjusted in the PCR op-
timization process. The prefixes ”53”, ”5”, and ”3” indicate the differences in the primer
sequence at the 5’ and 3’ end between the putative mRNA of the hsp60s gene and the
mRNA of the hsp60 gene. The partial sequence of the human chromosome 5 clone with
the hsp60s gene included is shown in Tables 2.10 and 2.11. The putative coding sequences
are marked in boldface. Primer sequences are underlined, their direction is marked.
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137941 AACCAGACAT AGATTGGCTG TATTGCTCTC ATAATTTGGC AGATGTCTGT ATGTTCCATT
138001 TATAGTACAA CTGCCACATT TATTTGCTTT TTAAAAGTGA TATATTAGCA CTCTGTCCCT
138098 first base hsp60s
138061 CACTCGCCGC CGACAACCTG TCTCGCCGCG CGCATGCCCT GCAGCCGCCC CACAGAAATG
>138095–112> >53start1v1> 138118–20 Startcodon hsp60s ORF 1
138121 CTTCGGTTAC CCACAGT CTT TCGCCAGATG AGACCAGTGT CCAGGGTACT GGCTCCTCAT
>138138–56> >3start1v3> >138156–74> >5start1v4>
138181 CTCACTCGAG CTTATGCCAA AGATGTAAAA TTTGGTGCAG ATGCCCGAGC CTTAATGCTT
138241 CAAGGTGTAG ACCTTTTAGC CGATGCTGTG GCCGTTACAA TGGAGCCAAA GGGAAGAACA
138301 GTGATTATTG AGCAGAGCTG GGGAAGTCCC AACGTAACAA AAGATGGTGT GACTGTTGCA
>138318–33> >53start1v5>
138361 AAGTCAATTG ACTTGAAGGA TAAATATAAA AACATTGGAG CTAAACTTGT TCAAGATGTT
138421 GCCAATAACA CAAATGAAGA ATCTGGGGAT GGCACTACCA CTGCTACTGT ACTGGCAGGC
138481 TCTATAGCCA AGGAAGGCTT CCAGAAGATT AGCAAAGGTG CTAATCCAGT GGAAATCAGG
138541 AGAGGTGTGA TGTTAGCTGT TGATGCTGTA ATTGCTGAAC TTAAAAAGCA GTCTAAACCT
138601 GTGACCACCC CTGAAGAAAT TGCACAGGTT GCTATGATTT CTGCAAATGG AGACAAAGAA
138661 ATTGGCAATA TC ATCTCTGA TGCAATGAAA AAGGTTGGAA GAAAGGGTGT CATCACAGTA
<138673–93< <5stop1v1< <138693–712< <3stop1v2<
138721 AAGGATGGAA AAACACTGAA TGATGAATTA GAAATTATTG AAGGCATGAA GTTTGATTGA
<138761–78< <5stop1v3< 138778–80 Stopcodon hsp60s ORF 1
138781 GGGTATATTT CTCCATACTT TATTAATACA TCAAAAGGTC AGAAATGTGA ATTCCAGGAT
138841 GCCTATGTTC TGTTGAGTGA AAAGAAAATT TCTAGTGTCC AGTCCATTGT ACCTGCTCTT
138901 GAAATTGCCA ATGCTCACCA TAAGCCTTTG GTGATAATCG CTGAAGATGT TGATGGAGAA
138961 GCTCTAAGTA CACTCATCTT GAATAGGCTA AAGGTTGGTC TTCAGGTTGT GGCAGTCAAG
139021 GCTCCAGGGT TTGGTGACAA TAGAAAGAAC CAACTTAAAG ATATGGCTAT TGCTACTGGT
139063–65 Startcodon hsp60s ORF 2
139081 GGTGCAGTGT TTGGAGAAGA GGGGTTGACC CTGAATCTTG AAGATGTTCA GCCTCATGAC
>139085–104> >3start2v1> >139104–25> >53start2v2>
boldface = putative coding sequence; underlined = primer
Table 2.10: hsp60s: Chr. 5 Clone (AC091873, base position 137941–139140, Reverse Com-
plementary Sequence); Position of RT–PCR Primer
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139141 TTAGGAAAAG TTGGAGAGGT CATTGTGACC AAAGACGATG CCATGCTCTT AAAAG GAAAA
>139196–216>
139201 GGTGACAAGG CTCAACTTGA AAAACGTATT CAAGAAATCA TTGGGCAGTT AGATGTCACA
>3start2v3> >139216–36> >5start2v4>
139261 ACTAGTGAAT ATGAAAAGGA AAAACTGAAT GAATGGCTGG CAAAACTTTC AGATGGAGTA
139321 GTTGTGCTGA AGTTTGGTGG GACAAGTGAT GTTGAAGTGA ATGAAAAGAA AGACAGAGTT
139381 ACAGATGCCC TTAATGCTAC AAGAGCTGCT GTTGAAGGAG GCATTGTTTT GGGAGGGGGT
139441 TTTGCCCTCC TTCGATGCAT TCCAGCCTTG GACTCATTGA CTCCAGCTAA TGAAGATCAA
139501 AAAATTGGTA TGGAAATTGT TAAAAGAACA CTCAAAATTC CAGCAATGAC CACTGCTACG
139561 AATGCAGGTG TTGAAGGATC TTTGATAGTT GAGAAAATTA TGCAAAATTC CTCAGAAGTT
139621 GGTTATGATG CTATGG TTGG AGATTTTATG AATATGGTAG AAAAAGGAAT TATTGACCCA
<139637–59< <53stop2v1< <139671–87<
139681 ACAAAGCTTG TGAGAACTGC TTTATTGGAT GCTGCTGGTG TGGCCTCTCT GTTAACTACA
<53stop2v2< <139687–708< <3stop2v3<
139741 GCAGAAGTTG TAGTCACAGA AATTCCTAAA GAAGAGAAGG ACCCTGGAAT GGGTGCAATG
139801 GGTGGAATGG GAGGTGGTAT GGGAGGTGGC ATGTTCTAAC TCCTAGACTA GTGCTTTACC
139837–39 Stopcodon hsp60s ORF 2
139861 TTTATTAATG AACTGTGACA GGAAGCCCAA GGCAGTGTTC CTCACCAATA ACTTCAGAGA
139921 AGTCAGTTGG AGAAAATGAA AAAAAGGCTG GCTGAAAATC ACTATAACCA TCAGTTACTG
139981 GTTTCAGTTG ACAAAATATA TAATGGTTTA CTGCTGTCAT TGTCCATGCC TACAGATAAT
140041 TTATTTTGTA TTTTTGAATA AAAAACATTT GTACATTCCT GATACTGGGT ACAAGAGCCA
140101 TGTACCAATG TACTGCTTTC AACCTAAATC ACTGAGGCAT TTTTACTACT ATTCTGTTAA
140161 AATCAGGATT TTAGTACTTG CCACCACCAG ATGAGAAGTT AAGCAGTCTT TCTATGGAGA
140221 GTGAGAATAG TTGTGTACAA AGTAGAGAAA TATCCAATTA TGTGACAACC TTTGTGTAAT
140273 last base hsp60s
140281 AAAAATTTGT TTAGTTAAAA AAAAGTGATG TATTAGACAA CATTCTGTGT TTTCCCTTTT
140341 TAAACATATT CACTTAATTT TTGAAACTAC TGTATGGGGT AATAACTTAT TATAAAAGGC
boldface = putative coding sequence; underlined = primer
Table 2.11: hsp60s: Chr. 5 Clone (AC091873, base position 139141–140400, Reverse Com-
plementary Sequence); Position of RT–PCR Primer
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Primer Sequence, 5′ −→ 3′ TM % GC length
53Start1v1 TGCCCTGCAGCCGCCCCA 76.14 77.78 18
3Start1v3 CTTTCGCCAGATGAGACCA 59.93 52.63 19
5Start1v4 AGTGTCCAGGGTACTGGCT 57.13 57.89 19
53Start1v5 CTGGGGAAGTCCCAAC 54.31 62.50 16
5Stop1v1 CTTTTTCATTGCATCAGAGAT 54.62 33.33 21
3Stop1v2 TGACACCCTTTCTTCCAACC 59.94 50.00 20
5Stop1v3 AATCAAACTTCATGCCTT 50.34 33.33 18
3Start2v1 CAGTGTTTGGAGAAGAGGGG 59.69 55.00 20
53Start2v2 GTTGACCCTGAATCTTGAAGAT 57.25 40.91 22
3Start2v3 GAAAAGGTGACAAGGCTCAAC 58.83 47.62 21
5Start2v4 CTTGAAAAACGTATTCAAGAA 52.54 28.57 21
53Stop2v1 TACCATATTCATAAAATCTCCAA 53.36 26.09 23
53Stop2v2 GCTTTGTTGGGTCAATA 49.76 41.18 17
3Stop2v3 CCAATAAAGCAGTTCTCACAAG 56.76 40.91 22
TM = melting temperature; % GC = amount of GC nucleotides; length = number of nucleotides
Table 2.12: hsp60s: RT–PCR Primer
2.2.9.2 Protocols and Programs for the RT–PCR of hsp60s
The protocol is shown in Table 2.13. For all reactions, the thermocycler was preheated to
50◦C before use. All base pair positions in the program tables for RT–PCR of hsp60s refer
to the human chromosome 5 clone CTD–2577N22, reverse complementary sequence. Due
to their complexity, the programs are shown in detail in Appendix A.3, Tables A.5, A.6,
A.7, A.8 and A.9.
Template RNA 100–200 ng
Primer forward 0.6 µM = 30 pmol in 50 µl
Primer reverse 0.6 µM = 30 pmol in 50 µl
5x OneStep RT–PCR Buffer 10.0 µl
5x Q–Solution 10.0 µl
dNTP Mix (10 mM = 400 µM in 50 µl) 2.0 µl
RNase Inhibitor (10 Units) 0.25 µl
One Step Enzyme Mix 2.0 µl
RNAse free water ad 50 µl
Table 2.13: hsp60s: RT–PCR Protocol
2.2.10 Agarose gel electrophoresis
Agarose gel electrophoresis was used for separation, identification and purification of
the PCR and RT–PCR products (DNA). DNA is a negatively charged molecule. Under
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electrical current, it moves from the cathode to the anode. The agarose matrix separates
the molecules according to their size; small linear molecules are moving faster in the gel
matrix than larger ones.
For identification and PCR optimization of the partial hsp60 gene (exon 5 with 5’ and
3’ boundaries) and all gel electrophoresis of RT–PCR products, NuSieve GTG Agarose
(BMA by Biozym Scientific GmbH, Germany) was used with gel concentrations between
1 % and 2 %. For the separation und purification of the hsp60s gene, Seakem Gold
Agarose (BMA/FMC by Biozym Scientific GmbH, Germany) was used with a gel con-
centration of 0.4%.
Running buffer for all gels was 1X TBE (Tris–Borate–EDTA), stock solution 10X TBE.
The chemicals Boric Acid, EDTA and Tris Base were molecular biology grade (Merck Eu-
rolab GmbH, Calbiochem–Novabiochem Corporation, Germany). All gels were stained
with Gel Star Nucleic Acid Gel Stain (BMA/FMC by Biozym Scientific GmbH), final con-
centration of 1X. For loading DNA on all gels, Triple Dye Loading Buffer 6X (BMA by
Biozym Scientific GmbH, Germany) was used.
The gel results were documented on a LKB Bromma MacroVue Transilluminator (LKB
Bromma, Sweden) at a wave length of 302 nm. Pictures were taken with a Polaroid
GelCam with the appropriate filter kit for the Gel Star staining, using a Polaroid Film
Type 667 Electrophoresis Film (Polaroid GmbH, Germany). For determining the size
of DNA fragments, the marker Gene ruler 100 bp DNA ladder plus, as well as the
Lambda DNA/Eco130I(StyI)/MluI Marker, 17 and Lambda Mix Marker, 19 (MBI Fer-
mentas GmbH, Germany) were used. The fragment sizes of the individual marker lad-
ders are shown in Table 2.14.
Gene Ruler 100 bp Lambda Marker 17 Lambda Marker 19
3000 bp 700 bp 26282 bp 2419 bp 48502 bp 17053 bp
2000 bp 600 bp 19329 bp 2205 bp 38416 bp 15004 bp
1500 bp 500 bp 9824 bp 1882 bp 33498 bp 12220 bp
1200 bp 400 bp 7743 bp 1489 bp 29946 bp 10086 bp
1031 bp 300 bp 6223 bp 1268 bp 24508 bp 8614 bp
900 bp 200 bp 5090 bp 956 bp 23994 bp 8271 bp
800 bp 100 bp 4254 bp 925 bp 19397 bp 1503 bp
3472 bp 458 bp
2690 bp 421 bp
74 bp
Table 2.14: DNA Marker Ladders
2.2.11 DNA Sequencing
The sequencing of the DNA was performed using Cycle Sequencing with fluorescent
marked ddNTPs (one for each nucleotide in the DNA), described in the Training Course
Manual for Sequencing of Applied Biosystems/Applera Deutschland GmbH, Germany
(ABI PRISM Training Course 1999). The Genetic Analyzer and all reagents were supplied
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by the same company. The sequencing reaction is similar to a PCR reaction. Statistically,
for each normal nucleotide a fluorescent marked ddNTP (dideoxy nucleotide triphos-
phate) is inserted into the DNA chain at any given position. The ddNTP lacks the 3’–OH
group, thus it can not accept an incoming nucleotide in a polymerase reaction and the
DNA chain is interrupted. The products marked in this manner differ by exactly one
base and are separated by capillary electrophoresis. The Genetic Analyzer 200/240V 310
(GA310) was used for capillary electrophoresis and analysis. The fluorescence was de-
tected by an argon laser and captured by a CCD camera. Later on, the collected data was
analysed by the GA310 collection software.
All sequencing reactions were performed with Big Dye Terminator Cycle Sequencing
Ready Reaction Kits, versions 1.0, 1.1, and 2.0. All reactions were performed at room
temperature. Sequencing reactions with kits version 1.1 and above needed a preheating
step in the program. The purification of the sequencing reactions was performed using
Centri Sep Spin columns. The polymer used in the capillary electrophoresis was POP–6,
performance optimized polymer 6. For short DNA fragments (up to 400 base pairs), the
green capillary was used (47cm x 50 µmid) with the Seq POP6 Rapid (1ml) Filterset E
module: injection time 10–30 seconds, injection voltage 2.5 kV, run voltage 15.0 kV, run
temperature 50◦C, run time 20–36 min. For longer fragments, the red capillary (61 cm x
50 µmid) was used with the Seq POP6 (1ml) Filterset E module: injection time 30 seconds,
injection voltage 2.5 kV, run voltage 12.2 kV, run temperature 50◦C, run time 120 min.
All sequencing primers were self constructed. The software used in this process was
Primer3 (Rozen and Skaletsky 2000). Furthermore, all sequencing protocols and pro-
grams to the research project were adapted according to the ABI PRISM Training Course
1999.
2.2.11.1 Sequencing of hsp60 exon 5 with boundaries
The sequencing of the partial hsp60 gene was performed with the PCR primers (XXLH-
SEXON5IL, XXLHSEXON5IR) and the additional sequencing primer XXLHSEXON5IIR
(Section 2.2.6). The protocol and programs are shown in Tables 2.15 and 2.16. The pro-
grams SXXLHSV1 and SXXLHSV2 were used with the Big Dye Terminator Cycle Se-
quencing Ready Reaction Kit version 1.0.; SXXLHSV3 and SXXLHSV4 were used with
the Kit versions 1.1 and 2.0.
Template DNA 80–200 ng
Big Dye Reaction Mix 4 µl
Sequencing Primer 5 pmol
HPLC–water ad 20 µl
Table 2.15: hsp60s, Exon 5 with Boundaries: Sequencing Protocol
46
Program Steps Program, Primer Program, Primer
SXXLHSV1 SXXLHSV2
XXLHSEXON5IL/IR XXLHSEXON5IIR
1. Denaturation 10 sec 96◦C 10 sec 96◦C
2. Annealing 05 sec 55◦C 05 sec 45◦C
3. Extension 4 min 60◦C 4 min 60◦C
4. Cycles Goto 1 24 times Goto 1 24 times
5. Hold Forever 8◦C Forever 8◦C
Program Steps Program, Primer Program, Primer
SXXLHSV3 SXXLHSV4
XXLHSEXON5IL/IR XXLHSEXON5IIR
1. Preheating 1 min 96◦C 1 min 96◦C
2. Denaturation 10 sec 96◦C 10 sec 96◦C
3. Annealing 05 sec 55◦C 05 sec 45◦C
4. Extension 4 min 60◦C 4 min 60◦C
5. Cycles Goto 1 24 times Goto 1 24 times
6. Hold Forever 8◦C Forever 8◦C
Table 2.16: hsp60, Exon 5 with Boundaries: Sequencing Programs SXXLHSV1,
SXXLHSV2, SXXLHSV3 and SXXLHSV4
2.2.11.2 Sequencing of hsp60s
The sequencing of the hsp60s gene was performed with the PCR primer (Section 2.2.7)
and additional sequencing primers. The primers for the sequencing of the hsp60s gene
were constructed based on the sequence of the human hsp60 mRNA and the sequence of
the human hsp60 genomic DNA (Table 2.17). The letter L stands for the forward primer
”left”, the letter R stands for the reverse primer ”right”. The mRNA sequence of the
human chaperonin gene 60 with the primers is shown in Tables 2.18, and 2.19. The coding
sequence is located from base 25 to 1746. Primer sequences are underlined, their direction
is marked. The protocol and program are shown in Tables 2.20 and 2.21.
Primer Sequence, 5′ −→ 3′ TM % GC length
XLS1L (XLLEFT) GAC GAC CTG TCT CGC CG 61.65◦C 70.59 17
XLS2R TTC TTT GTC TCC GTT TGC AG 60.50◦C 50.00 20
XLS3L CCT GTG ACC ACC CCT GAA G 61.55◦C 63.16 19
XLS4R AGA GCA TGG CAT CGT CTT TG 59.96◦C 47.62 21
XLS5L GAG AAG AGG GAT TGA CCC TG 58.66◦C 55.00 20
XLS6R TCA ATG ATT CCT TTT TCC ACC 58.87◦C 38.10 21
XLS7L GTT CCT CAG AAG TTG GTT ATG ATG 59.07◦C 41.67 24
XLS8R(XLRIGHT) ACA CAA AGG TTG TCA CAT AAT TGG 60.08◦C 37.50 24
TM = melting temperature; % GC = amount of GC nucleotides; length = number of nucleotides
Table 2.17: hsp60s: Sequencing Primers
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5’ GACGACCTGT CTCGCCGAGC . . .
genomic hsp60 >3669–3685> >XLS1L>
1 CACGCTTGCC GCCGCCCCGC AGAAATGCTT CGGTTACCCA CAGTCTTTCG CCAGATGAGA
25–27 startcodon
61 CCGGTGTCCA GGGTACTGGC TCCTCATCTC ACTCGGGCTT ATGCCAAAGA TGTAAAATTT
121 GGTGCAGATG CCCGAGCCTT AATGCTTCAA GGTGTAGACC TTTTAGCCGA TGCTGTGGCC
181 GTTACAATGG GGCCAAAGGG AAGAACAGTG ATTATTGAGC AGGGTTGGGG AAGTCCCAAA
241 GTAACAAAAG ATGGTGTGAC TGTTGCAAAG TCAATTGACT TAAAAGATAA ATACAAGAAC
301 ATTGGAGCTA AACTTGTTCA AGATGTTGCC AATAACACAA ATGAAGAAGC TGGGGATGGC
361 ACTACCACTG CTACTGTACT GGCACGCTCT ATAGCCAAGG AAGGCTTCGA GAAGATTAGC
421 AAAGGTGCTA ATCCAGTGGA AATCAGGAGA GGTGTGATGT TAGCTGTTGA TGCTGTAATT
481 GCTGAACTTA AAAAGCAGTC TAAACCTGTG ACCACCCCTG AAGAAATTGC ACAGGTTGCT
>505–523> >XLS3L>
541 ACGATTTCTG CAAACGGAGA CAAAGAAATT GGCAATATCA TCTCTGATGC AATGAAAAAA
<548–567< <XLS2R<
601 GTTGGAAGAA AGGGTGTCAT CACAGTAAAG GATGGAAAAA CACTGAATGA TGAATTAGAA
661 ATTATTGAAG GCATGAAGTT TGATCGAGGC TATATTTCTC CATACTTTAT TAATACATCA
721 AAAGGTCAGA AATGTGAATT CCAGGATGCC TATGTTCTGT TGAGTGAAAA GAAAATTTCT
781 AGTATCCAGT CCATTGTACC TGCTCTTGAA ATTGCCAATG CTCACCGTAA GCCTTTGGTC
841 ATAATCGCTG AAGATGTTGA TGGAGAAGCT CTAAGTACAC TCGTCTTGAA TAGGCTAAAG
901 GTTGGTCTTC AGGTTGTGGC AGTCAAGGCT CCAGGGTTTG GTGACAATAG AAAGAACCAG
961 CTTAAAGATA TGGCTATTGC TACTGGTGGT GCAGTGTTTG GAGAAGAGGG ATTGACCCTG
>1001–1020> >XLS5L>
1021 AATCTTGAAG ACGTTCAGCC TCATGACTTA GGAAAAGTTG GAGAGGTCAT TGTGACCAAA
1081 GACGATGCCA TGCTCTTAAA AGGAAAAGGT GACAAGGCTC AAATTGAAAA ACGTATTCAA
<1081–1096< <XLS4R<
1141 GAAATCATTG AGCAGTTAGA TGTCACAACT AGTGAATATG AAAAGGAAAA ACTGAATGAA
1201 CGGCTTGCAA AACTTTCAGA TGGAGTGGCT GTGCTGAAGG TTGGTGGGAC AAGTGATGTT
1261 GAAGTGAATG AAAAGAAAGA CAGAGTTACA GATGCCCTTA ATGCTACAAG AGCTGCTGTT
1321 GAAGAAGGCA TTGTTTTGGG AGGGGGTTGT GCCCTCCTTC GATGCATTCC AGCCTTGGAC
1381 TCATTGACTC CAGCTAATGA AGATCAAAAA ATTGGTATAG AAATTATTAA AAGAACACTC
1441 AAAATTCCAG CAATGACCAT TGCTAAGAAT GCAGGTGTTG AAGGATCTTT GATAGTTGAG
1501 AAAATTATGC AAAGTTCCTC AGAAGTTGGT TATGATGCTA TGGCTGGAGA TTTTGTGAAT
>1514–1537> >XLS7R>
1561 ATGGTGGAAA AAGGAATCAT TGACCCAACA AAGGTTGTGA GAACTGCTTT ATTGGATGCT
<1563–1583< <XLS6R<
underlined = primer
Table 2.18: hsp60 mRNA: Sequencing Primer on M34664 with additional 5’ bases (1–1620)
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1621 GCTGGTGTGG CCTCTCTGTT AACTACAGCA GAAGTTGTAG TCACAGAAAT TCCTAAAGAA
1681 GAGAAGGACC CTGGAATGGG TGCAATGGGT GGAATGGGAG GTGGTATGGG AGGTGGCATG
1741 TTCTAACTCC TAGACTAGTG CTTTACCTTT ATTAATGAAC TGTGACAGGA AGCCCAAGGC
1744–1746 Stopcodon
1801 AGTGTTCCTC ACCAATAACT TCAGAGAAGT CAGTTGGAGA AAATGAAGAA AAAGGCTGGC
1861 TGAAAATCAC TATAACCATC AGTTACTGGT TTCAGTTGAC AAAATATATA ATGGTTTACT
1921 GCTGTCATTG TCCATGCCTA CAGATAATTT ATTTTGTATT TTTGAATAAA AAACATTTGT
1981 ACATTCCTGA TACTGGGTAC AAGAGCCATG TACCAGTGTA CTGCTTTCAA CTTAAATCAC
2041 TGAGGCATTT TTACTACTAT TCTGTTAAAA TCAGGATTTT AGTGCTTGCC ACCACCAGAT
2101 GAGAAGTTAA GCAGCCTTTC TGTGGAGAGT GAGAATAATT GTGTACAAAG TAGAGAAGTA
2161 TCCAATTATG TGACAACCTT TGTGTAATAA AAATTTGTTT AA
<2162–2185< <XLS8R<
underlined = primer
Table 2.19: hsp60 mRNA: Sequencing Primer on M34664 (bases 1621–2202)
Template DNA 100 ng
Big Dye Reaction Mix 4 µl
Sequencing Primer 4 pmol
HPLC–water ad 20 µl
Table 2.20: hsp60s: Sequencing Protocol
1. 05 sec 96◦C Denaturation
2. 1.5 min 60◦C Annealing
3. 1.5 min 50◦C Extension
4. Goto 1, 24 times Cycles
5. Forever 4◦C Hold
Table 2.21: hsp60s: Sequencing Program AT3S, Primer XLS1L–XLS8R
2.2.11.3 Direct sequencing of PCR fragments with different size from SIDS DNA
The sequencing parameters are the same as for the partial hsp60 gene (Section 2.2.11.1),
and the hsp60s gene (Section 2.2.11.2).
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2.2.12 Software tools used
2.2.12.1 Primer construction
For primer construction, the Primer3 software was used (Rozen and Skaletsky 2000). This
software calculates certain characteristics of a primer. Some of these can be constrained
by the user to constant values beforehand. The most important feature is the melting
temperature TM, which directly influences the annealing temperature TA. At this tem-
perature, the binding between primer and DNA occurs in the PCR. Additionally, Primer3
determines the GC–concentration and the length of the primer, that also influence the
melting temperature.
2.2.12.2 Expression analysis
The most important feature of a gene is its expression (production of a protein). Before
actual experiments are performed, newly discovered genes can be tested with software.
Certain characteristics, such as transcription factor binding sites in the promoter region
of a gene, show consensus sequences. Based on the latter, software can detect these sites
in a DNA sequence and assumptions on a putative expression can be made.
The MATCH software was used for testing of putative transcription factor binding
sites of hsp60s. Match is a weight matrix–based tool for searching putative transcription
binding sites in DNA sequences. It uses the matrix library of the TRANSFAC Database,
version 7.4.1 (Section 2.1.3). Also the TRANSPLORER promoter and gene finder soft-
ware (TRANSPLORER 2004), version 1.2, was used for analysis of putative promoter
sequences of hsp60s. The matrices used in Transplorer 1.2 are from the TRANSFAC
Database. MATCH, TRANSPLORER and TRANSFAC were made available for this re-
search, courtesy of Biobase Biological Databases GmbH.
2.2.12.3 Protein parameters and alignment
If an open reading frame (ORF) is found in a DNA sequence, it can be translated into
a protein sequence. For humans, the standard genetic code is used. The translation of
the hsp60s gene from DNA to protein was performed with the EditSeq module of the
DNASTAR Lasergene 99 Software (EditSeq 1999; GATC GmbH, Germany). Based on the
protein sequence, various physical and chemical parameters can be calculated to classify
the putative protein. For determining the protein parameters of Hsp60s1 and Hsp60s2,
the ProtParam tool (  	
	
ﬀﬁﬂﬂ
ﬃ
 !" #ﬁ ) of the Swiss–Prot
Database (SWISSPROT 2004) was used. This tool allows, among others, the computa-
tion of the molecular weight, of the amino acid composition and the estimated half–life.
The protein sequence can also be used for an alignment. An alignment is the basic prin-
ciple of a sequence analysis (DNA and protein). Two or more sequences are compared in
a nucleotide by nucleotide (amino acid by amino acid) fashion. The same nucleotides or
amino acids in the same position are called a match; if they are different, they are called
a mismatch. Insertions or deletions between positions are called gaps. The Lipman–
Pearson algorithm was used for the protein alignment of Hsp60 and Hsp60s1/Hsp60s2.
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It constructs tables of k–tuples to find regions of similarity. The alignment is then opti-
mized using a trimmed–down version of the Needleman–Wunsch method. The original
research was done by Lipman and Pearson 1985 (Lipman and Pearson 1985). This algo-
rithm was applied using the MegAlign software (MegAlign 1999).
2.2.12.4 DNA sequence analysis
One major part of this thesis consists of a mutation analysis. SIDS cases and controls were
examined for genetic differences. Another major part of this thesis consists of the analysis
of a newly discovered gene, including an analysis of its possible phylogenetic tree. Both
parts are essentially performed with a sophisticated analysis of the DNA sequence.
The collection software of the Genetic Analyzer GA310 presents the results of a se-
quencing analysis in two forms: The DNA sequence, in FASTA format, e.g., ACT-
TACGT. . . . This is derived by interpreting the so–called electropherogram, a waveform
representation of the analogue signal captured by the CCD camera. If the incoming signal
is distorted, the software may not be able to to interpret it correctly. In these cases, manual
verification and/or translation of the electropherogram is required. For electropherogram
viewing and editing, the CHROMAS software, version 1.45, was used (McCarthy 1998).
For editing the FASTA–sequences, the EditSeq module of the DNASTAR Lasergene 99
Software (EditSeq 1999; GATC GmbH, Germany) was used.
The DNA sequences obtained from the SIDS cases and controls were then aligned with
a reference sequence (pairwise alignment), to detect any mutation. For the construction
of a phylogenetic tree, a multiple alignment is the prerequisite. Sequence alignment was
performed locally with the MegAlign module of the DNASTAR Lasergene 99 Software
(MegAlign 1999; GATC GmbH, Germany), except the Jotun–Hein algorithm, which was
performed with the more recent DNASTAR Lasergene Software, version 5.08, courtesy of
GATC GmbH. Pairwise alignment of DNA sequences was performed with the Wilbur–
Lipman and the Martinez/Needleman–Wunsch algorithms. Multiple alignment was per-
formed using the Jotun–Hein algorithm.
The Wilbur–Lipman method is used for highly divergent DNA sequences, e.g., se-
quences of unknown ancestry. Another application is the comparison of large nucleotide
sequences. Both applications are performed with a small k–tuple. For example if k has
the value of 5, the algorithm searches for exact matches of the length 5 in the matrix.
The Wilbur–Lipman method can be interpreted as a word method in a DotPlot setting
(Hansen 2001). The original research on this method was done by Wilbur and Lipman
1983 (Wilbur and Lipman 1983). The Martinez/Needleman–Wunsch method is used for
the pairwise alignment of closely related DNA sequences. The original research on this
method was done by Needleman and Wunsch (Needleman and Wunsch 1970) and Mar-
tinez (Martinez 1983). The Jotun–Hein Method constructs a phylogenetic tree by examin-
ing sequence pairs and creating the best possible arrangement of ancestral branches. This
method is used for multiple sequences that are related or possibly related. The original
research on this method was done by Hein (Hein 1990).
Multiple alignment can be performed on a grand scale. A DNA sequence can be aligned
to an entire database. For genomewide alignments with GenBank the Blast Tool was used.
The Blast algorithm (Basic Local Alignment Search Tool) is a heuristic search algorithm
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for fast database alignments. It is used for many different inputs (e.g., DNA, proteins;
small and large sequences) at GenBank (GENBANK 2004). The original research on this
method was done by Atschul et al. (Atschul et al 1990). The current version of this method
has been programmed by Atschul et al. (Atschul et al 1997).
2.2.12.5 Statistics
Statistical methods were applied to determine, if the results of the mutation analysis were
correlated with the Sudden Infant Death Syndrome or could be explained by chance. The
purpose of a statistical test is to determine if the obtained results provide a reason to re-
ject the null hypothesis (also called statistical hypothesis). This defines the probability
that a given result could also be a product of chance factors. An example of the null
hypothesis would be, that the sex has no influence on the risk of dying from Sudden In-
fant Death. A significant difference between a SIDS group and a control group rejects the
null hypothesis, indicating that the sex does have an influence on the risk of dying on
Sudden Infant Death. A finding (for example, the influence of the sex on Sudden Infant
Death) is described as statistically significant, if it can be demonstrated, that the probabil-
ity of obtaining such a difference by chance only is relatively low. The significance level,
or p–rating, describes the probability that a given result could have been originated by
chance. A p–rating of 0.05 (5 %) is considered significant, a p–rating of 0.01 (1 %) highly
significant. A p–rating of 0.10 (10 %) is considered a trend.
In this thesis, two types of data were analysed statistically: nominal and metric data.
Nominal characteristics are qualitative characteristics, e.g., sex. For these characteristics
the Chi–Square–Test was used. In case of an insufficient sample size, the exact Fisher–Test
was used. The tests were used in a two–tailed manner, testing for differences between
groups, e.g., male and female, SIDS cases and controls. Additionally, the binary logistic
regression was used. It allows an analysis of more than two nominal characteristics as
well as the integration of metric data in the results. Metric characteristics are quantita-
tive characteristics, e.g., the age. For testing if metric data was Gauss–distributed, the
Kolmogoroff–Smirnov–Test was used in a two–tailed manner. It is also possible to take
the skew as an indication for a Gauss–distribution, if it is used as a prerequisite for the
t–test (mean test). A skew between -1.5 and +1.5 can be assumed to be Gauss–distributed,
and enables the application of the t–test (Geerlings 2004). Statistical analyses were per-
formed with the Statistical Package for the Social Sciences (SPSS), version 11.5.1 (SPSS
2002).
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3 Results
The following text presents the major findings discovered by applying the experimental
procedures described in Chapter 2.
3.1 SIDS cases and controls
The SIDS cases are classified according to their SIDS criteria (defined in Section 1.7.3). To
this end, these risk factors and autopsy results were analysed based on the detail in the
autopsy protocols, supported by information from the German Study on Sudden Infant
Death (Findeisen et al 2003). Statistical methods were then applied to verify these results,
so that a random formation of the SIDS criteria could be ruled out.
The controls were chosen by the RM/MHH matched in age and sex to the SIDS cases,
thus only these characteristics of the controls could be evaluated. The age and sex data of
the individual SIDS cases and controls, as well as the information of the SIDS criteria is
listed in the Appendix (Tables A.1, A.2, A.3, A.4).
3.1.1 Sex Distribution
The sex distribution is shown in Table 3.1 and in Figure 3.1. 56 male and 35 female SIDS
cases were examined in this thesis. Statistically, there is a significant difference between
the number of male and female samples (Chi–Square–Test: p=0.028). More SIDS cases are
male than female. For the control group, 59 male and 49 female children were examined.
Statistically, there is no significant difference between the number of male and female
samples (Chi–Square–Test: p=0.336). No significant statistical difference was found com-
paring the sex of SIDS cases (N=91) and controls (N=108), Chi–Square–Test p=0.326.
SIDS Control
Sex Frequency % Frequency %
1 (♂) 56 61.54 59 54.63
2 (♀) 35 38.46 49 45.37
∑ 91 100 108 100
Table 3.1: SIDS Cases and Controls: Sex Distribution and Frequencies
53
010
20
30
40
50
60
70
%
SIDS Control
Sex
♂ white bar
♀ black bar
Figure 3.1: SIDS cases and Controls: Sex – Distribution and Frequency
3.1.2 Age Distribution
91 SIDS cases were examined, ranging in age from 13 to 341 days (1–12 months), and 108
controls, ranging from 103 to 361 days (3–12 months) of age. The statistical parameters
for the age in days are shown in Table 3.2.
Statistics SIDS Control
N 91 108
Arithmetic mean 116.5165 274.3704
Standard error arithmetic mean 8.05029 4.50798
Median 95.000 266.000
Deviation 76.79487 46.84825
skew 1.216 -0.709
Standard error skew 0.253 0.233
Minimum 13.00 103.00
Maximum 341.00 361.00
Table 3.2: SIDS Cases and Controls: Age in Days – Statistics
The frequencies and percentages of the SIDS cases and controls according to age and sex
are shown in Tables 3.3 and 3.4, the corresponding Figures are 3.2 and 3.3. The frequen-
cies and percentages comparing the ages of SIDS cases and controls are shown in Table
3.5 and Figure 3.4. The SIDS cases are Gauss–distributed. The Kolmogoroff–Smirnov–
Test calculated a p–rating of 0.053. For the controls, the same test calculated a p–rating
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of 0.001, indicating that the control are not Gauss–distributed. The reason for this odd-
ity lies within the nature of the controls: Most of the controls (N=104) are older than 8
months due the nature of paternity testing with blood phenotypes. Certain tests are only
possible after the child is about 8 months old (the phenotypes of the blood factors are not
developed until then). All younger controls are children who did not die of SIDS (N=4).
For comparison with SIDS cases, the chosen controls are suitable: By definition the age
of SIDS cases ranges between 8 and 365 days (Beckwith 2003, Findeisen et al 2003), all
controls are within these bounds.
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Age SIDS ♂ ♀
Month Frequency % Frequency % Frequency %
1 5 5.5 2 3.6 3 8.6
2 18 19.8 14 25.0 4 11.4
3 20 22.0 14 25.0 6 17.1
4 13 14.3 7 12.5 6 17.1
5 11 12.1 6 10.7 5 14.3
6 9 9.9 5 8.9 4 11.4
7 5 5.5 4 7.1 1 2.9
8 1 1.1 1 1.8 0 0.0
9 4 4.4 2 3.6 2 5.7
10 0 0.0 0 0.0 0 0.0
11 3 3.3 1 1.8 2 5.7
12 2 2.2 0 0.0 2 5.7
∑ 91 100.00 56 100.00 35 100.00
Table 3.3: SIDS cases: Age and Sex – Distribution and Frequency
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Figure 3.2: SIDS cases: Age and Sex – Distribution and Frequency
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Age SIDS ♂ ♀
Month Frequency % Frequency % Frequency %
1 0 0.0 0 0.0 0 0.0
2 0 0.0 0 0.0 0 0.0
3 0 0.0 0 0.0 0 0.0
4 2 1.9 1 1.7 1 2.0
5 1 0.9 1 1.7 0 0.0
6 1 0.9 1 1.7 0 0.0
7 1 0.9 1 1.7 0 0.0
8 0 0.0 0 0.0 0 0.0
9 55 50.9 29 49.2 26 53.1
10 19 17.6 11 18.6 8 16.3
11 15 13.9 7 11.9 8 16.3
12 14 13.0 8 13.6 6 12.2
∑ 108 100.00 59 100.00 49 100.00
Table 3.4: Controls: Age and Sex – Distribution and Frequency
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Figure 3.3: Controls: Age and Sex – Distribution and Frequency
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Age SIDS Control
(Month) Frequency % Frequency %
1 5 5.5 0 0.0
2 18 19.8 0 0.0
3 20 22.0 0 0.0
4 13 14.3 2 1.9
5 11 12.1 1 0.9
6 9 9.9 1 0.9
7 5 5.5 1 0.9
8 1 1.1 0 0.0
9 4 4.4 55 50.9
10 0 0.0 19 17.6
11 3 3.3 15 13.9
12 2 2.2 14 13.0
∑ 91 100 108 100
Table 3.5: SIDS Cases and Controls: Age in Month – Distribution and Frequency
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Figure 3.4: Sid cases and Controls: Age in Month – Distribution and Frequency
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3.1.3 Analysis of SIDS criteria
The SIDS criteria are shown in Table 3.6. The individual criteria are classified as being
”present” (asserted by the autopsy protocol) or ”not present” (controverted by the au-
topsy protocol or unknown). The complete information on the SIDS criteria for the indi-
vidual SIDS cases are shown in the Appendix (Section A.2, Tables A.3 A.4). The results of
the evaluation of epidemiological/general characteristic and autopsy data follow:
Male sex The SIDS cases contain more male than female children. The Chi–Square–Test
indicates a significant difference between the sexes, p=0.028 (Section 3.1.1).
Age between 2 to 4 month More than half of the SIDS cases died at this age (51 the 91,
see also Section 3.1.2).
Preterm Birth Only 13 of the 91 SIDS cases were documented preterm births. Most of the
autopsy protocols contained no information regarding a preterm birth. The ratio
between male and female children concurs with the entire sample.
Prone sleeping Over 70 % of the cases with a documented position in the death scene
(N=61) were found prone.
Heat stress The binary logistic regression shows, that age is statistically significant
(p=0.017). The higher the age, the higher is the probability of SIDS cases show-
ing heat stress in the death scene. This result should be taken cautiously due to the
relatively small number of samples showing heat stress (N=12).
Smoking Nicotine abuse by the mother was documented in 10 of 91 SIDS cases. Most of
the autopsy protocols contained no information regarding parents smoking.
Petechiae in Pleura About two third of the SIDS cases showed petechiae in the pleura.
The Chi–Square–Test indicates a significant difference between the sexes, p=0.004
(binary logistic regression: p=0.002). Male children dying on Sudden Infant Death
Syndrome have a much higher probability showing petechiae in the pleura than
female children.
Petechiae in Epicardium About two third of the SIDS cases showed petechiae in the
epicardium. The binary logistic regression shows that age is statistically significant
(p=0.047). The higher the age, the higher the probability of petechiae in the epi-
cardium of SIDS cases.
Petechiae in Thymus About two third of the SIDS cases showed petechiae in the thy-
mus. The binary logistic regression shows that age is statistically significant
(p=0.026). The higher the age, the higher the probability of petechiae in the thy-
mus of SIDS cases.
Oedemata in the respiratory tract About one third of the SIDS cases showed oede-
mata in the respiratory tract.
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Table 3.6: SIDS cases – Frequencies of SIDS criteria
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Foam in the respiratory tract About one third of the SIDS cases showed foam in the
respiratory tract. The Chi–Square–Test indicates a highly significant difference be-
tween the sexes, p=0.000 (binary logistic regression p=0.001). 27 male (90.00 % of the
30 documented cases), but only 3 female children (10.00 %) showed foam in the res-
piratory tract. Male children dying on Sudden Infant Death Syndrome have a much
higher probability of showing foam in the respiratory tract than female children.
Hemorrhage in the respiratory tract About two thirds of the SIDS cases showed hem-
orrhage in the respiratory tract. The Chi–Square–Test indicates a trend in differ-
ence between the sexes, p=0.069. The binary logistic regression confirms the trend:
p=0.039. Female children dying on Sudden Infant Death Syndrome have a higher
probability of showing hemorrhage in the respiratory tract than male children. The
binary logistic regression also shows a trend (p=0.094), indicating a connection be-
tween the age and hemorrhage in the respiratory tract. The higher the age, the lower
the probability of hemorrhage occurring in the respiratory tract of SIDS cases.
Based on the SIDS criteria it can be concluded, that the SIDS cases examined in this
thesis are typical SIDS cases.
3.2 Mutations in the human chaperonin gene hsp60
The research on gene variations in SIDS cases leads to the following conclusion: SIDS
cases show more variations than controls (see also Section 1.7.4). It was examined,
whether this effect occurs in the partial human hsp60 gene, namely in its exon 5 with
boundaries. To detect any mutation, both strands of the exon 5 and parts of the adjacent
introns 4 and 5 were amplified and sequenced in all SIDS cases and all controls. The
mutation analysis was verified using statistical methods, in order to disprove a possible
random formation of the mutations.
3.2.1 The mutation N158S in exon 5 of hsp60
The size of the hsp60 PCR fragment of exon 5 with boundaries (380 bp) was verified on an
agarose gel (Figure 3.5). The outer lanes, 1 and 6, show the Gene Ruler 100bp marker lad-
der, the inner lanes, 2. . . 5, show the hsp60 PCR fragment. The DNA and protein sequence
of exon 5 are shown in Table 3.7.
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Figure 3.5: 1% Agarose Gel; PCR product of the partial human hsp60 gene, including exon
5 with 5’ and 3’ boundaries just below 400 bp
gtt gct acg att tct gca aac gga gac aaa gaa att
V A T I S A N G D K E I
145 146 147 148 149 150 151 152 153 154 155 156
ggc aat atc atc tct gat gca atg aaa aaa gtt gga
G N I I S D A M K K V G
157 158 159 160 161 162 163 164 165 166 167 168
aga aag ggt gtc atc aca gta aag
R K G V I T V K
169 170 171 172 173 174 175 176
Table 3.7: Exon 5 of the human hsp60 gene: DNA and protein sequence
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The sequences obtained in this manner were aligned against the human hsp60 gene, us-
ing the Martinez/Needleman–Wunsch algorithm. No amino acid variation N158S (muta-
tion in the AAT codon) was found in either of the SIDS cases or controls. Furthermore, no
other mutation in the complete exon 5 of human hsp60 could be discovered (Table 3.8).
A subset of these results (sequencing of exon 5 in 60 SIDS cases and 60 controls) were
published in 2002 (Teske et al 2002).
DNA Sequence SIDS cases Controls
Variation N158S 0/91 (0 %) 0/108 (0 %)
Other mutations in exon 5 0/91 (0 %) 0/108 (0 %)
Table 3.8: Number of mutations in the exon 5 of the human hsp60 gene
3.2.2 The deletions in intron 5 of hsp60
In the search for the mutation N158S in the exon 5, parts of the adjacent upstream and
downstream introns (number 4 and 5) to exon 5 were also amplified and sequenced. In
the case of intron 4, no variations in the DNA of the hsp60 gene were found. However,
two kinds of deletion in the intron 5 of the human hsp60 gene were discovered, in both
SIDS cases and controls. The two deletions did not occur simultaneously in either SIDS
cases or controls. The distribution of the deletions is shown in Table 3.9.
The first deletion affects the bases AG at positions 8957–8958 in the human hsp60
gene, hence named deletion AG; the second is a deletion of 24 bases (TATGAT-
CAAAAGTTTGAGTTATCT) at positions 8885–8908, hence named deletion 24 (see Table
3.10). The deletions are marked in boxes.
DNA Sequence SIDS cases Controls
Deletions in intron 5 16/91 (17.60 %); 11 ♂, 5 ♀ 11/108 (10.20 %); 3 ♂, 8 ♀
Deletion AG 12/91 (13.20 %); 10 ♂, 2 ♀ 8/108 (7.40 %); 3 ♂, 5 ♀
Deletion 24 4/91 (4.40 %); 1 ♂, 3 ♀ 3/108 (2.80 %); 0 ♂, 3 ♀
Table 3.9: Number of mutations in the intron 5 of the human hsp60 gene
Deletion 24 The binary logistic regression with a p–rating of 0.043 indicates a statistically
significant difference between the SIDS cases and controls regarding the sex. All 3
controls with the deletion 24 are female. Of the 4 SIDS cases 3 were female. This
result should be considered cautiously due to the small number of deletions in each
group.
Deletion AG The binary logistic regression detects a statistically significant difference
between the SIDS cases and controls (p=0.036): More SIDS cases than controls show
the deletion AG (Figure 3.6). Among the SIDS cases, the male children show more
deletions AG than the female.
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Accumulated deletions in the entire intron 5 The binary logistic regression detects a
statistically significant difference between the SIDS cases and controls (p=0.036) in
the overall intron 5. The SIDS cases seem to be affected more with deletions in the
hsp60 gene than the controls (Figure 3.7).
8641 CCCCTGGATG GAAGTATCAA TTTGGAAGTT
ACTAGGAAAA GGTAAGGGAA CTGACTGAGG
>8681–8700> >XXLHSEXON5IL>
8701 ACACTAGGCT TACCTTTTAA TTTCGAAGAG
TAACTGGATT ATTTCAGGTT GCTACGATTT
8761 CTGCAAACGG AGACAAAGAA ATTGGCAATA
TCATCTCTGA TGCAATGAAA AAAGTTGGAA
8821 GAAAGGGTGT CATCACAGTA AAGGCAAGTG
8748–8843 exon 5
TGTTTGTATT TTTAAAGATA ATTTTGAGTT
8881 ATCT TATGAT CAAAA GTTTG AGTTATCT GA
<8896–8915< <XXLHSEXON5IIR<
TGATCAAAAC TGAATTTTTC AAACAGAAAA
8941 ATTCTGTTTT AAAAAC AG TG CTTTTTTTAT
TCCTTCATAT GTAGTCTCAG CACATGTATA
<8981–9001< <XXLHSEXON5IIIR<
9001 GAATAAAGTA CTTACTGTGT TTTATGTGAA
TTAGCCTTTG CTGCATGAAA TGAATCCATC
<9041–9060< <XXLHSEXON5IR<
boxes = deletions in intron 5
Table 3.10: Deletions in the intron 5 of the human hsp60 gene
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Figure 3.6: Binary logistic regression of the deletion AG in intron 5 in the human hsp60
gene in SIDS cases and Controls
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Figure 3.7: Binary logistic regression of the accumulated deletions in intron 5 in the human
hsp60 gene in SIDS cases and Controls
66
A comparison between SIDS cases and controls with regard to correlations of SIDS
criteria and deletions in the intron 5 of the human hsp60 gene, discovered only two sig-
nificant results:
• Male children seem to be affected more with a deletion AG than female, confirming
the risk factor ”male sex”, already explained above.
• Statistically significant more SIDS cases with a deletion AG showed no petechiae in
the thymus (binary logistic regression: p=0.017).
These results of the mutation analysis of exon 5 with boundaries are similar to other
genetic variations in Sudden Infant Death. All show the same phenomenon: SIDS cases
seem to have more genetic variations (deletions, polymorphisms, mutations) than con-
trols (for a detailed description, see Section 4.2).
3.3 hsp60s, a new member/pseudogene of the HSP60
family
3.3.1 Gene Sequence of hsp60s
The original intention was to amplify the coding part of the human genomic hsp60 gene
(exons 2–12 with introns, size 13248 base pairs) for the direct sequencing approach. The
latter was planned to be used in mutation analysis of SIDS cases and controls. When
the size of the expected hsp60 PCR fragment (13248 bp) was verified on an agarose gel
(Figure 3.8), no such fragment was found on the gel. Instead, a very prominent fragment
showed up at 2205 bp of the Lambda 17 marker ladder.
The fragment was extracted from the gel and the primers XLLEFT and XLRIGHT were
used for sequencing. The sequences obtained appeared to be very similar to the mRNA
of the human chaperonin gene (hsp60 gene). The fragment size (about 2200 bp) was
also similar to the size of the hsp60 mRNA (2202 bp). It was suspected to be either a
pseudogene or an inducible alternative to the hsp60 gene.
Inducible alternatives are known for some heat shock proteins, e.g., the human heat
shock protein gene hsp70. It exists in two forms: The first is the cognate or constitutive
form hsc70 (GAN Y00371), protein Hsc70 (SPAN P11142). It contains introns and is a
regular molecular chaperone and house–keeping gene (Tavaria et al 1996; Tavaria et al
1995). The second is the stress (especially heat) inducible intronless form hsp70 (GAN
BC002453), protein Hsp70 (SPAN P08107), which can be expressed very quickly in emer-
gency situations (Tavaria et al 1996; Wu et al 1985).
Based on the assumption that there may be a similar occurrence for the hsp60 gene,
it was decided to use the sequence of the hsp60 mRNA as a template for constructing
additional sequencing primers (Section 2.2.11.2). With these primers, it was possible to
sequence the entire fragment (Table 3.11) between the PCR primer pair XLLEFT and XL-
RIGHT. The putative start and stop codons are marked in boxes, the putative coding
sequences are marked in boldface. The fragment was named hsp60s (s for short) analo-
gously to the regular hsp60 gene, which is much longer. The GAN for hsp60s is AF380943
(Teske et al 2001).
The grade of similarity between the hsp60s gene and the human hsp60 gene mRNA
was determined, using the Martinez/Needleman–Wunsch algorithm. The result showed
a high similarity of 97.5 %, indicating that they are closely related. The hsp60s gene may
therefore be a member of the Chaperonin (HSP60) gene family. The alignment is shown
in Figures 3.9, 3.10, 3.11 and 3.12. The differences (substitutions) between the two genes
are marked in boxes.
Marker 17
26282 bp
19329 bp
3472 bp
2690 bp
2419 bp
2205 bp
1882 bp
1489 bp
1268 bp
Marker 17
hsp60s
 
9824 bp
7743 bp
6223 bp
5090 bp
4254 bp
1268 bp
1489 bp
1882 bp
2205 bp2419 bp
2690 bp
3472 bp
4254 bp
5090 bp
6223 bp
9824 bp
7743 bp
19329 bp
26282 bp
 
Marker 17 hsp60s
Figure 3.8: 0.4% Agarose gel: PCR product of hsp60s at 2205 bp of the Lambda 17 marker
ladder
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1 CCTGCAGCCG CCCCACAGAA ATG CTTCGGT TACCCACAGT CTTTCGCCAG ATGAGACCAG
putative Start Codon hsp60s1
61 TGTCCAGGGT ACTGGCTCCT CATCTCACTC GAGCTTATGC CAAAGATGTA AAATTTGGTG
121 CAGATGCCCG AGCCTTAATG CTTCAAGGTG TAGACCTTTT AGCCGATGCT GTGGCCGTTA
181 CAATGGAGCC AAAGGGAAGA ACAGTGATTA TTGAGCAGAG CTGGGGAAGT CCCAACGTAA
241 CAAAAGATGG TGTGACTGTT GCAAAGTCAA TTGACTTGAA GGATAAATAT AAAAACATTG
301 GAGCTAAACT TGTTCAAGAT GTTGCCAATA ACACAAATGA AGAATCTGGG GATGGCACTA
361 CCACTGCTAC TGTACTGGCA GGCTCTATAG CCAAGGAAGG CTTCCAGAAG ATTAGCAAAG
421 GTGCTAATCC AGTGGAAATC AGGAGAGGTG TGATGTTAGC TGTTGATGCT GTAATTGCTG
481 AACTTAAAAA GCAGTCTAAA CCTGTGACCA CCCCTGAAGA AATTGCACAG GTTGCTATGA
541 TTTCTGCAAA TGGAGACAAA GAAATTGGCA ATATCATCTC TGATGCAATG AAAAAGGTTG
601 GAAGAAAGGG TGTCATCACA GTAAAGGATG GAAAAACACT GAATGATGAA TTAGAAATTA
661 TTGAAGGCAT GAAGTTTGAT TGA GGGTATA TTTCTCCATA CTTTATTAAT ACATCAAAAG
putative Stop Codon hsp60s1
721 GTCAGAAATG TGAATTCCAG GATGCCTATG TTCTGTTGAG TGAAAAGAAA ATTTCTAGTG
781 TCCAGTCCAT TGTACCTGCT CTTGAAATTG CCAATGCTCA CCATAAGCCT TTGGTGATAA
841 TCGCTGAAGA TGTTGATGGA GAAGCTCTAA GTACACTCAT CTTGAATAGG CTAAAGGTTG
901 GTCTTCAGGT TGTGGCAGTC AAGGCTCCAG GGTTTGGTGA CAATAGAAAG AACCAACTTA
961 AAGAT ATG GC TATTGCTACT GGTGGTGCAG TGTTTGGAGA AGAGGGGTTG ACCCTGAATC
putative Start Codon hsp60s2
1021 TTGAAGATGT TCAGCCTCAT GACTTAGGAA AAGTTGGAGA GGTCATTGTG ACCAAAGACG
1081 ATGCCATGCT CTTAAAAGGA AAAGGTGACA AGGCTCAACT TGAAAAACGT ATTCAAGAAA
1141 TCATTGGGCA GTTAGATGTC ACAACTAGTG AATATGAAAA GGAAAAACTG AATGAATGGC
1201 TGGCAAAACT TTCAGATGGA GTAGTTGTGC TGAAGTTTGG TGGGACAAGT GAtGTTGAAG
1261 TGAATGAAAA GAAAGACAGA GTTACAGATG CCCTTAATGC TACAAGAGCT GCTGTTGAAG
1321 GAGGCATTGT TTTGGGAGGG GGTTTTGCCC TCCTTCGATG CATTCCAGCC TTGGACTCAT
1381 TGACTCCAGC TAATGAAGAT CAAAAAATTG GTATGGAAAT TGTTAAAAGA ACACTCAAAA
1441 TTCCAGCAAT GACCACTGCT ACGAATGCAG GTGTTGAAGG ATCTTTGATA GTTGAGAAAA
1501 TTATGCAAAA TTCCTCAGAA GTTGGTTATG ATGCTATGGT TGGAGATTTT ATGAATATGG
1561 TAGAAAAAGG AATTATTGAC CCAACAAAGC TTGTGAGAAC TGCTTTATTG GATGCTGCTG
1621 GTGTGGCCTC TCTGTTAACT ACAGCAGAAG TTGTAGTCAC AGAAATTCCT AAAGAAGAGA
1681 AGGACCCTGG AATGGGTGCA ATGGGTGGAA TGGGAGGTGG TATGGGAGGT GGCATGTTC T
1741 AA CTCCTAGA CTAGTGCTTT ACCTTTATTA ATGAACTGTG ACAGGAAGCC CAAGGCAGTG
putative Stop Codon hsp60s2
1801 TTCCTCACCA ATAACTTCAG AGAAGTCAGT TGGAGAAAAT GAAAAAAAGG CTGGCTGAAA
1861 ATCACTATAA CCATCAGTTA CTGGTTTCAG TTGACAAAAT ATATAATGGT TTACTGCTGT
1921 CATTGTCCAT GCCTACAGAT AATTTATTTT GTATTTTTGA ATAAAAAACA TTTGTACATT
1981 CCTGATACTG GGTACAAGAG CCATGTACCA ATGTACTGCT TTCAACCTAA ATCACTGAGG
2041 CATTTTTACT ACTATTCTGT TAAAATCAGG ATTTTAGTAC TTGCCACCAC CAGATGAGAA
2101 GTTAAGCAGT CTTTCTGTGG AGAGTGAGAA TAGTTGTGTA CAAAGTAGAG AAATATCCAA
2161 TTATGTGACA ACCTTT
boldface = putative coding sequences
Table 3.11: DNA Sequence of hsp60s; GAN AF380943 (Teske et al 2001)
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Figure 3.9: Alignment between human hsp60s DNA (AF380943) and human hsp60
mRNA (M34664), Bases AF380943 1–550
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Figure 3.10: Alignment between human hsp60s DNA (AF380943) and human hsp60
mRNA (M34664), Bases AF380943 551–1100
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Figure 3.11: Alignment between human hsp60s DNA (AF380943) and human hsp60
mRNA (M34664), Bases AF380943 1101–1650
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 Figure 3.12: Alignment between human hsp60s DNA (AF380943) and human hsp60
mRNA (M34664), Bases AF380943 1651–2176
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3.3.2 Protein Sequence of hsp60s
The first question to ask about any newly discovered DNA sequence concerns an open
reading frame. If one exists of a sufficient size, the gene may actually encode for a protein.
Using the EditSeq software with the standard genetic code, the hsp60s gene was trans-
lated into a protein sequence. Two open reading frames were found which are sufficiently
long to encode for a protein. They were named Hsp60s1 (GAN AAK60260, TrEMBL Ac-
cession Number Q96RI4, Table 3.12) and Hsp60s2 (GAN AAK60261, TrEMBL Accession
Number Q96RI3, Table3.13). Hsp60s1 contains 220 amino acids, base 21–683 in hsp60s,
and Hsp60s2 contains 258 amino acids, base 966–1742 in hsp60s.
1 MLRLPTVFRQ MRPVSRVLAP HLTRAY AKDV KFGADARALM LQGVDLLADA VAVTMEPKGR
putative mitochondrial leader peptide
61 TVIIEQSWGS PNVTKDGVTV AKSIDLKDKY KNIGAKLVQD VANNTNEESG DGTTTATVLA
121 GSIAKEGFQK ISKGANPVEI RRGVMLAVDA VIAELKKQSK PVTTPEEIAQ VAMISANGDK
181 EIGNIISDAM KKVGRKGVIT VKDGKTLNDE LEIIEGMKFD
boxes = putative mitochondrial leader peptide
Table 3.12: Putative protein sequence of Hsp60s1 (AAK60260), amino acids 1–220
1 MAIATGGAVF GEEGLTLNLE DVQPHDLGKV GEVIVTKDDA MLLKGKGDKA QLEKRIQEII
61 GQLDVTTSEY EKEKLNEWLA KLSDGVVVLK FGGTSDVEVN EKKDRVTDAL NATRAAVEGG
121 IVLGGGFALL RCIPALDSLT PANEDQKIGM EIVKRTLKIP AMTTATNAGV EGSLIVEKIM
181 QNSSEVGYDA MVGDFMNMVE KGIIDPTKLV RTALLDAAGV ASLLTTAEVV VTEIPKEEKD
241 PGMGAMGGMG GGMGGGMF
Table 3.13: Putative protein sequence of Hsp60s2 (AAK60261), amino acids 1–258
An analysis with the ProtParam tool obtained theoretical data on the chemical and
physical parameters of Hsp60s1 and Hsp60s2. The molecular weight of Hsp60s1 is about
23 kD, Hsp60s2 weighs about 27 kD. The TrEMBL entries also contain information on the-
oretical molecular functions. Both proteins, Hsp60s1 and Hsp60s2, are categorized into
the Chaperonin (HSP60) protein family, because of their similarity with other members.
Theoretical functions of both proteins include ATP binding, heat shock protein activity
and protein folding. Based on these findings, it was concluded that the hsp60s gene be-
longs to the Chaperonin (HSP60) family.
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The grade of similarity between the Hsp60s proteins and the human Hsp60 protein
was then determined, using the Lipman–Pearson algorithm. The protein translation of
the EditSeq software was used, covering the entire hsp60s gene, to obtain an equivalent
of the 573 amino acids of the Hsp60 protein (Figures 3.13 and 3.14). The similarity index
between the Hsp60 protein and the two putative proteins of 95.5 % is high, confirming
the suspected membership of hsp60s in the Chaperonin (HSP60) family. However, the
stop codon at the end of hsp60s1 could also indicate a pseudogene nature of the hsp60s
gene.
3.3.3 The mitochondrial leader peptide
The next step in protein analysis of unknown proteins is a search for characteristic se-
quences, indicating, for example, a cell compartment as destination or a putative struc-
ture. Both Hsp60s1 and Hsp60s2 were examined for such characteristics and one was
found in Hsp60s1. The first part of the Hsp60s1 putative protein resembles the leader
peptide for transport through the mitochondrial membrane.
Nearly all mitochondrial proteins are encoded in the nucleus and are synthesized in the
cytoplasm. They are carrying a special signaling peptide sequence, the so–called leader
peptide or transit peptide, at their amino terminal end. This short sequence marks the
proteins for import into the mitochondria (Lewin 2000). For reference, the first 26 amino
acids of Hsp60s1 are shown below their Hsp60 equivalent. Obviously, both leader pep-
tides are identical (Table 3.14). Under the assumption, that hsp60s is an expressed gene,
its protein product would thus be targeted to the mitochondrial matrix.
Hsp60 M(Met) L(Leu) R(Arg) L(Leu) P(Pro) T(Thr) V(Val) F(Phe) R(Arg) Q(Gln)
Hsp60s1 M(Met) L(Leu) R(Arg) L(Leu) P(Pro) T(Thr) V(Val) F(Phe) R Arg) Q(Gln)
Hsp60 M(Met) R(Arg) P(Pro) V(Val) S(Ser) R(Arg) V(Val) L(Leu) A(Ala) P(Pro)
Hsp60s1 M(Met) R(Arg) P(Pro) V(Val) S(Ser) R(Arg) V(Val) L(Leu) A(Ala) P(Pro)
Hsp60 H(His) L(Leu) T(Thr) R(Arg) A(Ala) Y(Tyr)
Hsp60s1 H(His) L(Leu) T(Thr) R(Arg) A(Ala) Y(Tyr)
Table 3.14: Mitochondrial leader peptide of Hsp60 and Hsp60s1
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 Figure 3.13: Alignment between human Hsp60s1/Hsp60s2 putative proteins and human
Hsp60 protein; amino acids 1–440 translated from AF380943 with standard
genetic code 76
Figure 3.14: Alignment between human Hsp60s1/Hsp60s2 putative proteins and human
Hsp60 protein; amino acids 441–573 translated from AF380943 with standard
genetic code
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3.3.4 Blast Search against the entire GenBank Database with
AF380943 (hsp60s genomic sequence)
Due to these contradictory results regarding the nature of the hsp60s gene, it was not
possible to decide, whether the hsp60s gene is an expressed member, or a pseudogene
member (pseudogene of hsp60) of the HSP60 family. To obtain further information, a
Blast search with the hsp60s sequence against the entire GenBank Database was con-
ducted. Especially the genomic upstream region of the hsp60s gene was of great interest,
to determine possible promoter sequences such as a heat shock element.
In Table 3.15 a selection of sequences with the highest similarities (scores) to the hsp60s
gene is shown. The score is an assigned value of the GenBank alignment, referring to a
match between two sequences: The higher the score, the better the alignment. Most of
the hits in the Blast search are different clones of the hsp60 gene mRNA.
The highest similarity between a chromosomal location and the hsp60s gene existed for
chromosome 5. Thus, it was assumed that the hsp60s gene is located on chromosome 5.
For an analysis of the genomic surroundings of the hsp60s gene, the chromosome 5 clone
CTD–2577N22 (GAN AC091873) was used. The base position of hsp60s on this clone
is 28788–266613. Here, the reverse complementary sequence of the clone is employed,
placing the hsp60s gene from bases 138098–140723. The open reading frame hsp60s1 is
positioned from base 138118–138780, and the open reading frame 2 (hsp60s2) is posi-
tioned from base 139063–139839. The only difference between hsp60s and its equivalent
sequence on chromosome 5 is a substitution of a G in position 2117 of hsp60s to an A on
chromosome 5.
To gain further understanding of a putative pseudogene nature of the hsp60s gene,
the sequences of the other hsp60–pseudogenes were examined. Five pseudogenes of the
hsp60 gene are known, but more may exist in the human genome. The sequences on the
chromosomes 12 (GAN AC097104), 4 (GAN AC109811), 3 (GAN AC097360) and 8 (GAN
AC131269) may be pseudogenes.
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GAN and Description Similarity with
AF380943 (%)
and Score
Homo sapiens
AC091873 Homo sapiens chromosome 5 clone CTD–2577N22 99 % (4264)
AC138940 Homo sapiens chromosome 5 clone RP11–704G19 99 % (4230)
BC002676 Homo sapiens heat shock 60kDa protein 1 97% (3858)
(Chaperonin), mRNA, cDNA clone MGC:4084, complete cds
NM_002156 Homo sapiens heat shock 60kDa protein 1 (Chaperonin) (HSPD1), 97 % (3858)
nuclear gene encoding mitochondrial protein, transcript variant 1, mRNA
M22382 HUMPMMPP1 Human mitochondrial matrix protein P1 97 % (3850)
(nuclear encoded) mRNA, complete cds
NM_199440 Homo sapiens heat shock 60kDa protein 1 (Chaperonin) (HSPD1), 97 % (3846)
nuclear gene encoding mitochondrial protein, transcript variant 2, mRNA
BC067082 Homo sapiens heat shock 60kDa protein 1 (Chaperonin), 97 % (3842)
transcript variant 1, mRNA (cDNA clone MGC:71259), complete cds
M34664 HUMHSP60A Human chaperonin (HSP60) mRNA, complete cds 97 % (3842)
BC003030 Homo sapiens heat shock 60kDa protein 1 (Chaperonin), 97 % (3834)
mRNA (cDNA clone MGC:4335), complete cds
BC047350 Homo sapiens heat shock 60kDa protein 1 (Chaperonin), 97 % (3715)
mRNA (cDNA clone IMAGE:4214709)
AC097104 Homo sapiens (chr.) 12 BAC RP11–153M3 (Roswell Park Cancer 95 % (3491)
Institute Human BAC Library) complete sequence
AC109811 Homo sapiens BAC clone RP13–539F13 (chr.) 4, complete sequence 93 % (3118)
AC097360 Homo sapiens chromosome 3 clone RP11–344C13, complete sequence 92 % (2991)
AC131269 Homo sapiens chromosome 8, clone RP11–416I21, complete sequence 91 % (2179)
Homo sapiens, known pseudogenes
NG_001148 Homo sapiens heat shock 60kDa protein 1 (chaperonin) 89 % (2016)
pseudogene 4(HSPDP4), also: M34663 HUMHP604A
NG_001146 Homo sapiens heat shock 60kDa protein 1 (chaperonin) 88 % (1532)
pseudogene 2 (HSPDP2); also: M34662 HUMHP602A
NG_001147 Homo sapiens heat shock 60kDa protein 1 (chaperonin) 90 % (1445)
pseudogene 3 (HSPDP3) on chromosome 8; also: M34661 HUMHP603A
NG_000920 Homo sapiens heat shock 60kDa protein 1 (chaperonin) 90 % (1257)
pseudogene 7 (HSPDP7) on chromosome 21
NG_001145 Homo sapiens heat shock 60kDa protein 1 (chaperonin) 90 % (1216)
pseudogene 1 (HSPDP1); also: M34660 HUMHP601A
Animals
M22383.1 CRUP1P Chinese hamster P1 protein mRNA, complete cds 89 % (2399)
NM_022229 Rattus norvegicus heat shock protein 60 (liver) (Hsp60), mRNA 89 % (2137)
BC016400 Mus musculus heat shock protein 1 (Chaperonin), mRNA 89 % (2135)
(cDNA clone MGC:6709), complete cds
BS000169 Pan troglodytes chromosome 22 clone: RP43–042E01, map 22, 90 % (1279)
complete sequences
Table 3.15: Results of the Blast search; searching the GenBank database with hsp60s
(AF380943)
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Based on the results of the Blast search, a genealogical tree of the hsp60s gene was
constructed (Figure 3.15). It traces the different relationships between the hsp60s gene,
the hsp60 gene mRNA and the pseudogenes of hsp60. The similarity indices between the
genes were obtained with the Martinez/Needleman–Wunsch algorithm (Table 3.16). The
phylogenetic tree was created using the Jotun–Hein Method (see Section 2.2.12.4). The
closest relative to the hsp60s gene is the hsp60 mRNA, while the pseudogenes of hsp60
show fewer similarities.
Figure 3.15: Phylogenetic Tree of the human hsp60s, hsp60 and hsp60–pseudogenes using
the Jotun–Hein–Method
Sequence Length Similarity to hsp60s Consensus Length
pseudogene 1 (NG001145) 1868 bp 87.4 %; AF380943: 1–1831, NG001145: 67–1868 1842 bp
pseudogene 2 (NG001146) 1875 bp 85.0 %; AF380943: 1–1841, NG001146: 99–1875 1853 bp
pseudogene 3 (NG001147) 1879 bp 88.8 %; AF380943: 1–1817, NG001147: 91–1879 1822 bp
pseudogene 4 (NG001148) 1950 bp 87.3 %; AF380943: 1–1852, NG001148: 91–1950 1887 bp
pseudogene 7 (NG000920) 2549 bp 72.4 %; AF380943: 1–2176, NG000920: 165–2549 2511 bp
hsp60 mRNA (M34664) 2202 bp 97.5 %; AF380943: 1–2176, M34664: 5–2181 2177 bp
Table 3.16: Length and Similarity of the human hsp60s, hsp60 and pseudogenes of hsp60
The hsp60s gene is related more closely to the hsp60 gene mRNA than to any hsp60
pseudogene. However, even this additional data cannot ascertain the true nature of the
hsp60s gene.
3.3.5 Analysis of the hsp60s gene and flanking sequences
With the Blast Search, see last Section, it was possible to identify the human chromosome
of the hsp60s gene: Chromosome 5. The clone CTD–2577N22 was used for analysing the
upstream region of the hsp60s gene, looking for putative promoter elements. Assuming
the possibility of the hsp60s gene being the ”emergency” (stress inducible) variant of
hsp60, it was tried to identify promoter regions in the hsp60s gene similar to those in the
hsp60 gene. Especially it was searched for the characteristic promoter element of heat
shock genes (heat shock element, see also Section 1.4).
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The promoter sequence of the hsp60 gene is shown in Table 3.17. Its heat shock element
is located in the bases 3408–3428.
5’T–TTC–T3’ 5’G–GAA–A3’ 5’G–TTC–T 3’ 5’G–GAA–CC3’
Two protein binding sequences, otherwise known as GC–boxes or SP1–elements, are
located in bases
3504–3510 GGGCGGG and 3591–3597 GGGCGGG .
The heat shock element is located 1238 bases upstream of the ATG and 991 bases up-
stream of the beginning of the hsp60 mRNA. Using the EditSeq, Transplorer and Match
programs, a search for putative promoter sequences was conducted on the hsp60s gene.
Eukaryotic promoter sequences can be composed of several modules spanning more than
one thousand bases. Thus, 1500 bases upstream of the hsp60s gene’s ORF1 start codon
were examined (see Table 3.18). A putative heat shock element was found, located in the
bases 137140–137159.
5’G–GAA–T3’ 5’T–GAA–C3’ 5’T–TTC–T3’ 5’A–GAA–A3’ .
The putative heat shock element is located 978 bases upstream of the ATG from
Hsp60s1. No GC–boxes similar to the ones in the hsp60 gene were found. But just
upstream the ORF 1 start codon, a highly GC–rich region (bases 138065–72, 138084–93,
138104–110) exists, which may include possible GC–boxes.
The Match Software was used to test the promoter regions for the binding of transcrip-
tion factors. The Transfac database contains a great number of transcription factors, but is
not complete. It may be possible, that more than the following transcription factors bind.
Again, the hsp60 gene was used as a template for identifying similar regions in the hsp60s
gene. The only transcription factor in the Transfac Database binding the heat shock ele-
ment of the hsp60 gene is the heat shock transcription factor 1 (HSF1) of Saccharomyces
cerevisiae, SPAN P10961. For hsp60s, the program produced the same hit as for hsp60,
heat shock transcription factor 1 (HSF1) of Saccharomyces cerevisiae. Additionally, the
human heat shock transcription factor 1 (HSF1) was found, SPAN Q00613. The latter is
the typical eukaryotic DNA–binding protein that specifically binds heat shock promoter
elements (HSE) and activates transcription. The putative heat shock element and binding
site for the typical eukaryotic transcription factor point to an expression of the hsp60s
gene.
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3001 CGTACGCCTC AGACAGGCCC GGGCCTGCAG GCCTCGGGGC CACGCGGGAC TCACCATTAC
T3057: start p10cds
3061 TCCCTCCGCC TCAGACTCGT ACTCTGCTCT AGTGTAGCGC CGCAAAGAGA CTCGCAGTCC
C3098: start p10mRNA G3099: start pro p60
3121 GGCCCTGGCG ACACGTGAAA AAATCACCCA GCGCGCAGGC GCGCTCGCCC CAGCGGTCGC
3181 CGCTAGCCCC CTCGCCCCTC CCAGGGAGGG AGGGCGGTCG CCCCGACGCG CACCGCGATT
3241 CGCCCCAAGG GCCCTGCGCA GGACGCTGAC GCGAAGACTC GGAGGCGGAA GAAAAAAGGA
3301 GCTGTTTCTA GGCTTTTCTA GGCGCCCAGC CGAGGTGAAA GAACTACCCC TTCGTCCCCT
3361 CCCGGAAATG ACGCGATTTG ACCCTTGAGC CGTAGGGAGC GCGGCAT TTT CTGGAAAGTT
3408–3428 heat shock element
3421 CTGGAACC GA GCGAGGCCCG GGAACTAGAC TAAGCCGGCC GGAGAGGGCT GAGCGCGCTA
3481 GCACACCCTG CGCGGGTAGG GAG GGGCGGG GCTCGCGCGC AGGGTGTGCA GATTGCAGGG
3504–3510 proteinbind seq
3541 CCCGGGCTGA CGGGAAGTGG GTGGGAGCTG CCTGCACACG CGGTGCCGCG GGGCGGG AGT
3591–3597 proteinbind seq
3601 AGAGGCGGAG GGAGGGGACA CGGGCTCATT GCGGTGTGCG CCCTGCACTC TGTCCCTCAC
C3654 start p10gene; C3655 p60gene/mRNA
3661 TCGCCGCCGA CGACCTGTCT CGCCGAGCGC ACGCCTTGCC GCCGCCCCGC AGGTACGCGG
3721 CCTTCCCGCA CCACCTCCCC CCGGCTCCTG CGACCCCCGA GTGGGCCTTCA CTCCTCTGCG
3781 GTCCAGCTGG AGGGTGCGGG CGGCGACAAC CTGGAGTTCC GCACCGCGCC GCACCGCAGG
3841 CCCAGGCCTG CGGGTCCAGG CCTCGCGGGT CCATGCGGGT TCCATCACGT GCGACGCGGA
3901 TCCTGGACCT CGGCTGGGCG CGGGAGGGAC AACTCGTGGG GTTTGAATTT GGGGGATTGT
3961 AACCACTTAG GCCCGCTGGT GCAACCTGCG CCTGGCCGAC TTCAGGGAAC CGGGGAGGGT
4021 GGTGTACGTG AGGGAACCGC TTTTTTCCCC CGCAGGCAGC TGGGATACCG CGCCTCCAGT
4081 CTTGACCTTG CTGGGGGCGT T CGGAAAGAA GGACACGTGG GCTCGCGCCG AGTGGGCCGG
4141 GCCGCCGCCC CCAGCATCGC GGCCTTGCTG GTTGCTCTGA TACAGTAGCC TTGGGTGGAT
4201 CCATGGAGAC ACTTTGCTGA GCGGCTATTT GCACCGTCAG GAATACTTTT AACTTCCCTG
4261 GTCACTTGGA TTTGTAACTT GCCTCTCTCC GGCTGACTTG GTTTCTCAGG GGCCACAGTT
4321 GGAGTGGGTC TGCCCACAAG GCCGTTTTCG CGGTGAAAGA TTAACTCGTT TTTGGCGGCA
4381 GGGATAGGTG GCCGTGGGGA AGGAGCCGCA TGTGCTTTGT GCTGGTGCTA TAGGTCAGGC
4441 GCCGGCCGGG GCGGCCTCTT TAGCTTGCGC TAGTGGCTGA TGTTCCGAAG CTGCGGCGCC
4501 TTCCGTCATT CAGGCGTAGT GGCTGGCGGA GGTCAGCCAG GCTCAGCATC TCACGTTGCT
4561 TGCTCTGTTG CACAGGTGGG CATGTTTGTT CTGCAGCGCA CCACGGGTGG TAGTTCTGAT
4621 GATCTTTTTG CTTCCATCCC CAGAAATGCT TCGGTTACCC ACAGTCTTTC GCCAGATGAG
4646–4648 Start (Begin CDS)
4681 ACCGGTGTCC AGGGTACTGG CTCCTCATCT CACTCGGGCT TATGCCAAAG ATGTAAAATT
4741 TGGTGCAGAT GCCCGAGCCT TAATGCTTCA AGGTGTAGAC CTTTTAGCCG ATGCTGTGGC
4801 CGTTACAATG GGGCCAAAGG TACCAGTATT TTTATTTTAT TGTAATTACG GTATTATTAA
boxes = promoter elements; boldface = exons; Startcodon = ATG in exon 2 bases 4646–4648
Table 3.17: Promoter region of the human hsp60 gene; Bases 3099–3654 (AF250915)
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136321 CAGTGCACCC CAGCTCTCAG TATTTTTGAT CGTGAGAGAG AAAGTTTCAT GGAGTCAGGG
136381 TTTATCAATT TCTTGTTCTG AAGAGTGGGA TTTTGCACTC AAGTGCAGAG TTGAATCATC
136441 CATCATTTCC AGAGTACAAA AACATAGGAA ACTTCACCTG TGTTTCTAGT GACTGTCTCT
136501 AAAGTTATAT ATTTAATGCC AGGGCACTTC TTTAGCTACC CCTCGGGGAG AATAATAAAA
136561 TCTTAGTTTT TTATTTATAA GCCATCTATT AAGTGACCAC TATTTTAGCA GCTCACACTG
136621 CACTATGCAC AGAGAATATA AGGTATAAAA ATGAATGAAA AAGAAAAATG AAAAAAAACT
136681 GCTGAAATGT AGTATTCTAA AAACTTTATT TTATATGATT TCTTTTGGGA AACTCAGAAA
136741 ATACTTCTCA TTTGCAACTC TCTCTTCTTT CCTAAAACAG GAAAGGAACT TAACAATATT
136801 TATGGAGCTA TTACAATGTG TCAAACATTG TGCAAAACAT TTTATATGCA TTCTTATATT
136861 TAATGCTTAA ACCCATCCTA TTTTCTATTA TTTGCACCAT TTCTATAAAT GCAAAACTAA
136921 CATCTAGATG ATGACACGGG TTGTCTGGAG TCTTGACTTT TAGTTAAGTG GTGGAGCTGG
136981 GGCAAACTCA AACAGTTGAC ACCAAAGCCA TTGCTCACAG CCACTACCCT AGTCCACCTC
137041 CAGGGAACAG AGAAGTTCTT CATAAAATAA CTAAGCTGTT TTATTTTGTT TGTTTGGACA
137101 TTCTTGGCAC AACATATTTT TTCCATTTTT TTTAAATTT G GAATTGAACT TTCTAGAAA T
137140–137159 putative heat shock element
137161 ACACTACTCA TTTTTGTTTA CTTAAGTAAA CAAATAGTCT ATTTGGTTAA ACTTCGTATC
137221 ATTTTTATAT ATTAGTTTAT CTGATACAAA ATGGTTACTA ATGGATCTGC ATATATAATT
137281 TCAAATTACC TGAATACTTA AAAAGTATGC AAGGAATTTT CCACAGTAGC TACACTTGCC
137341 TAAGATCAGA TATGCATAAT ATGTTTTGAA TCATGGATCT TTTTTCTTTT GTTCTTATTA
137401 ATATCATTTA AAAATCTAGC ACCATTGTAA TTCACATGTT GATACTCTGC AAAAATGAGA
137461 AGAAATCAGT CTAATATCCA GGCTGTGAAT GTAGATGCAT TTTGATAGTT TATGATGTAT
137521 TGATTGGAAA TTCAAGATAA ATAATAAGCG TTTTACTAAA ATGAAAACTA GATTACAAAG
137581 CAATATTTGT AAAGATATAT CAAACAATAT TGCCAGTATT TAATTAGAGC CAATGTTCAG
137641 GTTTCAGTAA TACCATTTTA GCTTCAGACG GTTATTGTCA CTGGATTTCT TTGTTATGCC
137701 ATTATAAATT AAGCAATGAT GCATCATGAT GATTCTTCCA TTACTGGAAG TCACATTTTA
137761 TCTGAATTTA TTCTCATGTC CAAATGTTTG TGACGTATAT TTAATTTGCT TATTGCCACA
137821 TGCACAGCCA CACACAGAGG ATGACGTAAA GCAATCATAG AAATTAACAA AAAGACGTAT
137881 TTTTATTACT TTATCAGTAT TTCAAATTGA TTTTTTAATC AGAAAAAAAC AGGTTATTTG
137941 AACCAGACAT AGATTGGCTG TATTGCTCTC ATAATTTGGC AGATGTCTGT ATGTTCCATT
138001 TATAGTACAA CTGCCACATT TATTTGCTTT TTAAAAGTGA TATATTAGCA CTCTGTCCCT
138098 Begin hsp60s 138118–20 Startcodon hsp60s ORF 1
138061 CACT CGCCGC CG ACAACCTG TCT CGCCGCG CGC ATGCCCT GCA GCCGCCC CACAGAAATG
138065–72, 138084–93, 138104–110: GC–rich region, possible GC–boxes
138121 CTTCGGTTAC CCACAGT CTT TCGCCAGATG AGACCAGTGT CCAGGGTACT GGCTCCTCAT
138181 CTCACTCGAG CTTATGCCAA AGATGTAAAA TTTGGTGCAG ATGCCCGAGC CTTAATGCTT
boxes = putative promoter elements; boldface = putative coding sequence; Startcodon = ATG bases 138118–138120
Table 3.18: Putative Promoter sequences of the human hsp60s gene on chromosome 5
(AC091873)
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3.3.6 Test of expression
Based on the results of the alignments and the computational promoter analysis, the pos-
sibility of the hsp60s gene being expressed exists. RT–PCR primer were constructed for
various alternatives deemed likely (shown below) of a putative hsp60s mRNA. To con-
struct primer specific to hsp60s, the hsp60s and hsp60 genes were aligned. Due to the
high sequence similarity, in some cases the suitable primer regions differed only by one
nucleotide. The primer and other reaction parameters are shown in Section 2.2.9.1.
Because of the ubiquitous nature of stress and heat shock proteins, they are expressed
in almost every tissue (see Section 1.2). Blood was used for the isolation of the messenger
RNA (mRNA) for the RT–PCR, because it is easily obtained and can be processed quickly
after withdrawal. Messenger RNA is generally short lived compared to DNA. Its half life
ranges from seconds up to several minutes (depending on the nature of the gene, e.g.,
the mRNAs of house–keeping genes show a longer stability). The blood was obtained
from one of the test persons whose hsp60s genomic DNA was previously sequenced. The
isolation protocol is shown in Section 2.2.3. A number of possible alternatives for the
nature of a potential mRNA of hsp60s were considered:
Alternative 1: One mRNA exists, including both ORFs, ORF1 and ORF2. The mRNA
starts between the putative HSE (137140–137159) and the start codon of hsp60s1
(138118–20) and ends downstream of the second stopcodon (between 139839–
140723). This would necessitate a readthrough of the TGA stopcodon of ORF1.
Alternative 2: One mRNA exists, including both ORFs, ORF1 and ORF2. The mRNA
starts at the start codon of hsp60s1 (138118) and ends downstream of the second
stopcodon (between 139839–140723). This would necessitate a readthrough of the
TGA stopcodon of ORF1.
Alternative 3a/3b: Two mRNAs exist, one for ORF1 and one for ORF2. The mRNA for
ORF1 (3a) starts between the putative HSE (137140–137159) and the start codon of
hsp60s1 (138118) and ends downstream of the ORF1 stopcodon (between 138780–
139063). The mRNA for ORF2 (3b) starts at the start codon of hsp60s2 (139063) and
ends downstream of the ORF2 stopcodon (between 139839–140723).
Alternative 4a/4b: Two mRNAs exist, one for ORF1 and one for ORF2. The mRNA for
ORF1 (4a) starts at the start codon of hsp60s1(138118) and ends downstream of the
ORF1 stopcodon (between 138780–139063). 4b is the same as 3b.
Table 3.19 shows a graphical view of the different mRNA alternatives that were con-
sidered. The human chromosome 5 clone CTD–25777N22 is shown as the reverse com-
plementary sequence, because the original clone found in the Blast search was the minus
strand. All positions are referring to the reverse complementary sequence. The specific
primers for each of the alternatives are shown in Table 3.20. The detailed description is
shown in Section 2.2.9.1. The primers are chosen to be hsp60s–specific and are set in-
side the putative mRNAs. Each forward primer was paired with each reverse primer.
The primer combinations and programs are described in detail in Appendix A.3. For all
forward and reverse primer combinations associated with an alternative, a RT–PCR was
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performed. The results were verified on agarose gels (1% gel NuSieve GTG agarose/
TBE–Buffer).
5’ Chromosome 5 clone CTD–2577N22 (AC091873), rev. complementary sequence: Bases 137041–140400 3’
Chr. 5 hsp60s (AF380943, 1–2176): Bases 138098–140723 Chr. 5
putative HSE Chr. 5 Begin ATG TGA hsp60s ATG TAA End
hsp60s ORF1 ORF2 hsp60s
137140–137159 138098 138118–138780 139063–139839 140723
mRNA alternative 1
mRNA alternative 2
mRNA alternative 3a mRNA alternative 3b
mRNA alternative 4a mRNA alternative 4b (3b)
Table 3.19: Putative RNA alternatives of the human hsp60s gene
None of the alternatives tested lead to a positive match: Thus, It can be stated with cer-
tainty, that the hsp60s gene is not expressed in unstressed blood. However, the possibility
remains that the gene is expressed in other tissues. Furthermore, it may be possible, that
the hsp60s gene is only expressed under stress conditions. For example, the inducible
form of the human hsp70 gene can only be detected under stress. The blood used in the
experiment was obtained under non–stressed conditions. An attempt to procure blood
from heat–stressed patients (children with high fever) for an appropriate analysis was
initiated, but ultimately failed due to lack of support by MHH pediatric clinic.
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5’ Chromosome 5 clone CTD–2577N22 (AC091873), rev. complementary sequence: Bases 137041–140400 3’
Chr. 5 hsp60s (AF380943, 1–2176): Bases 138098–140723 Chr. 5
putative HSE Chr. 5 Begin ATG TGA hsp60s ATG TAA End
hsp60s ORF 1 ORF2 hsp60s
137140–137159 138098 138118–138780 139063–139839 140723
mRNA alternative 1
53Start1v1 =⇒
⇐= 53Stop2v1
⇐= 53Stop2v2
⇐= 3Stop2v3
mRNA alternative 2
3Start1v3 =⇒
5Start1v4 =⇒
53Start1v5 =⇒
⇐= 53Stop2v1
⇐= 53Stop2v2
⇐= 3Stop2v3
mRNA alternative 3a mRNA alternative 3b
53Start1v1 =⇒ 3Start2v1 =⇒
53Start2v2 =⇒
3Start2v3 =⇒
5Start2v4 =⇒
⇐= 5Stop1v1 ⇐= 53Stop2v1
⇐= 3Stop1v2 ⇐= 53Stop2v2
⇐= 5Stop1v3 ⇐= 3Stop2v3
mRNA alternative 4a mRNA alternative 4b (3b)
3Start1v3 =⇒
5Start1v4 =⇒
53Start1v5 =⇒
⇐= 5Stop1v1
⇐= 3Stop1v2
⇐= 5Stop1v3
Table 3.20: RT–PCR Primer for the different putative RNA alternatives of the human
hsp60s gene
3.4 Direct sequencing of PCR products obtained from
DNA of SIDS victims
For forensic and research applications, it is often necessary to amplify and sequence DNA
obtained from corpses. Here, the degradation of the DNA is an everpresent problem, lim-
iting the length of PCR fragments and the quality of a sequencing reaction. In this thesis,
PCR was performed on genomic DNA isolated from victims of Sudden Infant Death.
The blood samples themselves were obtained during the autopsies. In times before the
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widespread use of DNA analysis, such blood samples were taken and simply frozen for
successive toxicological analyses. Some of these samples were only cooled in a refrigera-
tor for a few months before actually being frozen. In some of the SIDS cases, the genomic
and mitochondrial DNA had to be isolated from 15 year old frozen blood samples. The
newest samples were less than one day old (the DNA was isolated immediately after tak-
ing the sample during the autopsy). These DNAs were then used for the PCR reaction
(see Section 2.2.8) with a direct sequencing approach. The success of the PCR reactions
was verified on agarose gels before the sequencing reaction was carried out.
The PCRs were performed with the GeneAmp XLPCR Kit and the Qiagen ProofStart
DNA Polymerase (Section 2.2.8). The PCR products were either purified from agarose
gels or were directly purified (Section 2.2.5.1). The sequencing reactions were performed
using the ”Cycle Sequencing” method with the Big Dye Terminator Cycle Sequencing
Ready Reaction Kit; the purification of the sequencing reactions was performed us-
ing Centri Sep Spin columns (Section 2.2.11). Up to a fragment length of 400 bases, a
PCR/direct sequencing approach was successful for all blood samples from SIDS cases
regardless of the samples’ age. A gel picture is shown in Figure 3.5. Above 400 bp, the
success of this approach depended on the date of DNA isolation after taking the blood
sample during the autopsy. In Figure 3.16, a fragment of 2.2 kB is shown.
The difference between the successes of PCR is clearly visible. The PCR was most
successful when genomic DNA isolated at the day of the autopsy, was amplified. The
fragments from samples with an age of 1 year, 5 years and 11 years were less distinct, but
showed almost no differences on the gel. The fragments from samples 14 and 15 years old,
appeared only as a barely visible band on the gel. Even with an apparent success in the
PCR step, a following sequencing reaction succeeded only for the most recent sample. In
summary, for a successful PCR/direct sequencing approach on DNA from corpse blood:
If the fragments to be amplified are longer than 400 bases, it is most important to isolate
the DNA quickly after taking the sample.
26282 bp
19329bp 
9824 bp
7743 bp
6223 bp
5090 bp
4254 bp
3472 bp
2690 bp
2419 bp
2205 bp
1882 bp
1489 bp
1268 bp
Marker 17
 
Day of Autopsy 5 years 11 years 1 year14 years 15 years
DNA Isolation from blood of SID cases taken during autopsy, Time frame
Figure 3.16: 0.4% Agarose gel: PCR of the hsp60s DNA from SIDS cases (fragment at 2205
bp of the Lambda marker 17)
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4 Discussion
The interpretation of the experimental results of this thesis (Chapter 3), confirm the in-
creased occurrence of genetic variations in Sudden Infant Death Syndrome.
4.1 SIDS cases
4.1.1 Epidemiological data
In this thesis, 91 SIDS cases from the years 1987 to 2001 and 108 controls from the years
1994 to 1999 were investigated. Both sample sets originated from Lower Saxony, Ger-
many. Epidemiological data on birth rates and the incidence of Sudden Infant Death
in Lower Saxony (Table 4.1) were obtained from the ”Niedersächsisches Landesamt für
Statistik, Hannover” (department of statistics, state of Lower Saxony, Germany). As
usual, the SIDS incidence is expressed as the annual rate of SIDS infant mortality, the
number of cases per 1000 live births.
Year SIDS incidence Year SIDS incidence Year SIDS incidence
1987 1.1 1992 1.2 1997 0.6
1988 1.3 1993 1.0 1998 0.8
1989 1.6 1994 0.8 1999 0.6
1990 1.6 1995 0.8 2000 0.6
1991 1.5 1996 0.8 2001 0.7
Table 4.1: SIDS incidence in Lower Saxony in the years 1987–2001
The incidence in Lower Saxony corresponds to the rates in other Western countries in
these years, including all of Germany (Hunt and Hauck 2004; Jorch 2000). It is notewor-
thy, however, that the incidence significantly decreases after 1992. In some countries (e.g.,
United States of America, Great Britain) the ”back–to–sleep” campaigns were launched
at this time, after the prone sleeping position was discovered as a risk factor. This cam-
paign encouraged parents to put the children on their backs for sleeping (if not medically
contraindicated). Germany did not launch a direct campaign, but the supine sleeping po-
sition was recommended by pediatricians. It is often assumed that the reduced incidence
of Sudden Infant Death was due to the propagation of supine sleeping.
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4.1.2 SIDS criteria
The sample of SIDS cases examined in this thesis exhibited the typical autopsy results:
About two thirds of the SIDS cases showed petechiae in the pleura, epicardium and thy-
mus; often in all three tissues. Also, two thirds of the SIDS cases featured hemorrhage in
the respiratory tract. About one third had foam or oedemata in the respiratory tract.
The typical epidemiological factors were also present. The sample contained more male
than female cases. More than half of the SIDS cases died within the age of 2 to 4 months.
For 61 SIDS cases, the death scene position was documented in the autopsy protocols.
70.5 % of these 61 cases were discovered prone. Evidence of the additional risk factors
preterm birth, heat stress and smoking could not be verified due to insufficient detail in
the case reports. In summary, the cases studied in this thesis showed the typical charac-
teristics associated with Sudden Infant Death.
4.2 Mutations in the human chaperonin gene 60
In recent years, research into Sudden Infant Death was extended to the molecular level,
leading to knowledge of many genetic variations. The latter include metabolic disorders
(Vockley and Whiteman 2002) as well as mutations in sodium and potassium channel
genes (Wedekind et al 2001) and polymorphisms in the serotonin transporter gene 5–
HTT (Weese–Mayer et al 2003; Narita et al 2001). Furthermore, a polymorphism was
described for the interferon–γ gene (Gordon et al 2002) and an insertion mutation for the
TSPYL gene (Puffenberger et al 2004). Additionally, many mutations of the mitochondrial
genome are now known, being associated with SIDS (Reimann et al 2004; Opdal et al
1998; Hofmann et al 1997). All research yielded the same result: SIDS cases exhibit more
mutations/genetic variations than controls. A selection of studies on genetic variants of
genomic DNA in Sudden Infant Death Syndrome is shown in Table 4.2.
Heat stress has been associated with the Sudden Infant Death Syndrome for more than
20 years by now (Guntheroth and Spiers 2001; Einspieler 2000; Kurz 2000c; Kleemann et
al 1998; Sawczenko and Fleming 1996; Kleemann et al 1996; Kleemann 1996; Ponsonby
et al 1992; Fleming et al 1992; Stanton1984). Despite this fact and despite the advances
in molecular biology over the last 20 years, very few studies have examined a possible
connection between SIDS and heat shock protein genes. Rahim et al (Rahim et al 1996)
described restriction fragment length polymorphisms (RFLPs) for certain restriction en-
zymes in human heat shock protein genes (hsp60, 70, 90). Bross et al. (Bross et al 2001)
reported two mutations in the coding region of the hsp60 gene.
The only heat shock protein gene that showed distinctive features in Sudden Infant
Death was the hsp60 gene. Thus, the efforts were concentrated on this gene. At first, it
was tried to confirm what Bross et al. called a rare disease allele: the mutation N158S, an
amino acid exchange in position 158 from asparagine to serine. This codon is located in
the exon 5 of the human chaperonin60 gene. Neither the N158S mutation, nor any other
mutation in the exon5 was found.
With the PCR and sequencing protocols, parts of the adjacent upstream and down-
stream introns to exon 5, introns 4 and 5, were also amplified and sequenced. Intron 4
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Study, Author Gene Variation SIDS cases, tissue Controls, tissue SIDS
for DNA isolation for DNA isolation associated
Bross et al. 2001 hsp60 N158S 65 10 yes
Bross et al. 2001 hsp60 G573A 65 10 no
Rahim et al. 1996 hsp60 MspI–RFLP 12, liver 26, placenta yes
Rahim et al. 1996 hsp60 ScaI–RFLP 12, liver 21, placenta no
Rahim et al. 1996 hsp70 BglI–RFLP 12, liver 19, placenta no
Rahim et al. 1996 hsp70 PstI–RFLP 12, liver 19, placenta no
Rahim et al. 1996 hsp70 PvuII–RFLP 12, liver 28, placenta no
Rahim et al. 1996 hsp90 Sau961–RFLP 12, liver 26, placenta no
Weese–Mayer et al. 2003 5–HTT LP 87 87 yes
Narita et al. 2001 5–HTT LP 27, brain 115, blood yes
Gordon et al. 2002 IFN–γ LP 10, blood 10, blood yes
Puffenberger et al. 2004 TSPYL1 457–458insG 4, blood no controls yes
Teske 2004 hsp60 N158S 91, blood 108, blood no
Teske 2004 hsp60 deletions intron 5 91, blood 108, blood yes
Teske 2004 hsp60 deletion AG 91, blood 108, blood yes
Teske 2004 hsp60 deletion 24 91, blood 108, blood no
Table 4.2: Known genetic variants in Sudden Infant Death Syndrome
showed no mutations, but in intron 5, two different kinds of deletion were found. The
first is a deletion of the bases AG in positions 8957–8958. The second is a deletion of 24
bases (TATGATCAAAAGTTTGAGTTATCT) in positions 8885–8908.
In summary, the SIDS cases show significantly more mutations of deletion AG (p=0.036
in the binary logistic regression) than the controls and more mutations (deletions) in the
entire intron 5 (p=0.036 in the binary logistic regression) than the controls. These find-
ings correspond to other studies: SIDS cases show more mutations than the controls.
However, no mutation so far can be interpreted as sole reason for Sudden Infant Death
Syndrome.
4.2.1 Deletions in intron 5 as putative sites for splicing and
transcription regulation
In higher eukaryotes most genes are interrupted, having a distinct exon–intron sequence.
The coding exons are often very small compared to the large non–coding introns. At the
primary transcript on the hnRNA level the introns are spliced and the exon sequences
remain as the protein template. According to Lewin (Lewin 2000) the splice junctions
show a characteristic consensus sequence, also known as the GT–AG rule: An intron starts
5’ (also called left or donor site) with a GT and ends 3’ (also called right or acceptor site)with
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an AG. 18 to 40 bases upstream of the 3’ splice site is the location of the branch site (animal
consensus sequence Py80NPy80Py87Pu75APy95), which is crucial for the splicing process.
It cannot be verified, whether the deletions in intron 5 do disrupt the splicing process.
Since the deletions are located near the 5’ end, they most likely neither affect the donor
and acceptor sites, nor the branch site.
However, it interesting to notice that intron 5 belongs to class of introns with an alterna-
tive donor site GC–AG. Not all introns do have the GT–AG donor–acceptor sites. Different
splice sites are known: GC–AG, GG–AG, GT–TG, GT–CG, CT–AG (Burset et al 2000). Ac-
cording to Clark and Thanaraj (Clark and Thanaraj 2002; Thanaraj and Clark 2001), GC
splice sites account only for 1.1 % of the donor sites. GT–AG introns and GC–AG introns
are spliced by the U2–type spliceosome, which is the standard spliceosome in metazoans.
For the GC–AG introns, a mismatch exists between the donor site and the U1 snRNA in
the intron position 2 (C). It has been proposed, that there may be a compensation in the
sequence around the donor site to maximize base pair formation with the other positions
in the U1 snRNA. GC–AG introns have a high average length and a prevalence toward
alternative forms. It is suggested, that they are highly regulated. It could not be demon-
strated, that the deletion AG and the deletion 24 are located within an important regulatory
region for the splicing of the GC–AG intron 5 of the human hsp60 gene.
The Match software was used in conjunction with matrices from the Transfac Database
to check the possibility, whether the deletions affect the gene regulation on the level of
transcription of the hsp60 gene. In the region of deletion 24, Match found two hits:
1. The first is the transcription factor HNF–3α in two species, human (Homo sapi-
ens) and rat (Rattus norvegicus). HNF–3α is Hepatocyte Nuclear Factor 3 Alpha
(HNF3A). According to the Swiss–Prot entry, HNF3A is transcription activator for a
number of liver genes such as AFP, albumin, tyrosine aminotransferase and PEPCK.
It interacts with the cis–acting regulatory regions of these genes.
2. The second is the Cdc5 transcription factor of human Homo sapiens (cell division
control protein 5, no Swiss–Prot entry). According to the Transfac Database, Cdc5
is a transcriptional activator and a transcriptional regulator of cell cycle G2 phase
progression and mitotic entry.
In the region of deletion AG the Match software found one hit: MEF–2 (Myocyte–specific
enhancer factor 2) in three species, human (Homo sapiens), mouse (Mus musculus) and
rat (Rattus norvegicus). In humans, four MEF–2 factors exist, MEF2 A, B, C, D. The hits
in the Transfac Database refer to the factors MEF2A (SPAN Q02078) and MEF2D (SPAN
Q14814). MEF2A is a transcription factor which binds specifically to the MEF2 element
present in the regulatory regions of many muscle–specific genes. It activates transcription
via this element and may be involved in muscle–specific and/or growth factor–related
transcription. MEF2D has the same functions as MEF2A. The nature of the deletions
(positions inside of the hsp60 gene) suggests that they are most likely not affected by
transcription factors. However, it may be possible, that the deleted positions are part of
an enhancer binding site. The Transfac Database did not contain any information on this
possibility.
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4.2.2 A putative mechanism for the influence of a hsp60 gene
mutation on Sudden Infant Death
It is known, that mutations in the human hsp60 gene can have fatal effects: The amino
acid exchange V721I (valine to isoleucine) is a disease–causing mutation for hereditary
spastic paraplegia SPG13 (Hansen et al 2002). Assuming a mutation either affecting the
coding sequence or an important binding site in the non–coding part, the following sce-
nario for a connection between Sudden Infant Death and the human Chaperonin60 could
be constructed: In Figure 4.1, possible general mechanisms following Chaperonin muta-
tions, are shown (Slavotinek and Biesecker 2001).
Figure 4.1: Possible disease mechanisms following Chaperonin mutations (based on
Slavotinek and Biesecker 2001)
• Mechanism a) represents a mutation, that creates a defective subunit either unable
to bind a substrate or with a reduced binding ability.
• Mechanism b) represents a mutation that produces an unstable protein or an ex-
panded polyQ–tract (Glutamin) prone to increased aggregation.
• Mechanism c) represents a mutation that impairs the ability of a Chaperonin to tar-
get a misfolded protein for degradation in the proteasome.
These mutation possibilities in the gene can lead, for example, to amino acid exchanges
and splicing defects, ultimately altering the protein structure. The Chaperonin is unable
to carry out its normal function in protein folding. The crucial factor for this kind of
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mutation is, that the protein still exists, but may not be able to function properly. Such
a damaged Chaperonin, emerging from a mutation in the hsp60 gene, could be the en-
dogenous factor in the multifactorial genesis of the Sudden Infant Death Syndrome (Kurz
2000b). The other two factors are a vulnerable infant, because of its developmental stage
and an exogenous factor, in this case, heat stress.
In summary, the child has a weakened immune system or a weakened thermoregula-
tion because of its developmental state. It suffers from considerable heat stress due to an
infection with high fever and/or a much too warm environment. Prone sleeping may in-
crease heat stress. Because of the damaged Chaperonin, it can not cope fully with the heat
stress. Each factor alone is not severe enough. All factors in conjunction provoke deadly
consequences. Thus, a mutation in the hsp60 gene may be a necessary, but not sufficient
factor in the genesis of SIDS.
4.3 hsp60s, a new member/pseudogene of the HSP60
family
The original intention to amplify the coding part of the human hsp60 gene, resulted in an
unexpected outcome: Instead of the anticipated 13.2 kB fragment, a very prominent 2.2
kB fragment showed up on the agarose gel. The fragment was extracted from the gel and
the PCR primer were used for sequencing. The sequences obtained were very similar to
the mRNA of the human hsp60 gene. The putative 5’ part of the gene contained a start-
codon, ATG, followed by an open reading frame. The first part of this translated ORF
(26 amino acids) is identical to that of the Hsp60 protein. It resembles the so–called mi-
tochondrial leader peptide, a small protein sequence serving as a targeting signal for the
mitochondrial import. The GAN for the newly discovered fragment, which was named
hsp60s (s for short, comparing it to the much longer regular hsp60 gene), is AF380943
(Teske et al 2001).
The high similarity between the fragment and the mRNA of hsp60 and the existence
of a putative ORF with a mitochondrial leader peptide could have been evidence of an
expressed gene. It was suspected to be an inducible variant of the hsp60 gene, which is
already known for other heat shock genes, such as hsp70. The gene exists in two forms: A
constitutive or cognate form for house keeping purposes and an intronless inducible form
for the stress response. Based on the assumption that the fragment could be the inducible
variant of the hsp60 gene, the hsp60 mRNA was used as a template to construct primer
for sequencing the entire fragment (2176 bp). It showed a 97.5 % similarity to the human
hsp60 mRNA in an alignment with the Martinez/Needleman–Wunsch algorithm.
Instead of a single open reading frame as in the regular hsp60 gene, two putative ORFs
were found. They were translated from the DNA with the EditSeq software using the
standard genetic code and named Hsp60s1 and Hsp60s2 (short Heat Shock protein 60 1
and 2). Both are sufficiently long to encode proteins: Hsp60s1 contains 220 amino acids,
Hsp60s2 contains 258 amino acids. Generally, a peptide longer than 100 amino acids is
considered a protein. An analysis with the ProtParam tool confirmed the similarity with
the Hsp60 protein. Theoretically, both putative proteins show Chaperonin functions.
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Gupta 1995 (Gupta 1995) documented certain characteristics based on the sequences of
the members of the HSP60 family and their evolution (see below). These characteristics
indicate clearly that the hsp60s gene is a member of the chaperonin gene family:
1. ”Most Hsp60 sequences contain one or more repeats of the amino acid sequence
GGM or GGGM at their C–terminal end.” The end of the ORF Hsp60s2 reads as
follows: putative amino acid sequence GGMGGGMGGGM.
2. ”The mitochondrial homologues in all of the eukaryotic species examined are en-
coded by nuclear genes and contain a characteristic N–terminal leader sequence
(rich in basic and hydroxylated amino acids such as Arg, Lys, Ser and Thr) that is
required for the mitochondrial import of the protein.” The N–terminal sequence (26
amino acids, mitochondrial leader peptide) of the ORF Hsp60s1 is exactly the same
as in the Hsp60 protein.
3. ”The global alignment of Hsp60 sequences has identified a number of signature
sequences that are uniquely shaped among (a) members of the Gram–negative α–
purple subdivision of bacteria and mitochondrial homologues, and (b) between
cyanobacteria and chloroplast homologues.” The signature sequences between
Hsp60 and Hsp60s1/Hsp60s2 are identical.
However, the stop codon at the end of Hsp60s1 could be evidence of a pseudogene
nature of hsp60s. Many pseudogenes originate from failed copies of mRNA that are
reintegrated into the DNA, and have an altered sequence. Often they incorporate stop
codons.
To obtain further information on the nature of the hsp60s gene, a Blast search against
GenBank was conducted and chromosome 5 was determined as the location of the hsp60s
gene. With this data, the greatest interest lay in the upstream region of the gene. If the
promoter contains a heat shock element, a characteristic promoter element in heat shock
genes, an expression could yet be possible. A putative heat shock element was discov-
ered, located 978 bases upstream of the ATG from Hsp60s1. A test with the Match soft-
ware against the transcription factor database Transfac found the putative heat shock
element suitable for binding the human heat shock transcription factor 1. HSF1 is the
typical eukaryotic DNA–binding protein that specifically binds heat shock promoter ele-
ments (HSE) and activates transcription.
With these findings it was hypothesized, that the hsp60s gene could be expressed. For
verification, several hypothetical mRNA sequences were formulated for hsp60s, includ-
ing those requiring a readthrough to the TGA stop codon of the hsp60s1 ORF. RT–PCRs
were performed with diverse primers to test these hypotheses.
However, none of the sequences considered could be confirmed: Based on these results,
it can be concluded, that the hsp60s gene is most likely a pseudogene of the hsp60 gene.
It may still be possible, that the hsp60s gene is expressed in tissue other than blood. Ad-
ditionally, it may only be expressed under stress conditions (our expression analysis was
carried out under non–stress conditions). While the required experiments are outside the
scope of this work, they could be considered in future research.
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4.3.1 Stop codon readthrough in eukaryotes, application to hsp60s
If the stop codon of hsp60s1 is overread, a continuous open reading frame emerges with
a slightly altered protein sequence, but the same length (573 amino acids) as the regular
Hsp60 protein. The similarity in an alignment with the Lipman–Pearson algorithm be-
tween the putative protein of a continous ORF of hsp60s and the Hsp60 protein was 95.5
%.
Considering the possibility of a stop codon readthrough, known to exist in the human
genome, it was decided to take a closer look on this phenomenon. The stop codon of the
hsp60s1 open reading frame is UGA, called opal. Termination codons are not represented
by a tRNA. Release factors catalyze the termination of the protein synthesis. A so–called
nonsense suppressor tRNA is able to read the stopcodon and incorporates an amino acid;
the protein translation carries on to the next stop codon. The description nonsense sup-
pressor was named after the nonsense mutation: a point mutation creating a stop codon
and thus a premature termination of the protein synthesis. Nonsense suppressor tR-
NAs, making a readthrough of a stop codon possible (translational readthrough), exist
in prokaryotes and eukaryotes. They are known in bacteria (E. Coli), yeast, mammals
(e.g., rabbits), avians (e.g., chickens) and amphibia (O’Neill et al 1985; Pratt et al 1985).
The bacterial UGA suppressor tRNA, derived from the tryptophan tRNA, has an altered
conformation of the anticodon loop. It allows a pairing between the anticodon ←−CCA and
the regular codon for tryptophan (UGG) as well as a pairing with the termination codon
UGA. In eukaryotes, the bovine liver contains a tRNASer with the anticodon ←−CCA , that
should respond to tryptophan, but in fact it responds to UGA. ”The codon–anticodon recog-
nition of either wild type or mutant tRNA cannot be predicted entirely from the relevant triplet
sequences, but is influenced by other features of the molecule.” (Lewin 2000).
O’Neill et al. (O’Neill et al 1985) discovered a gene for an opal suppressor tRNA in
humans with a ←−TCA anticodon, demonstrating that the mature tRNA reads the termi-
nation codon UGA. Lee et al. (Lee et al 1989; Lee et al 1990) proved the existence of a
unique opal suppressor seryl–tRNA in higher vertebrates. They found a single gene for
this tRNA in humans and chicken. More important this tRNA serves as a selenocysteyl–
tRNA (tRNASec), being the donor for the unique amino acid selenocysteine in response
to specific UGA codons. A readthrough of the UGA stop codon to incorporate selenocys-
teine needs a secis sequence (selenocysteine insertion sequence) downstream of the UGA, the
tRNASec and a specific, GTP–dependant translation factor (SelB in bacteria). The secis ele-
ment forms a distinct secondary structure of the mRNA, a stem loop with a non–Watson–
Crick motif downstream of the UGA in the 3’ untranslated region (Grundner–Culemann
et al 1999).
The incorporation of selenocysteine is a characteristic of selenoproteins like glutathione
peroxidase enzymes, iodothyronine deiodinase enzymes and thioredoxin reductase (TR).
The human heat shock protein 60 does not belong to this protein class. Based on the
close relationship between the hsp60 gene and the hsp60s gene it can be assumed, that
the hsp60s gene does not encode for a selenoprotein either. Despite the low likelihood,
the prior findings do not completely exclude the possibility for a readthrough of the opal
stop codon at the end of the hsp60s1.
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4.4 Direct sequencing of PCR products obtained from
DNA of SIDS victims
Most of the current forensic test kits work with sequence lengths between 100 and 350
bases for fragment length analysis of genomic DNA (for example the AmpFLSTR Profiler
Plus, Cofiler, and Profiler Plus ID PCR Amplification Kits of Applied Biosystems). These
test kits contain specified primers to identify individual humans. A similar approach
(with appropriate primers) would be possible for any fragment with a maximum length
of 350 bases. However, these methods do not include an analysis of the DNA sequence.
Thus, they are not usable for a mutation analysis of all bases on an entire fragment.
A successful PCR/direct sequencing approach was demonstrated for fragments up to
400 bases for DNA from blood samples of SIDS victims. Even DNA from 15 year old
blood samples could be analysed with these methods. If the DNA is isolated from corpse
blood shortly after blood withdrawal during an autopsy, the genomic DNA can be used
for PCR and direct sequencing up to lengths of 2.2 kB. However, this requires a relatively
fresh corpse, the autopsy must be performed no more than a few days after death. In SIDS
cases, the autopsy often takes place shortly after death. Blood samples should be taken
during the autopsy and the DNA should be isolated as quickly as possible, enabling the
application of molecular biology methods for mutation analysis and further research on
Sudden Infant Death Syndrome.
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5 Summary and Future Work
Sudden Infant Death Syndrome (SIDS) is still one of the leading causes of infant death
in Germany and other Western countries. It is certainly the most enigmatic one. To-
day, many risk factors and other characteristics are known, but the genesis is still not
completely understood. A genetic predisposition or a genetic defect have long been sus-
pected to be a part of Sudden Infant Death Syndrome. As one candidate for such a defect,
variations in the human heat shock protein gene 60 (chaperonin60, hsp60) were examined
between SIDS cases and controls.
The cases showed typical characteristics of Sudden Infant Death Syndrome (SIDS). For
example, a characteristic epidemiological trait and by now well known risk factor is prone
sleeping. Over 70 % of 61 SIDS cases, where the body position in death was documented,
were found prone. Sex is another risk factor: male children are more likely to suffer from
Sudden Infant Death than female children. The sample includes about two thirds of boys.
Overall, the SIDS cases show the typical age distribution, with a peak between 2 and 4
months. Typical autopsy results include petechiae in the pleura, epicardium and thymus,
as well as hemorrhage in the respiratory tract. Over two thirds of the examined cases
showed either one or all of the characteristics. The controls were age and sex matched
children encountered in paternity testing.
A connection between heat stress and Sudden Infant Death has been known for over
twenty years. Many SIDS victims were found soaked in sweat or had infectious diseases,
that induce high fever, shortly before death. Hyperthermia and ultimately heat shock are
strong risk factors for SIDS. The most important molecular factors for heat stress response
in the cell are heat shock (stress) proteins. These proteins have two different tasks in the
cell: As molecular chaperones, they assist in protein folding following synthesis. As part
of the stress response, they maintain protein stability under stress circumstances. Dam-
aged proteins are refolded; if the damage is too severe, the proteins are degraded. The
human Hsp60, whose exon 5 and boundaries were analysed in SIDS cases and controls,
is a protein of the mitochondrial matrix. It binds to partly folded proteins and assists in
correct folding. Furthermore, it is involved in the assembly of multimeric complexes.
No difference between SIDS cases and controls in the DNA sequence of the exon 5 of the
hsp60 gene could be detected. But the SIDS cases showed a statistically significant higher
amount of deletions in the intron 5 than the controls. This confirms other research results
on DNA variations in SIDS cases. Overall, the SIDS cases showed more mutations than
the controls. The Sudden Infant Death Syndrome is generally viewed as a multifactorial
process. A genetic defect is thus assumed to be necessary, but not sufficient for the genesis
of SIDS. The deletions in intron 5 do not disrupt any known regulatory sequences (donor,
acceptor, branch site). But since intron 5 belongs to the rare GC–AG intron class, which
is assumed to be highly regulated, the deletions may have an impact on other regulatory
sites.
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During the research in the human hsp60 gene, a previously undocumented gene of the
Chaperonin (HSP60) family was discovered. It shows a high similarity in length and se-
quence (97.5 %) to the mRNA of the hsp60 gene. The genomic sequence does not contain
introns and is much shorter compared to the regular hsp60 gene. Thus, it was named
hsp60s (s for short). Because of the similarity and a mitochondrial leader peptide se-
quence at the N–terminal end of the putative protein, it was assumed to be an inducible
variant of the hsp60 gene. After fully sequencing it, two open reading frames instead of
the single one in hsp60 were found. A readthrough to the stop codon of the first ORF
would lead to a continous ORF. Stop codon readthrough exists in the human genome,
but only on rare occasions. An expression analysis (reverse transcriptase PCR on RNA
from blood) of the hsp60s gene showed no results. It can be concluded, that the hsp60s
gene is a pseudogene of the human chaperonin60 gene. However, it may still be possible,
that hsp60s is only expressed under stress (the expression analysis was carried out under
non–stress conditions) and/or in tissues other than blood.
The results from the present thesis can be applied to practical forensics. DNA fragments
of different sizes from up to 15 year old blood samples of SIDS cases were amplified and
sequenced. The amplification and direct sequencing of genomic DNA from corpses is
becoming more and more important in forensics as older unsolved criminal cases will be
examined again. It was demonstrated, that the approach of PCR and direct sequencing of
DNA isolated from corpses, is possible for lengths up to 400 bases, even in older samples.
Research on Sudden Infant Death is like a puzzle. Due to the multifactorial genesis
every result adds another piece to the whole picture. Until recently, most of the research
was conducted in either epidemiological or anatomical fashion. This lead to the recog-
nition of risk factors, such as prone sleeping, heat stress and smoking. The following
”back–to–sleep” campaigns (putting babies in a supine sleep position, instead of a prone
position, if not medically contraindicated) reduced the SIDS incidence in many countries.
An autopsy is absolutely necessary in any case of Sudden Infant Death. It enables the
diagnosis ”Sudden Infant Death” and distinguishes it from filicide and other causes of
death.
This thesis clearly shows, that a molecular biological approach should be included in
the research of the Sudden Infant Death Syndrome. As mentioned before, Sudden Infant
Death probably has a genetic component. These genetic defects are most likely to differ
out in different SIDS cases. It was suspected, that the heat shock response plays a vital role
in Sudden Infant Death. Therefore, more genes of heat shock proteins should be analysed
in SIDS cases compared to appropriate controls. Applying the micro array technique
could be very promising. Before specific genes or parts of these genes are analysed, a
general human micro array analysis and/or a micro array analysis emphasizing on heat
shock genes should be carried out to determine differences and abnormalities in the total
gene expression between SIDS cases and controls.
A very important part in the ongoing research on Sudden Infant Death should be
strong partnership between epidemiology, forensic medicine, and molecular biology. The
knowledge and abilities of the researchers in epidemiology and forensic medicine estab-
lished the foundation for further work. Now it is time to broaden that knowledge and
let molecular biologists apply the methods of the 21st century to the research on Sudden
Infant Death Syndrome.
98
6 Bibliography
ABI PRISM Training Course (1999): ”Sequencing Analysis (310) Manual.”; Applied
Biosystems/Applera Deutschland GmbH.
Ahn SG, Thiele DJ (2003): ”Redox regulation of mammalian heat shock factor 1 is essen-
tial for Hsp gene activation and protection from stress.”; Genes & Development; 17;
pp. 516–528.
American Academy of Pediatrics, Task Force on Infant Sleep Position and Sudden Infant
Death Syndrome (1999): ”Changing Concepts of Sudden Infant Death Syndrome:
Implications for Infant Sleeping Environment and Sleep Position (RE9946).”;  
ﬂ$$$%

ﬂ&ﬁﬀ'(ﬃ))*ﬀ+," #ﬁ .
Anfinsen CB (1973): ”Principles that Govern the Folding of Protein Chains.”; Science;
Vol. 181, No. 4096; pp. 223–230.
Atschul SF, Gish W, Myers WMEW, Lipman DJ (1990): ”Basic local alignment search
tool.”; Journal of Molecular Biology; Vol. 215; pp. 403–410.
Atschul SF, Madden TL, Schäffer AA, Zhang J, Zhang Z, Miller W, Lipman DJ (1997):
”Gapped BLAST and PSI–BLAST: a new generation of protein database search pro-
grams.”; Nucleic Acids Research; Vol 25; pp. 3389–3402.
Bach V, Telliez F, Libert J–P (2002): ”The interaction between sleep and thermoregulation
in adults and neonates.”; Sleep Medicine Reviews; Vol. 6, No. 6; pp. 481–492.
Becker J, Craig E (1994): ”Heat–shock proteins as molecular chaperones.”; European
Journal of Biochemistry/FEBS; 219; pp. 11–23.
Beckwith JB (2003): ”Defining the Sudden Infant Death Syndrome.”; Archives of pedi-
atrics & adolescent medicine; Vol. 157; pp. 286–290.
Beckwith JB (1993): ”A proposed new definition of the sudden infant death syndrome.”;
In: ”Second SIDS International Conference 1992.”; ed Walker AM, McMillan C; Peri-
natology Press; Ithaca New York USA; pp. 421–424.
Beckwith JB (1970): ”Discussion of terminology and definition of the sudden infant
death syndrome.”; In: ”Sudden Infant Death Syndrome. Proceedings of the Sec-
ond International Conference on Causes of Sudden Death in Infants.”; ed Bergman
AB, Beckwith JB, Ray CG; University of Washington Press; Seattle; pp. 14–22; 1970.
Beere HM, Green DR (2001): ”Stress management – heat shock protein–70 and the regu-
lation of apoptosis.”; Trends in Cell Biology; Vol. 11, No. 1; pp. 6–10.
99
Benjamin IJ, McMillan DR (1998): ”Stress (Heat Shock) Proteins, Molecular Chaperones
in Cardiovascular Biology and Disease.”; Circulation Research; 83; pp. 117–132.
Berry PJ (1992): ”Pathological findings in SIDS.” Journal of Clinical Pathology; Vol. 45
(Supplement); pp. 11–16.
Blackwell CC, Weir DM (1999): ”The role of infection in sudden infant death syndrome.”;
FEMS Immunology and Medical Microbiology; Vo. 25; pp. 1–6.
Blackwell CC, Weir DM, Busuttil A (1999): ”Infection, inflammation and sleep: more
pieces to the puzzle of sudden infant death syndrome (SIDS).”; APMIS; 107; pp.
455–473.
Bross P, Hansen JJ, Li Z, Nyholm M, Kølvraa S, Lundemose J, Bolund L, Yang H,
Gregersen N (2001): ”Absence of prevalent sequence variations in the HSP60 and
HSP10 chaperonin genes in 65 cases of Sudden Infant Death Syndrome (SIDS).”;
American Journal of Human Genetics 69 (4); p. 2193; Supplement October.
Bukau B, Horwich AL (1998): ”The Hsp70 and Hsp60 Chaperone Machines.”; Cell; Vol
92.; pp. 351–366.
Burset M, Seledtsov IA, Slovyev VV (2000): ”Analysis of canonical and non–canonical
splice sites in mammalian genomes.”; Nucleic Acids Research; Vol. 28, No. 21; pp.
4364–4375.
Byard RW, Krous HF (2003): ”Sudden Infant Death Syndrome: Overview and Update.”;
Pediatric and Developmental Pathology; Vol. 6 (2); pp. 112–127.
Carrascosa JL, Llorca O, Valpuesta JM (2001): ”Structural comparison of prokaryotic and
eukaryotic chaperonins.”; Micron; 32; pp. 43–50.
Cell Stress & Chaperones (2000): ”Instruction to Authors.”; Cell Stress & Chaperones;
Vol. 5, No. 1.
Cohen G, Han Z–Y, Grailhe R, Gallego J, Gaultier C, Changeux J–P, Lagercrantz H
(2002): ”β2 nicotinic acetylcholine receptor subunit modulates protective responses
to stress: A receptor basis for sleep–disordered breathing after nicotine exposure.”;
Proceedings of the National Academy of Sciences; Vol. 99 No. 20; pp. 13272–13277.
Clark F, Thanaraj TA (2002): ”Categorization and characterization of transcript–
confirmed constitutively and alternatively spliced introns and exons from human.”;
Human Molecular Genetics; Vol. 11, No. 4; pp. 451–464.
De Maio A (1999): ”Heat Shock Proteins: Facts, Thoughts and Dreams.”; Shock; Vol. 11,
No. 1; pp. 1–12.
De Maio A (1995): ”The Heat Shock Response.”; New Horizons; Vol. 3, No. 2; pp.
198–207.
100
DOE Joint Genome Institute and Stanford Human Genome Center (2003): ”Homo sapi-
ens chromosome 5 clone RP11–704G19, complete sequence.”; GenBank Accession
Number AC138940; National Institute of Health, USA;  ﬂ$$$"-#(.#'/"-0ﬁ1!"-#'1 
ﬀ2 .
DOE Joint Genome Institute and Stanford Human Genome Center (2002): ”Homo sapi-
ens chromosome 5 clone CTD–2577N22, complete sequence.”; GenBank Accession
Number AC091873; National Institute of Health, USA;  ﬂ$$$"-#(.#'/"-0ﬁ1!"-#'1 
ﬀ2 .
Douglas AS, Helms PJ, Joliffe IT (1998): ”Seasonality of sudden infant death syndrome
in mainland Britain and Ireland 1985–95.”; Archives of Disease in Childhood; Vol.
79; pp. 269–270.
Durlach J, Pagés N, Bac P, Bara M, Guiet–Bara A (2002): ”Magnesium deficit and sudden
infant death syndrome (SIDS): SIDS due to magnesium deficiency and SIDS due to
various forms of magnesium depletion: possible importance of the chronopatho-
logical from.”; Magnesium Research; Vol. 15 (3/4); pp. 269–278.
Edenhofer F, Rieger R, Famulok M, Wendler W, Weiss S, Winnacker EL (1996): ”Prion
Protein PrPc Interacts with Molecular Chaperones of the Hsp60 Family.”; Journal of
Virology; Vol. 70, No. 7; pp. 4724–4728.
EditSeq (1999); Software for Windows 32 EditSeq 4.05; DNASTAR Incorporated; 1989–
2000.
Einspieler C (2000): ”Risikofaktoren für den plötzlichen Säuglingstod – Poten-
tielle Risikofaktoren aus der Umgebung des Säuglings.”; In: ”Der plötzliche
Säuglingstod. Ein Ratgeber für Ärzte und Betroffene.”; ed Kurz R, Kenner T, Po-
ets CF; Textbook; Springer–Verlag Wien; pp. 161–175.
Elabbassi EM, Bach V, Makki M, Delanaud S, Telliez F, Leke A, Libert J–P (2001): ”Assess-
ment of dry heat exchanges in newborns: influence of body position and clothing in
SIDS.”; Journal of Applied Physiology; Vol. 91; pp. 51–56.
Ellis RJ (2001): ”Macromolecular crowding: an important but neglected aspect of the
intracellular environment.”; Current Opinion in Structural Biology; 11; pp. 114–119.
Ellis RJ (1990): ”The molecular chaperone concept.”; Seminars in Cell Biology; 1; pp.
1–9.
Ellis RJ (1987): ”Proteins as molecular chaperones.”; Nature; Vol. 328; pp. 378–379.
Falkowska–Podstawka M, Wernicki A (2003): ”Heat shock protein in health and dis-
ease.”; Polish Journal of Veterinary Sciences; Vol. 6, No. 1; pp. 61–70.
Fernandes M, O’Brien T, Lis JT (1994): ”Structure and Regulation of Heat Shock Gene
promoters.”; In: ”The Biology of Heat Shock Protein and Molecular Chaperones.”;
ed Morimoto RI, Tissiéres A, Georgopoulos C; Cold Spring Harbor Laboratory
Press; pp. 375–393.
101
Findeisen M, Vennemann M, Brinkmann B, Ortmann C, Röse I, Köpcke W, Jorch G, Ba-
janowski T, GeSID group (2003): ”German Study on Sudden Infant Death (GeSID):
design, epidemiological and pathological profile.”; in print.
Fink AL (1999): ”Chaperone–mediated protein folding.”; Physiological Reviews; Vol. 70,
No. 2; pp. 425–449.
Fleming PJ, Azaz Y, Wigfield R (1992): ”Development of thermoregulation in infancy:
Possible implications for SIDS.”; Journal of Clinical Pathology; Vol 45, Supplement;
pp. 17–19.
Forsyth KD (1999): ”Immune and inflammatory response in sudden infant death syn-
drome.”; FEMS Immunology and Medical Microbiology; Vol. 25; pp. 79–83.
Fracella F, Rensing L (1995): ”Streßproteine: Ihre wachsende Bedeutung in der Medi-
zin.”; Naturwissenschaften; 82; pp.303–309.
Frejtag W, Zhang Y, Dai R, Anderson MG, Mivechi NF (2001): ”Heat Shock Factor–4
(HSF–4a) represses Basal Transcription through Interaction with TFIIF.”; Journal of
Biological Chemistry; Vol. 276, No. 18; pp. 14685–14694.
Frydman J (2001): ”Folding of newly translated proteins in vivo: The Role of Molecular
Chaperones.”; Annuela Reviews in Biochemistry; 70; pp. 603–647.
Frydman J, Nimmesgern E, Ohtsuka K, Hartl FU (1994): ”Folding of nascent polypeptide
chains in a high molecular mass assembly with molecular chaperones.”; Nature; Vol.
370; pp. 111–117.
Galland BC, Taylor BJ, Bolton DPG (2002): ”Prone versus supine sleep position: A review
of the physiological studies in SIDS research.”; Journal of Paediatrics and Child
Health; 38; pp. 332–338.
Gauczynski S, Hundt C, Leucht C, Weiss S (2001): ”Interaction of prion proteins with
cell surface receptors, molecular chaperones, and other molecules.”; Advances in
Protein Chemistry; Vol. 57; pp. 229–272.
GDB (2004): ”The Genome Database.”;  ﬂ$$$34. ; The Hospital For Sick Chil-
dren; Toronto, Ontario, Canada; 1998–2002; Johns Hopkins University; Baltimore
Maryland; United States of America; 1990–2002; RTI International; 2003–2004.
Geerlings H (2004): ”A skew between -1.5 and +1.5 can be assumed Gauss–distributed.”;
personal communication with Dipl. Math. H. Geerlings, Department of Biostatis-
tics, Medical School Hannover.
GENBANK (2004): ”Genetic Sequence Data Bank.”; National Institute of Health, USA;
 ﬂ$$$5-#(.6'/5-0ﬁ1!"-#'1 3ﬀ2 ; 1988–2004
Gibson E (2000): ”Infant Sleep Position Practices 2 Years Into the ”Back to Sleep” Cam-
paign.”; Clinical Pediatrics (Philadelphia); Vol. 39(5); pp. 285–289.
102
Glass JI, Lefkowitz EJ, Glass JS, Heiner CR, Chen EY, Cassell GH (2000): ”The complete
sequence of the mucosal pathogen Ureaplasma urealyticum.”; Nature; 407; pp. 450–
453.
Gordon AE, MacKenzie DAC, El Ahmer OR, Al Madani OM, Braun JM, Weir DM, Busut-
til A, Blackwell CC (2002): ”Evidence for a genetic component in Sudden Infant
Death Syndrome.”; Child: Care, Health and Development; 28, Supplement 1; pp.
27–29.
Grantcharova V, Alm EJ, Baker D, Horwich AL (2001): ”Mechanisms of protein folding.”;
Current Opinion in Structural Biology; 11 (1); pp. 70–82.
Grundner–Culemann E, Martin GW III, Harney JW, Berry MJ (1999): ”Two distinct SE-
CIS structures capable of directing selenocysteine incorporation in eukaryotes.”;
RNA; 5; pp. 625–635.
Gupta RS (1995): ”Evolution of the chaperonin families (HSP60, HSP10 and TCP–1) of
proteins and the origin of eukaryotic cells.”; Molecular Microbiology; 15(1); pp. 1–
11.
Guntheroth WG, Spiers PS (2001): ”Thermal Stress in Sudden Infant Death: Is there an
Ambiguity With the Rebreathing Hypothesis?”; Pediatrics; Vol. 107(4); pp. 693–698.
Hahn GM, Shiu EC, Auger EA (1991): ”Mammalian Stress Proteins Hsp70 and Hsp28
Coinduced by Nicotine and either Ethanol or Heat.”; Molecular and Cellular Biol-
ogy; Vol. 11, No. 12; pp. 6034–6040.
Hansen A (2001): ”Bioinformatik – Ein Leitfaden für Naturwissenschaftler.”; Textbook;
Birkhäuser Verlag; Basel, Boston, Berlin.
Hansen JJ, Bross P, Westergaard M, Nyholm Nielsen M, Eiberg H, Børglum A, Mogensen
J, Kristiansen K, Bolund L, Gregersen N (2003a): GenBank–Entry: AJ250915: ”Homo
sapiens p10 gene for chaperonin 10 (Hsp10 protein) and p60 gene for Chaper-
onin60 (Hsp60 protein).”; GenBank Accession Number AJ250915; National Institute
of Health, USA;  ﬂ$$$5-#(.6'/5-0ﬁ175-6'8 3ﬀ2 ; November 1999–December 2003.
Hansen JJ, Bross P, Westergaard M, Nyholm Nielsen M, Eiberg H, Børglum A, Mogensen
J, Kristiansen K, Bolund L, Gregersen N (2003b): ”Genomic Structure of the human
mitochondrial chaperonin genes: HSP60 and HSP10 are localised head to head on
chromosome 2 separated by a bidirectional promoter.”; Human Genetics 112; pp.
71–77.
Hansen JJ, Dürr A, Cournu–Rebeix I, Georgopoulus C, Ang D, Nyholm Nielsen M,
Davoine C–S, Brice A, Fontaine B, Gregersen N, Bross P (2002): ”Hereditary Spastic
Paraplegia SPG13 is Associated with a Mutation in the Gene Encoding the Mito-
chondrial Chaperonin Hsp60.”; American Journal of Human Genetics; 70; pp. 1328–
1332.
103
Hardy Havens D, Zink RL (1994): ”The ”Back To Sleep” Campaign.”; Journal of pe-
diatric health care : official publication of National Association of Pediatric Nurse
Associates & Practitioners; Vol. 8; pp.240–242.
Hartl FU (1996): ”Molecular chaperones in cellular protein folding.”; Nature; Vol. 381;
pp. 571–580.
Hasday JD, Singh IS (2000): ”Fever and the heat shock response: distinct, partially over-
lapping processes.”; Cell Stress & Chaperones; 5 (5); pp. 471–480.
He H, Soncin F, Grammatikakis N, Li Y, Siganou A, Gong J, Brown SA, Kingston RE,
Calderwood SK (2003): ”Elevated Expression of Heat Shock Factor (HSF) 2A Stimu-
lates HSF1–induced Transcription during Stress.”; The Journal of Biological Chem-
istry; Vol. 278, No. 37; pp. 35465–35475.
Hein JJ (1990): ”Unified approach to alignment and phylogenies.”; Methods in Enzy-
mology; Vol. 183; pp. 626–645.
Helweg–Larsen K, Lundemose JB, Øyen N, Skjærven R, Alm B, Wennergren G,
Markestad T, Irgens LM (1999): ”Interactions of infectious symptoms and modi-
fiable risk factors in sudden infant death syndrome. The Nordic Epidemiological
SIDS study.”; Acta Pædiatrica; 88; pp. 521–527.
Hofmann S, Jaksch M, Bezold R, Mertens S, Aholt S, Paprotta A, Gerbitz K–D (1997):
”Population genetics and disease susceptibility: characterization of central Euro-
pean haplogroups by mtDNA gene mutations, correlation with D loop variants and
association with disease.”; Human Molecular Genetics; Vol. 6 No. 11; pp. 1835–
1846.
Hunt CE (2001): ”Sudden Infant Death Syndrome and Other Causes of Infant Mortality;
Diagnosis, Mechanisms and Risk for Recurrence in Siblings.”; American Journal of
Respiratory and Critical Care Medicine; Vol. 164; pp. 346–357.
Hunt CE, Hauck FR (2004): ”Sudden Infant Death Syndrome.” In: ”Nelson Textbook of
Pediatrics.”; ed Behrmann RE, Kliegmann R, Jenson HB; Textbook ; Saunders.
Jindal S, Dudani AK, Singh B, Harley CB, Gupta RS (1989): ”Primary structure of a
Human Mitochondrial Protein Homologous to the Bacterial and Plant Chaperonins
and to the 65–Kilodalton Mycobacterial Antigen.”; Molecular and Cellular Biology;
Vol. 9, No. 5; pp. 2279–2283.
Jorch G (2000): ”SIDS–Mortalit"at im deutschsprachigen Raum und weltweit.”; In: ”Der
plötzliche Säuglingstod. Ein Ratgeber für Ärzte und Betroffene.”; ed Kurz R, Kenner
T, Poets CF; Textbook; Springer–Verlag Wien; pp. 21–38.
Katinka MD, Duprat S, Cornillot E, Metenier G, Thomarat F, Prensier G, Barbe V, Peyre-
taillade E, Brottier P, Wincker P, Delbac F, El Alaoui H, Peyret P, Saurin W, Gouy M,
Weissenbach J, Vivares CP (2001): ”Genome sequence and gene compaction of the
eukaryote parasite Encephalitozoon cuniculi.”; Nature; 407; pp. 757–762.
104
Kel AE, Gößling E, Reuter E, Cheremushkin E, Kel–Margoulis OV, Wingender E
(2003): ”MATCH: a tool for searching transcription factor binding sites in DNA
sequences.”; Nucleic Acids Research; Vol. 31 No. 13; pp3576–3579.
Kleemann WJ (2000): ”Obduktionen: Histologische Untersuchungen.”; In: ”Der plöt-
zliche Säuglingstod. Ein Ratgeber für Ärzte und Betroffene.”; ed Kurz R, Kenner T,
Poets CF; Textbook; Springer–Verlag Wien; pp. 71–81.
Kleemann WJ (1996): ”Der plötzliche Kindstod – Epidemiologie, Morphologie, Patho-
genese”; Habilitationsschrift; Institut für Rechtsmedizin; Medizinische Hochschule
Hannover.
Kleemann WJ (1991): ”Plötzlicher Säuglingstod – Dokumentation eines Fachge-
sprächs.”; Düsseldorf; 15. Mai.
Kleemann WJ, Rognum TO (2000): ”Obduktionen: Makroskopische Befunde.” In: ”Der
plötzliche Säuglingstod. Ein Ratgeber für Ärzte und Betroffene.”; ed Kurz R, Kenner
T, Poets CF; Textbook; Springer–Verlag Wien; 60–70.
Kleemann WJ, Schlaud M, Fieguth A, Hiller AS, Rothämel T, Tröger HD (1998): ”Body
and head position, covering of the head by bedding and risk of sudden infant death
(SID); International Journal of Legal Medicine; 112; pp. 22–26.
Kleemann WJ, Schlaud M, Poets CF, Rothämel T, Tröger HD (1996): ”Hyperthermia in
Sudden Infant Death.”; International Journal of Legal Medicine; 109; pp. 139–142.
Köstl G, Kerbl R (2000): ”Risikofaktoren für den plötzlichen Säuglingstod – SIDS und
Frühgeburtlichkeit, Perinatale Risikofaktoren und Besonderheiten des Frühgebore-
nen.” In: ”Der plötzliche Säuglingstod. Ein Ratgeber für Ärzte und Betroffene.”; ed
Kurz R, Kenner T, Poets CF; Textbook; Springer–Verlag Wien; pp. 151–157.
Kubota H, Hynes G, Carne A, Ashworth A, Wilison K (1994): ”Identification of six Tcp–
1 related genes encoding divergent subunits of the TCP–1 containing chaperonin.”;
Current Biology; Vol. 4, No. 2; pp. 89–99.
Kurz R (2000a): ”Die Diagnose –”SIDS”– eine Verlegenheitsdiagnose? Definition und
Klassifikation.” In: ”Der plötzliche Säuglingstod. Ein Ratgeber für Ärzte und Be-
troffene.”; ed Kurz R, Kenner T, Poets CF; Textbook; Springer–Verlag Wien; pp. 17–
20.
Kurz R (2000b): ”SIDS – ein multifaktorielles Geschehen?” In: ”Der plötzliche
Säuglingstod. Ein Ratgeber für Ärzte und Betroffene.”; ed Kurz R, Kenner T, Po-
ets CF; Textbook; Springer–Verlag Wien; pp. 211–214.
Kurz R (2000c): ”Risikofaktoren für den plötzlichen Säuglingstod – Infektionen.” In:
”Der plötzliche Säuglingstod. Ein Ratgeber für Ärzte und Betroffene.”; ed Kurz R,
Kenner T, Poets CF; Textbook; Springer–Verlag Wien; pp. 176–180.
Kurz R, Kenner T, Poets CF (2000): ”Der plötzliche Säuglingstod. Ein Ratgeber für Ärzte
und Betroffene.”; Textbook; Springer–Verlag Wien.
105
Laskey RA, Honda BM, Mills AD, Finch JT (1978): ”Nucleosomes are assembled by an
acidic protein which binds histones and transfers them to DNA.”; Nature; Vol. 275;
pp. 416–420.
Latchman DS (2001): ”Heat shock proteins and cardiac protection.”; Cardiovascular Re-
search; 51; pp. 637–646.
Lee BJ, Rajagopalan M, Kim YS, You KH, Jacobson KB, Hatfield DL (1990): ”Selenocys-
teine tRNA[Ser]Sec Gene is Ubiquitous within the Animal Kingdom.”; Molecular and
Cellular Biology; Vol. 10, No. 5; pp. 1940–1949.
Lee BJ, Worland PJ, Davis JN, Stadtman TC, Hatfield DL (1989): ”Identification of a
Selenocysteyl–tRNASer in Mammalian Cells That Recognizes the Nonsense Codon,
UGA.”; The Journal of Biological Chemistry; Vol. 264, No. 17; pp. 9724–9727.
Levinthal C (1968): ”Are there pathways for protein folding.”; Journal de Chimie
Physique et de Physico–Chimie Biologique; 65; pp. 44–45.
Levy–Rimler G, Bell RE, Ben–Tal N, Azem A (2002): ”Type I chaperonins: not all are
created equal.”; FEBS Letters; 529; pp. 1–5.
Levy–Rimler G, Viitanen P, Weiss C, Sharkia R, Greenberg A, Niv A, Lustig A, Delarea Y,
Azem A (2001): ”The effect of nucleotides and mitochondrial chaperonin 10 on the
structure and chaperone activity of mitochondrial chaperonin60.”; European Jour-
nal of Biochemistry; 268; pp. 3465–3472.
Lewin, B (2000): ”Genes VII.”; Textbook; Oxford university Press.
Lipman DJ, Pearson WR (1985): ”Rapid and sensitive protein similarity searches.”; Sci-
ence; 227; pp. 1435–1441.
Mage DT, Donner M (1997): ”A genetic basis for the sudden infant death syndrome sex
ratio.”; Medical Hypotheses; Vol. 48; pp. 137–142.
Maguire M, Coates ARM, Henderson B (2002): ”Chaperonin60 unfolds its secrets of
cellular communication.”; Cell Stress & Chaperones; 7 (4); pp. 317–329.
Martin CC, Tsang CH, Beiko RG, Krone PH (2002): ”Expression and genomic organiza-
tion of the zebrafish chaperonin gene complex.”; Genome; 45; pp. 804–811.
Martinez HM (1983): ”An efficient method for finding repeats in molecular sequences.”;
Nucleic Acids Research; 11; pp. 4926–4634.
Mathew A, Mathur SK, Jolly C, Fox SG, Kim S, Morimoto RI (2001): ”Stress–Specific
Activation and Repression of Heat Shock Factors 1 and 2.”; Molecular and Cellular
Biology; Vol. 21, No. 21; pp. 7163–7171.
Matys V, Fricke E, Geffers R, Gö"sling E, Haubrock M, Hehl R, Hornischer K, Karas
D, Kel AE, Kel–Margoulis OV, Kloos DU, Land S, Lewicki–Potapov B, Michael
H, Münch R, Reuter I, Rotert S, Saxel H, Scheer M, Thiele S, Wingender E (2003):
106
”TRANSFAC: transcriptional regulation, from patterns to profiles.” Nucleic Acids
Research; Vol. 31; pp. 374–378. (BIOBASE Biological Databases GmbH, Halchter-
sche Strasse 33, D–38304 Wolfenbüttel,  ﬂ$$$".6' .
ﬃ,34ﬀ )
McCarthy C (1998): ”Chromas Version 1.45.”; School of Health Science; Griffith
University; Gold Coast Campus; Southport Queensland; Australia;  ﬂ$$$
ﬀ( -&ﬁﬂ0'179(ﬃ!	
ﬀ(1 ﬀﬀ&
/" #ﬁ ; 1996–1998.
MegAlign (1999): Software for Windows 32 MegAlign 4.05; DNASTAR Incorporated;
1993–2000.
Minowada G, Welch WJ (1995): ”Clinical Implications of the Stress Response.”; The Jour-
nal of Clinical Investigation; Vol. 95; pp. 3–12.
MITOMAP (2004): ”A Human Mitochondrial Genome Database.”;  	ﬂ$$$
:'0
ﬂ .
Morimoto RI (1998): ”Regulation of the heat shock transcriptional response: cross talk
between a family of heat shock factors, molecular chaperones, and negative regula-
tors.”; Genes & Development; 12; pp. 3788–3796.
Morimoto RI, Jurivich DA, Kroeger PE, Mathur SK, Murphy SP, Nakai A, Sarge K,
Abravaya K, Sistonen LT (1994): ”Regulation of Heat Shock Gene Transcription by a
Family of Heat Shock Factors.”; In: ”The Biology of Heat Shock Protein and Molec-
ular Chaperones.”; ed Morimoto RI, Tissiéres A, Georgopoulos C; Cold Spring Har-
bor Laboratory Press; pp. 417–455.
Morimoto RI, Tissières A, Georgopoulos C (1994): ”Progress and Perspectives on the
Biology of Heat shock Proteins and Molecular Chaperones.”; In: ”The Biology of
Heat Shock Protein and Molecular Chaperones.”; ed Morimoto RI, Tissiéres A, Geor-
gopoulos C; Cold Spring Harbor Laboratory Press; pp. 1–30.
Mullis K, Faloona F, Scharf S, Saiki R, Horn G, Erlich H (1986): ”Specific enzymatic
amplification of DNA in vitro: the polymerase chain reaction.”; Cold Spring Harbor
Symposium in Quantitative Biology; 51; pp. 263–73.
Narita N, Narita M, Takashima S, Nakayama M, Nagai T, Okado N (2001): ”Serotonin
Transporter Gene Variation Is a Risk Factor for Sudden Infant Death Syndrome in
the Japanese Population.”; Pediatrics; Vol. 107 No. 4; pp. 690–692.
Needleman SB, Wunsch CD (1970): ”A general method applicable to the search for sim-
ilarities in the amino acid sequence of two proteins.”; Journal of Molecular Biology;
Vol. 48; pp. 443–453.
Nelson EAS, Wong Y, Yu L, Fok T, Li K (2002): ”Effects of Hyperthermia and Muramyl
Dipeptide on IL–1β, IL–6, and Mortality in a Neonatal Rat Model.”; Pediatric Re-
search; Vol. 52, No. 6; pp. 886–891.
107
Neuer A, Spandorfer SD, Giraldo P, Rosenwaks Z, Witkin SS (2000): ”The role of heat
shock protein in reproduction.”; Human Reproduction Update; Vol. 6, No. 2; pp.
149–159.
OMIM (2000): ”Online Mendelian Inheritance in Man.”; McKusick–Nathans Institute for
Genetic Medicine, Johns Hopkins University (Baltimore, MD) and National Center
for Biotechnology Information, National Library of Medicine (Bethesda, MD);  
ﬂ$$$5-#(.6'/5-0ﬁ17"-#'1 ;ﬂ2:'<0 .
O’Neill VA, Eden FC, Pratt K, Hatfield DL (1985): ”A Human Opal Suppressor tRNA
Gene and Pseudogene.”; The Journal of Biological Chemistry; Vol. 260, No. 4; pp.
2501–2508.
Opdal SH, Rognum TO, Vege Å, Stave AK, Dupuy BM, Egeland T (1998): ”Increased
number of substitutions in the D–loop of mitochondrial DNA in the sudden infant
death syndrome.”; Acta Pædiatrica; 87; pp. 1039–1044.
Parsell DA, Lindquist S (1994): ”Heat Shock Proteins and Stress Tolerance.”; In: ”The Bi-
ology of Heat Shock Protein and Molecular Chaperones.”; ed Morimoto RI, Tissiéres
A, Georgopoulos C; Cold Spring Harbor Laboratory Press; pp. 457–494.
Pirkkala L, Nykänen P, Sistonen L (2001): ”Roles of the heat shock transcription factors
in regulation of the heat shock response and beyond.”; The FASEB journal : official
publication of the Federation of American Societies for Experimental Biology; 15 (7);
pp. 1118–1131.
Pochon NA, Mach B (1996): ”Genetic complexity of the human hsp60 gene.” ; Interna-
tional Immunology; Vol. 8, No. 2; pp. 221–230.
Pockley AG (2003): ”Heat shock proteins as regulators of the immune response.”; The
Lancet; Vol. 362; pp. 469–476.
Pockley AG (2001): ”Heat shock proteins, anti–heat shock protein reactivity and allograft
rejection.”; Transplantation; No. 11; pp. 1503–1507.
Poets CF, Jorch G (2000): ”Plötzlicher Säuglingstod.”; Deutsche Akademie für Kinder-
heilkunde und Jugendmedizin; Monatsschrift Kinderheilkunde; pp. 1064–1066.
Poets CF, Schlaud M, Kleemann WJ, Rudolph A, Diekmann U, Sens B (1994): ”Sudden
Infant Death and maternal cigarette smoking: results from the Lower Saxony Peri-
natal Working Group.”; European Journal of Pediatrics; Vol. 154; pp. 326–329.
Pollack HA, Frohna JG (2002): ”Infant Sleep Placement After the Back to Sleep Cam-
paign.”; Pediatrics; Vol. 109 No. 4; pp. 608–614.
Ponsonby AL, Dwyer T, Gibbons LE, Cochrane JA, Jones ME, McCall MJ (1992): ”Ther-
mal environment and sudden infant death syndrome: case–control study.”; BMJ;
Vol 304 (6822); pp. 277–282.
108
Pratt K, Eden FC, You KH, O’Neill VA, Hatfield D (1985): ”Conserved sequences in
both coding and 5’ flanking regions of mammalian opal suppressor tRNA genes.”;
Nucleic Acids Research; Vol. 13, No. 13; pp. 4765–4775.
Puffenberger EG, Hu-Lince D, Parod JM, Craig DW, Dobrin SE, Conway AR, Donarum
EA, Strauss KA, Dunckley T, Cardenas JF, Melmed KR, Wright CA, Liang W,
Stafford P, Flynn CR, Morton DH, Stephan DA (2004): ”Mapping of sudden infant
death with dysgenesis of the testes syndrome (SIDDT) by a SNP genome scan and
identification of TSPYL loss of function.”; Proceedings of the National Academy of
Sciences; 101(32); pp. 11689-11694.
Qiagen OneStep RT–PCR Kit (2002): ”Handbook.”; Qiagen GmbH Germany; May 2002.
Qiagen ProofStart DNA Polymerase (2002): ”PCR Handbook.”; Qiagen GmbH Ger-
many; February 2002.
QIAquick PCR purification Kit (2001): ”QIAquick Spin Handbook.”; Qiagen GmbH Ger-
many; March 2001.
Rahim RA, Boyd PA, Patrick WJA, Burdon RH (1996): ”Human heat shock protein gene
polymorphisms and sudden infant death syndrome.”; Archives of Disease in Child-
hood; 75; pp. 451–452.
Ranford JC, Coates ARM, Henderson B (2000): ”Chaperonins are cell–signaling pro-
teins: the unfolding biology of molecular chaperones.”; Expert Reviews in Molecu-
lar Medicine; Sep. 15 ; pp. 1–17.
Ranford JC, Henderson B (2002): ”Chaperonins in disease: mechanisms, models, and
treatments.”; Journal of Clinical Pathology: Molecular Pathology; 55; pp. 209–213.
Raza MW, Essery SD, Elton RA, Weir DM, Busuttil A, Blackwell CC (1999): ”Exposure
to cigarette smoke, a major risk factor for sudden infant death syndrome: effects of
cigarette smoke on inflammatory responses to viral infection and bacterial toxins.”;
FEMS Immunology and Medical Microbiology; Vol. 25; pp. 145–154.
Reimann I, Teske A, Rothämel T: ”Mutations in the mitochondrial D–Loop and Sudden
Infant Death Syndrome.” (in progress)
Riße M (2002): ”Tod im Neugeborenen– und Säuglingsalter.”; Archiv für Kriminologie;
Vol. 205 (5–6); pp. 169–179.
Ritossa F (1962): ”A New Puffing Pattern Induced by Temperature Shock and DNP in
Drosophila.”; Experientia Basel; 18; pp. 571–573.
Rognum TO (2000): ”Obduktionen: Immunologische und mikrobiologische Unter-
suchungen.”; In: ”Der plötzliche Säuglingstod. Ein Ratgeber für Ärzte und Betrof-
fene.”; ed Kurz R, Kenner T, Poets CF; Textbook; Springer–Verlag Wien; pp. 82–91.
Roll P (2000): ”Plötzlicher Säuglingstod und Kriminalität.”; In: ”Der plötzliche
Säuglingstod. Ein Ratgeber für Ärzte und Betroffene.”; ed Kurz R, Kenner T, Po-
ets CF; Textbook; Springer–Verlag Wien; pp. 107–116.
109
Rozen S, Skaletsky HJ (2000): ”Primer3 on the WWW for general users and for biologist
programmers.” In: ”Bioinformatics Methods and Protocols: Methods in Molecu-
lar Biology.” ed Krawetz S, Misener S; Humana Press; Totowa, NJ; pp. 365–386.
”Primer3”; Code available at  ﬂ$$$:=ﬂ-&1#,"$6'>?:'@4ﬀﬂ-0AﬃBﬃﬃ$

ﬂ & ﬀ0'<#ﬀCD" 6ﬁ .
Ryan MT, Herd SM, Sberna G, Samuel MM, Hoogenrad NJ, Høj PB (1997a): ”The genes
encoding mammalian chaperonin60 and chaperonin10 are linked head–to–head and
share a bidirectional promoter.”; Gene; 196; pp. 9–17.
Ryan MT, Naylor DJ, Høj PB, Clark MS, Hoogenrad NJ (1997b): ”The Role of Molecular
Chaperones in Mitochondrial protein Import and Folding.”; International Review
of Cytology; Vol. 174; pp. 127–193.
Sawczenko A, Fleming PJ (1996): ”Thermal Stress, Sleeping Position, and the Sudden
Infant Death Syndrome.”; Sleep; 19 (10 Supplement); pp. S267–270.
Schlaud M, Eberhard C, Trumann B, Kleemann WJ, Poets CF, Tietze KW, Schwartz FW
(1999): ”Prevalence and Determinants of Prone Sleeeping Position in Infants: Re-
sults from Two Cross–Sectional Studies on Risk Factors in Germany; American Jour-
nal of Epidemiology; Vol. 150 No. 1; pp. 51–57.
Schlaud M, Kleemann WJ, Poets CF, Sens B (1996): ”Smoking during Pregnancy and
Poor Antenatal Care: Two Major Preventable Risk Factors for Sudden Infant Death
Syndrome.”; International Journal of Epidemiology; Vol. 25 No. 5; pp. 959–965.
Schwartz PJ, Stramba–Badiale M, Segantini A, Austoni P, Bosi G, Giorgetti R, Grancini
F, Marni ED, Perticone F, Rosti D, Salice P (1998): ”Prolongation of the QT Interval
and the Sudden Infant Death Syndrome.”; The New England Journal of Medicine;
Vol. 388, No. 24; pp. 1709–1714.
Sherman MY, Goldberg AL (2001): ”Cellular Defenses against Unfolded Proteins: A Cell
Biologist Thinks about Neurodegenerative Diseases.”; Neuron; Vol. 29; pp. 15–32.
Singh B, Gupta RS (1992): ”Expression of Human 60–kD Heat Shock protein (HSP60 or
P1) in Escherichia Coli and the Development and Characterization of Correspond-
ing Monoclonal Antibodies.”; DNA and Cell Biology; Vol. 11, No. 6; pp. 489–496.
Slavotinek AM, Biesecker LG (2001): ”Unfolding the role of chaperones and chaperonins
in human disease.”; Trends in Genetics; Vol. 17, No. 9; pp. 528–535.
Soltys BJ, Gupta RS (1999): ”Mitochondrial–matrix proteins at unexpected locations: are
they exported?”; Trends in Biochemical Sciences; 24 (5); pp. 174–177.
SPSS (2002): ”Statistical Package for the Social Sciences.”; SPSS for Windows version
11.5.1; SPSS Inc.; November 2002.
Srivastava PK, Amato RJ (2001): ”Heat shock proteins: the ”Swiss Army Knife” vaccines
against cancers and infectious agents.”; Vaccine; 19; pp. 2590–2597.
110
Stanton AN (1984): ”Overheating and cot death.”; The Lancet: 2 (8413); pp. 1199–1201.
Sterner R, Liebl W (2001): ”Thermophilic Adaptation of proteins.”; Critical Reviews in
Biochemistry and Molecular Biology;n 36 (1); pp. 39–106.
Studie des BMBF Pl"otzlicher S"auglingstod (1998): ”Studienhandbuch Hauptphase
1998–2002”; Westf"alische Wilhelmsuniversit"at M"unster.
SWISSPROT (2004): ”Swiss–Prot Protein Knowledgebase.”; ExPASy (Expert Protein
Analysis System) proteomics server; Swiss Institute of Bioinformatics (SIB); Euro-
pean Bioinformatics Institute (EBI);  	ﬂ$$$
ﬀ ﬀ ; 1998–2004.
Sztankay Á, Trieb K, Grubeck–Loebenstein B (1993): ”Die Rolle von Streßproteinen in
der Medizin.”; Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und ver-
wandte Gebiete; 44; pp. 811–818.
Tanabe M, Sasai N, Nagata K, Liu X–D, Liu PCC, Thiele DJ, Nakai A (1999): ”The Mam-
malian HSF4 Gene Generates Both an Activator and a Repressor of Heat Shock
Genes by Alternative Splicing.”; The Journal of Biological Chemistry; Vol. 274, No.
39; pp. 27845–27856.
Tavaria M, Gabriele T, Anderson RL, Mirault M–E, Baker E, Sutherland G, Kola I
(1995): ”Localization of the Gene Encoding the Human Heat Shock Cognate Pro-
tein, HSP73, to Chromosome 11.”; Genomics; 29; pp. 266–268.
Tavaria M, Gabriele T, Kola I, Anderson RL (1996): ”A hitchhikers’s guide to the human
Hsp70 family.”; Cell Stress & Chaperones; 1 (1); pp. 23–28.
Teske A, Rothämel T, Kleemann WJ, Tröger HD (2002): ”Investigating a possible relation
between the amino acid variation N158S of the human heat shock protein Hsp60
and increased susceptibility to Sudden Infant Death Syndrome (SIDS).” The Amer-
ican Journal of Human Genetics; Vol. 71; No. 4; p. 503; Supplement October.
Teske A, Rothämel T, Kleemann WJ, Tröger HD (2001): ”GenBank–Entry: AF380943;
Homo sapiens short heat shock protein 60 Hsp60s1 and short heat shock protein 60
Hsp60s2 genes, complete cds.”; ; GenBank Accession Number AF380943; National
Institute of Health, USA;   $$$"-0(.6'/"-&ﬁ175-6'8 ;ﬂ2 ; May 2001– October 2003.
Thanaraj TA, Clark F (2001): ”Human GC–AG alternative intron isoforms with weak
donor sites show enhanced consensus at acceptor exon positions.”; Nucleic Acids
Research; Vol. 29, No. 12; pp. 2581–2593.
Thirumalai D, Lorimer GH (2001): ”Chaperonin–mediated protein folding.”; Annual
Review of Biophysics and Biomolecular Structure.; 30; pp. 245–269.
Tissières A, Mitchell HK, Tracy UM (1974): ”Protein synthesis in salivary glands of
Drosophila melanogaster: Relation to chromosome puffs.”; Journal of Molecular
Biology; 85 (3); pp. 389–398.
111
Tokunaga K, Nakamura Y, Sakata K, Fujimori K, Ohkubo M, Sawada K, Sakiyama
S (1994): ”HUMGAPDH, Human glyceraldehyde–3–phosphate dehydrogenase
(GAPDH) mRNA, complete cds. ”; GenBank Accession Number M33197; National
Institute of Health, USA;   $$$"-0(.6'/"-&ﬁ175-6'8 ;ﬂ2 ; November 1994.
TRANSPLORER (2004): ”Software for promoter and gene finding.”; Version 1.2; Biobase
GmbH Wolfenbüttel Germany (BIOBASE Biological Databases GmbH, Halchter-
sche Strasse 33, D–38304 Wolfenbüttel,  ﬂ$$$".6' .
ﬃ,34ﬀ .
TrEMBL (1998–2004): ”TrEMBL: Computer–annotated supplement to Swiss–Prot.”;
Contains all the translations of EMBL nucleotide sequence entries not yet integrated
in Swiss–Prot.; Swiss Institute of Bioinformatics (SIB); European Bioinformatics In-
stitute (EBI);  ﬃﬂ$$$ﬃ
 	ﬀ .
Valdes–Dapena M (1992): ”A pathologist’s perspective on the sudden infant death syn-
drome.”; Pathology annual; Part I Vol. 27; pp. 133–164.
Van Noort J, Amor S (1998): ”Cell Biology of Autoimmune Diseases.”; International
Review of Cytology; Vol. 178; pp. 127–206.
Vege Å, Rognum TO (1999): ”Inflammatory responses in sudden infant death syndrome
– past and present views.”; FEMS Immunology and Medical Microbiology; Vol. 25;
pp. 67–78.
Venner TJ, Singh B, Gupta RS (1993): ”HUMHSP60A, Human chaperonin (HSP60)
mRNA, complete cds. ”; GenBank Accession Number M34664; National Institute
of Health, USA;  ﬂ$$$5-#(.6'/5-0ﬁ175-6'8 3ﬀ2 ; June 1993.
Venner TJ, Singh B, Gupta RS (1990): ”Nucleotide sequences and novel structural fea-
tures of human and Chinese hamster hsp60 (chaperonin) gene families.”; DNA and
cell biology; 9 (8), pp. 545–552.
Verbeke P, Fonager J, Clark BFC, Rattan SIS (2001): ”Heat Shock Response and Ageing:
Mechanisms and Applications; Cell Biology International; Vol. 25, No. 9; pp. 845–
857.
Vockley J, Whiteman DAH (2002): ”Defects of mitochondrial β–oxidation: a growing
group of disorders.”; Neuromuscular Disorders; 12: pp. 235–246.
Walter, S (2002): ”Structure and function of the GroE chaperone.”; Cellular and Molecu-
lar Life Sciences; 59; pp. 1589–1597.
Wedekind H, Smits JPP, Schulze–Bahr E, Arnold R, Veldkamp MW, Bajanowski T,
Borggrefe M, Brinkmann B, Warnecke I, Funke H, Bhuiyan ZA, Wilde AAM, Bre-
ithardt G, Haverkamp W (2001): ”De novo mutation in the SCN5A gene associated
with early onset of sudden infant death.”; Circulation; 104; pp. 1158–1164.
Weese–Mayer DE, Berry–Kravis EM, Maher BS, Silvestri JM, Curran ME, Marazita ML
(2003): ”Sudden Infant Death Syndrome: Association With a promoter Polymor-
phism of the Serotonin Transporter Gene.”; American Journal of Medical Genetics;
117A: pp. 268–274.
112
Welch WJ (1993a): ”How cells respond to stress.”; Scientific American; May 1993; pp.
34–41.
Welch WJ (1993b): ”Heat shock proteins functioning as molecular chaperones: their role
in normal and stressed cells.”; Philosophical transactions of the Royal Society of
London. Series B, Biological sciences.; 339; pp. 327–333.
Wickner S, Maurizi MR, Gottesman S (1999): ”Posttranslational Quality Control: Fold-
ing, Refolding and Degrading Proteins.”; Science; Vol 286; pp. 1888–1893.
Wilbur WJ, Lipman DJ (1983): ”Rapid similarity searches of nucleic acid and protein
data banks.”; Proceedings of the National Academy of Sciences USA; Vol. 80; pp.
726–730.
Willinger M (1995): ”SIDS prevention.”; Pediatric Annals; Vol. 24(7); pp. 358–364.
Willinger M, James LS, Catz C (1991): ”Defining the sudden infant death syndrome
(SIDS): deliberations of an expert panel convened by the National Institute of Child
Health and Human Development.”; Pediatric Pathology; Vol. 11; pp677–684.
Willison KR, Kubota H (1994): ”The Structure, Function, and Genetics of the Chaperonin
Containing TCP–1 (CCT) in Eukaryotic Cytosol.”; In: ”The Biology of Heat Shock
Protein and Molecular Chaperones.”; ed Morimoto RI, Tissiéres A, Georgopoulos C;
Cold Spring Harbor Laboratory Press; pp. 299–312.
Wu B, Hunt C, Morimoto RI (1985): ”Structure and Expression of the Human Gene En-
coding Major Heat Shock Protein HSP70.”; Molecular and Cellular Biology; Vol. 5,
No. 2; pp. 330–341.
Wu C (1995): ”Heat Shock Transcription Factors: Structure and Regulation.”; Annual
review of cell and developmental biology; 11; pp. 441–469.
Wu C, Clos J, Haroun RI, Kim S–J, Rabindran SK, Westwood JT, Wisniesski J, Yim G
(1994): ”Structure and Regulation of Heat Shock Transcription Factor.”; In: ”The Bi-
ology of Heat Shock Protein and Molecular Chaperones.”; ed Morimoto RI, Tissiéres
A, Georgopoulos C; Cold Spring Harbor Laboratory Press; pp. 395–416.
Wynn RM, Song JL, Chuang DT (2000): ”GroEL/GroES Promote Dissocia-
tion/Reassociation Cycles of a Heterodimeric Intermediate during α2β2 Protein as-
sembly.”; The Journal of Biological Chemistry; Vol. 275; pp. 2786–2794.
XLPCR Kit (1997): ”GeneAmp XLPCR Kit Manual.”; Applied Biosystems/Applera
Deutschland GmbH; December 1997.
Xu Z, Horwich AL, Sigler PB (1997): ”The crystal structure of the asymmetric GroEL–
GroES–(ADP)7 chaperonin complex.”; Nature; Vol. 388; pp. 741–750.
Yon JM (2002): ”Protein folding in the post–genomic era.”; Journal of Cellular and Molec-
ular Medicine; Vol. 6, no. 3; pp. 307–327.
113
Zeilstra–Ryalls J, Fayet O, Georgopoulos C (1991): ”The universally conserved GroE
(Hsp60) Chaperonins.”; Annual Review of Microbiology; 45; 301–325.
Zhang Y, Frejtag W, Dai R, Mivechi NF (2001): ”Heat Shock Factor–4 (HSF–4a) is a Re-
pressor of HSF–1 Mediated Transcription.”; Journal of Cellular Biochemistry; 82;
pp. 692–703.
Zügel U, Kaufmann SHE (1999): ”Role of Heat Shock Proteins in Protection from and
Pathogenesis of Infectious Diseases.”; Clinical Microbiology Reviews; Vol. 12, No.
1; pp. 19–39.
114
A Appendix
A.1 Individual SIDS cases and controls
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Sample Sex Age Sample. Sex Age Sample Sex Age
1 m 135 45 f 74 82 f 117
4 m 43 46 m 30 83 f 28
5 m 78 47 m 90 84 m 95
6 f 58 48 m 56 85 f 98
7 m 66 49 f 49 86 m 97
8 m 179 50 m 54 87 f 115
9 m 32 51 f 47 88 f 89
10 m 39 52 m 72 89 m 41
11 m 57 53 f 13 90 m 180
12 f 68 54 m 70 91 m 101
13 f 151 55 m 62 92 m 43
14 m 134 56 m 84 93 m 193
15 m 183 57 f 185 94 m 72
16 m 131 58 m 148 95 m 35
17 m 263 59 m 36 98 f 96
18 m 78 60 m 45 102 f 81
19 m 169 61 f 56 103 f 143
20 f 137 62 f 61
21 m 100 63 f 146
22 m 92 64 m 162
23 m 77 65 m 29
24 m 270 66 f 95
26 f 335 67 f 258
27 f 241 68 m 155
28 m 185 69 m 54
31 f 151 70 m 216
32 f 320 71 f 162
33 f 84 72 m 78
34 f 103 73 m 62
35 m 77 74 f 21
38 m 197 75 m 134
39 m 150 76 f 138
40 m 107 77 f 314
41 f 137 78 m 39
42 m 59 79 m 114
43 f 167 80 f 341
44 m 308 81 m 68
Sample = Sample Number, Sex: m = male, f = female, Age = age in days
Table A.1: SIDS cases – Age and Sex
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Sample Sex Age Sample Sex Age Sample Sex Age
1 f 350 43 f 247 93 m 276
2 m 301 44 m 241 94 f 271
3 f 291 45 m 293 95 f 360
5 f 346 46 f 243 96 m 248
6 m 243 49 f 263 97 f 267
7 f 245 50 m 262 98 f 309
8 f 266 51 f 323 99 m 247
9 m 359 52 m 248 108 f 247
10 m 288 53 m 314 110 m 267
11 f 305 54 m 252 111 m 247
12 m 297 55 f 349 112 f 321
13 f 251 56 m 347 114 m 188
14 f 270 57 m 263 116 f 349
15 m 250 59 f 292 118 f 246
16 m 318 61 f 300 120 f 296
19 f 241 62 m 260 122 m 316
20 m 247 63 m 305 123 f 290
21 m 353 64 f 254 126 f 264
22 m 361 65 m 273 127 m 249
23 f 263 66 m 283 128 m 254
24 f 250 67 m 253 130 m 253
25 m 347 68 f 329 131 f 264
f6 m 317 69 m 243 138 m 350
27 m 340 70 f 280 139 f 247
28 m 274 71 f 291 140 m 243
29 m 344 72 f 241 141 m 265
31 m 247 73 m 272 145 f 247
32 m 292 75 m 285 147 f 328
33 m 244 76 f 244 149 f 328
34 f 257 77 m 250 156 m 262
36 m 268 80 m 314 200 m 103
37 m 247 85 f 244 201 m 144
38 f 243 87 m 248 204 f 103
39 f 258 89 f 244 205 m 168
40 f 335 90 m 271
41 f 270 91 m 245
42 f 305 92 m 266
Sample = Sample Number, Sex: m = male, f = female, Age = age in days
Table A.2: Controls – Age and Sex
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A.2 Individual SIDS Criteria
Sample Sample number
Sex Sex: 1 = male, 2 = female
Age Age in days
PrBi Preterm birth: 1 = yes, 0 = no, or no information available
DSIP Death Scene Investigation Position: 1 = prone, 2 = supine, 3 = side, 0 = no informa-
tion available
DSIT Death Scene Investigation Temperature: 1 = indication of possible hyperthermia
(high body temperature, fever or sweating), 0 = none, or no information available
NiMo Nicotine Abuse by mother: 1 = yes, 0 = no, or no information available
PetP Petechiae in Pleura: 1 = yes, 0 = no, or no information available
PetE Petechiae in Epicardium: 1 = yes, 0 = no, or no information available
PetT Petechiae in Thymus: 1 = yes, 0 = no, or no information available
RToe Respiratory tract oedemata: 1 = yes, 0 = no, or no information available
RTfo Respiratory tract foam: 1 = yes, 0 = no, or no information available
RThe Respiratory tract hemorrhage: 1 = yes, 0 = no, or no information available
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Sample Sex Age PrBi DSIP DSIT NiMo PetP PetE PetT RToe RTfo RThe
1 1 135 0 1 0 0 1 1 1 0 0 0
4 1 43 0 0 0 0 0 1 0 1 1 1
5 1 78 0 3 0 0 1 0 0 1 1 0
6 2 58 0 2 0 1 0 1 1 1 0 1
7 1 66 1 2 0 1 1 0 0 0 0 0
8 1 179 0 2 0 1 1 1 1 1 0 0
9 1 32 0 1 0 0 1 0 0 1 0 0
10 1 39 1 0 0 0 0 1 1 1 0 1
11 1 57 0 1 0 0 1 1 1 1 0 0
12 2 68 0 0 0 0 0 1 1 0 0 1
13 2 151 0 1 0 0 0 0 0 0 0 1
14 1 134 0 1 0 0 1 1 1 0 0 0
15 1 183 0 1 0 0 1 0 1 0 1 0
16 1 131 1 1 0 0 1 0 1 1 1 0
17 1 263 0 1 0 0 1 1 1 1 1 0
18 1 78 0 0 0 0 1 0 1 0 0 0
19 1 169 0 2 0 0 1 1 1 1 0 0
20 2 137 0 1 0 0 1 0 1 1 0 1
21 1 100 0 1 0 0 1 0 0 1 0 0
22 1 92 0 2 0 0 1 1 0 1 0 1
23 1 77 0 1 0 0 0 0 0 1 1 0
24 1 270 0 1 1 0 0 0 1 1 0 0
26 2 335 0 2 1 0 1 1 1 1 0 1
27 2 241 1 1 1 0 1 1 1 0 0 1
28 1 185 0 0 0 0 1 1 1 0 1 0
31 2 151 0 1 1 1 1 1 1 0 0 0
32 2 320 0 0 0 0 1 1 1 0 0 0
33 2 84 0 1 0 0 1 0 0 1 0 1
34 2 103 0 1 0 0 0 0 0 1 0 1
35 1 77 1 1 0 1 1 1 0 1 1 0
38 1 197 0 3 0 0 1 1 1 1 1 0
39 1 150 0 1 1 0 1 1 1 0 1 0
40 1 107 0 1 0 0 1 1 0 1 1 1
41 2 137 0 0 0 0 0 0 0 1 0 0
42 1 59 0 0 0 0 0 0 1 0 0 1
43 2 167 1 1 1 1 0 1 1 0 0 1
44 1 308 0 1 0 0 0 1 0 0 1 1
45 2 74 0 1 1 0 1 1 1 0 0 1
46 1 30 0 3 0 0 1 1 0 1 1 1
47 1 90 0 2 0 0 1 1 1 1 1 0
48 1 56 0 0 0 0 1 1 0 0 0 1
49 2 49 0 0 0 0 0 0 1 0 0 1
50 1 54 1 1 1 0 0 0 1 1 0 1
51 2 47 0 0 0 0 0 0 0 0 0 0
52 1 72 0 0 0 0 1 0 0 0 0 1
Table A.3: SIDS cases – SIDS criteria, samples 1–52
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Sample Sex Age PrBi DSIP DSIT NiMo PetP PetE PetT RToe RTfo RThe
53 2 13 0 3 0 1 0 0 0 1 0 1
54 1 70 0 1 0 0 1 1 1 1 1 1
55 1 62 0 0 0 0 1 1 1 0 0 1
56 1 84 0 1 0 1 1 1 1 1 1 1
57 2 185 0 1 0 0 1 1 1 0 0 1
58 1 148 0 1 1 0 0 1 1 0 0 0
59 1 36 0 2 0 0 1 1 1 0 0 1
60 1 45 0 0 0 0 0 0 0 0 0 1
61 2 56 0 0 0 0 0 1 1 0 1 0
62 2 61 0 0 0 0 0 0 1 0 1 1
63 2 146 0 1 0 0 1 1 1 0 1 1
64 1 162 1 2 0 0 1 0 1 0 0 1
65 1 29 0 0 0 0 1 1 0 0 1 1
66 2 95 0 1 0 0 1 1 1 0 0 1
67 2 258 0 1 0 0 1 1 1 0 0 1
68 1 155 0 0 0 0 1 1 1 0 1 1
69 1 54 0 0 0 0 1 1 1 0 0 1
70 1 216 0 0 1 0 1 0 0 1 0 1
71 2 162 0 0 0 0 0 0 1 0 0 0
72 1 78 1 1 0 0 1 1 1 1 1 1
73 1 62 0 2 0 0 1 1 1 0 0 1
74 2 21 0 0 0 0 0 0 1 0 0 1
75 1 134 0 0 0 0 0 1 1 0 0 1
76 2 138 1 0 0 0 1 1 1 1 0 1
77 2 314 0 0 0 0 0 1 1 0 0 1
78 1 39 0 1 0 1 0 1 1 0 1 1
79 1 114 0 2 0 0 1 0 1 0 1 1
80 2 341 0 1 0 0 1 1 1 0 0 1
81 1 68 0 0 0 0 1 0 1 0 0 1
82 2 117 0 2 0 0 0 0 0 0 0 1
83 2 28 0 1 0 0 1 0 0 1 0 0
84 1 95 0 2 0 0 1 1 1 0 0 1
85 2 98 0 0 0 0 1 0 1 0 0 1
86 1 97 0 0 0 0 1 0 1 0 0 1
87 2 115 1 1 0 0 1 1 1 1 0 1
88 2 89 1 0 0 0 0 0 0 0 0 1
89 1 41 0 1 0 0 1 1 1 0 1 1
90 1 180 1 1 1 0 1 1 1 1 1 0
91 1 101 0 2 0 0 1 0 0 0 1 1
92 1 43 0 1 0 0 1 1 1 0 1 1
93 1 193 0 1 0 0 1 1 1 0 0 0
94 1 72 0 1 0 0 1 1 1 1 1 0
95 1 35 0 0 0 0 1 1 0 0 1 0
98 2 96 0 1 0 0 1 1 1 0 0 0
102 2 81 0 1 1 1 0 1 1 1 0 1
103 2 143 0 1 0 0 1 1 0 0 0 0
Table A.4: SIDS cases – SIDS criteria, samples 53–103
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A.3 RT–PCR programs for verifying hsp60s mRNA
Possibilities
RT–PCR step Program, Primer Program, Primer
RT1V1A RT1V2A
53Start1v1 53Start1v1
53Stop2v1 53Stop2v2
1.Reverse Transcription 30 min 50◦C 30 min 50◦C
2.Initial PCR Activation 15 min 95◦C 15 min 95◦C
3.Denaturation 1 min 94◦C 1 min 94◦C
4.Annealing 1 min 48◦C 1 min 45◦C
5.Extension 1.45 min 72◦C 1.45 min 72◦C
6.Cycles Goto 3 30 times Goto 3 30 times
7.Final Extension 10 min 72◦C 10 min 72◦C
8.Hold Forever 4◦C Forever 4◦C
Expected Fragment Size 1565 bp (138095–139659) 1593 bp(138095–139687)
RT–PCR step Program, Primer Program, Primer Program, Primer
RT1V3A RT1V3B RT1V3D
53Start1v1 53Start1v1 53Start1v1
3Stop2v3 3Stop2v3 3Stop2v3
1.Reverse Transcription 30 min 50◦C 30 min 56◦C 30 min 50◦C
2.Initial PCR Activation 15 min 95◦C 15 min 95◦C 15 min 95◦C
3.Denaturation 1 min 94◦C 1 min 94◦C 1 min 94◦C
4.Annealing 1 min 52◦C 1 min 52◦C 1 min 56◦C
5.Extension 1.45 min 72◦C 1.45 min 72◦C 1.45 min 72◦C
6.Cycles Goto 3 30 times Goto 3 30 times Goto 3 30 times
7.Final Extension 10 min 72◦C 10 min 72◦C 10 min 72◦C
8.Hold Forever 4◦C Forever 4◦C Forever 4◦C
Expected Fragment Size 1614 bp(138095–139708) 1614 bp(138095–139708) 1614 bp(138095–139708)
Table A.5: RT–PCR Programs for verifying hsp60s mRNA Alternative 1
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RT–PCR step Program, Primer Program, Primer Program, Primer
RT2V1A RT2V2A RT2V3A
3Start1v3 3Start1v3 3Start1v3
53Stop2v1 53Stop2v2 3Stop2v3
1.Reverse Transcription 30 min 50◦C 30 min 50◦C 30 min 50◦C
2.Initial PCR Activation 15 min 95◦C 15 min 95◦C 15 min 95◦C
3.Denaturation 1 min 94◦C 1 min 94◦C 1 min 94◦C
4.Annealing 1 min 48◦C 1 min 45◦C 1 min 52◦C
5.Extension 1.45 min 72◦C 1.45 min 72◦C 1.45 min 72◦C
6.Cycles Goto 3 30 times Goto 3 30 times Goto 3 30 times
7.Final Extension 10 min 72◦C 10 min 72◦C 10 min 72◦C
8.Hold Forever 4◦C Forever 4◦C Forever 4◦C
Expected Fragment Size 1522 bp (138138–139659) 1550 bp (138138–139687) 1571 bp (138138–139708)
RT–PCR step Program, Primer Program, Primer Program, Primer
RT2V4A RT2V5A RT2V6A
5Start1v4 5Start1v4 5Start1v4
53Stop2v1 53Stop2v2 3Stop2v3
1.Reverse Transcription 30 min 50◦C 30 min 50◦C 30 min 50◦C
2.Initial PCR Activation 15 min 95◦C 15 min 95◦C 15 min 95◦C
3.Denaturation 1 min 94◦C 1 min 94◦C 1 min 94◦C
4.Annealing 1 min 48◦C 1 min 45◦C 1 min 52◦C
5.Extension 1.45 min 72◦C 1.45 min 72◦C 1.45 min 72◦C
6.Cycles Goto 3 31 times Goto 3 30 times Goto 3 30 times
7.Final Extension 10 min 72◦C 10 min 72◦C 10 min 72◦C
8.Hold Forever 4◦C Forever 4◦C Forever 4◦C
Expected Fragment Size 1504 bp (138156–139659) 1532 bp (138156–139687) 1553 bp (138156–139708)
RT–PCR step Program, Primer Program, Primer Program, Primer
RT2V7A RT2V8A RT2V9A
53Start1v5 53Start1v5 53Start1v5
53Stop2v1 53Stop2v2 3Stop2v3
1.Reverse Transcription 30 min 50◦C 30 min 50◦C 30 min 50◦C
2.Initial PCR Activation 15 min 95◦C 15 min 95◦C 15 min 95◦C
3.Denaturation 1 min 94◦C 1 min 94◦C 1 min 94◦C
4.Annealing 1 min 48.5◦C 1 min 45◦C 1 min 50◦C
5.Extension 1.30 min 72◦C 1.30 min 72◦C 1.30 min 72◦C
6.Cycles Goto 3 30 times Goto 3 30 times Goto 3 30 times
7.Final Extension 10 min 72◦C 10 min 72◦C 10 min 72◦C
8.Hold Forever 4◦C Forever 4◦C Forever 4◦C
Expected Fragment Size 1370 bp (138318–139659) 1549 bp(138318–139687) 1391 bp (138318–139708)
Table A.6: RT–PCR Programs for verifying hsp60s mRNA Alternative 2
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RT–PCR step Program, Primer Program, Primer Program, Primer
RT3AV1A RT3AV2A RT3AV2B
53Start1v1 53Start1v1 53Start1v1
5Stop1v1 3Stop1v2 3Stop1v2
1.Reverse Transcription 30 min 50◦C 30 min 50◦C 30 min 56◦C
2.Initial PCR Activation 15 min 95◦C 15 min 95◦C 15 min 95◦C
3.Denaturation 1 min 94◦C 1 min 94◦C 1 min 94◦C
4.Annealing 1 min 50◦C 1 min 55◦C 1 min 55◦C
5.Extension 1 min 72◦C 1 min 72◦C 1 min 72◦C
6.Cycles Goto 3 30 times Goto 3 30 times Goto 3 30 times
7.Final Extension 10 min 72◦C 10 min 72◦C 10 min 72◦C
8.Hold Forever 4◦C Forever 4◦C Forever 4◦C
Expected Fragment Size 599 bp (138095–138693) 618 bp (138095–138712) 618 bp (138095–138712)
RT–PCR step Program, Primer Program, Primer
RT3AV2D RT3AV3A
53Start1v1 53Start1v1
3Stop1v2 5Stop1v3
1.Reverse Transcription 30 min 50◦C 30 min 50◦C
2.Initial PCR Activation 15 min 95◦C 15 min 95◦C
3.Denaturation 1 min 94◦C 1 min 94◦C
4.Annealing 1 min 60◦C 1 min 46◦C
5.Extension 1 min 72◦C 1 min 72◦C
6.Cycles Goto 3 30 times Goto 3 30 times
7.Final Extension 10 min 72◦C 10 min 72◦C
8.Hold Forever 4◦C Forever 4◦C
Expected Fragment Size 618 bp (138095–138712) 684 bp (138095–138678)
RT–PCR step Program, Primer Program, Primer Program, Primer
RT3BV1A RT3BV2A RT3BV3A
3Start2v1 3Start2v1 3Start2v1
53Stop2v1 53Stop2v2 3Stop2v3
1.Reverse Transcription 30 min 50◦C 30 min 50◦C 30 min 50◦C
2.Initial PCR Activation 15 min 95◦C 15 min 95◦C 15 min 95◦C
3.Denaturation 1 min 94◦C 1 min 94◦C 1 min 94◦C
4.Annealing 1 min 48◦C 1 min 45◦C 1 min 52◦C
5.Extension 1 min 72◦C 1 min 72◦C 1 min 72◦C
6.Cycles Goto 3 30 times Goto 3 30 times Goto 3 30 times
7.Final Extension 10 min 72◦C 10 min 72◦C 10 min 72◦C
8.Hold Forever 4◦C Forever 4◦C Forever 4◦C
Expected Fragment Size 575 bp (139085–139659) 603 bp (139085–139687) 624 bp (139085–139708)
Table A.7: RT–PCR Programs for verifying hsp60s mRNA Alternatives 3a and 3b
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RT–PCR step Program, Primer Program, Primer Program, Primer
RT3BV4A RT3BV5A RT3BV6A
53Start2v2 53Start2v2 53Start2v2
53Stop2v1 53Stop2v2 3Stop2v3
1.Reverse Transcription 30 min 50◦C 30 min 50◦C 30 min 50◦C
2.Initial PCR Activation 15 min 95◦C 15 min 95◦C 15 min 95◦C
3.Denaturation 1 min 94◦C 1 min 94◦C 1 min 94◦C
4.Annealing 1 min 48◦C 1 min 45◦C 1 min 52◦C
5.Extension 1 min 72◦C 1 min 72◦C 1 min 72◦C
6.Cycles Goto 3 30 times Goto 3 30 times Goto 3 30 times
7.Final Extension 10 min 72◦C 10 min 72◦C 10 min 72◦C
8.Hold Forever 4◦C Forever 4◦C Forever 4◦C
Expected Fragment Size 556 bp (139104–139659) 584 bp (139104–139687) 605 bp (139104–139708)
RT–PCR step Program, Primer Program, Primer Program, Primer
RT3BV7A RT3BV8A RT3BV9A
3Start2v3 3Start2v3 3Start2v3
53Stop2v1 53Stop2v2 3Stop2v3
1.Reverse Transcription 30 min 50◦C 30 min 50◦C 30 min 50◦C
2.Initial PCR Activation 15 min 95◦C 15 min 95◦C 15 min 95◦C
3.Denaturation 1 min 94◦C 1 min 94◦C 1 min 94◦C
hline 4.Annealing 1 min 48◦C 1 min 45◦C 1 min 52◦C
hline 5.Extension 1 min 72◦C 1 min 72◦C 1 min 72◦C
6.Cycles Goto 3 30 times Goto 3 30 times Goto 3 30 times
7.Final Extension 10 min 72◦C 10 min 72◦C 10 min 72◦C
8.Hold Forever 4◦C Forever 4◦C Forever 4◦C
Expected Fragment Size 464 bp (139196–139659) 492 bp (139196–139687) 513 bp (139196–139708)
RT–PCR step Program, Primer Program, Primer Program, Primer
RT3BV10A RT3BV11A RT3BV12A
5Start2v4 5Start2v4 5Start2v4
53Stop2v1 53Stop2v2 3Stop2v3
1.Reverse Transcription 30 min 50◦C 30 min 50◦C 30 min 50◦C
2.Initial PCR Activation 15 min 95◦C 15 min 95◦C 15 min 95◦C
3.Denaturation 1 min 94◦C 1 min 94◦C 1 min 94◦C
4.Annealing 1 min 48◦C 1 min 45◦C 1 min 48◦C
5.Extension 1 min 72◦C 1 min 72◦C 1 min 72◦C
6.Cycles Goto 3 30 times Goto 3 30 times Goto 3 30 times
7.Final Extension 10 min 72◦C 10 min 72◦C 10 min 72◦C
8.Hold Forever 4◦C Forever 4◦C Forever 4◦C
Expected Fragment Size 444 bp (139216–139659) 472 bp (139216–139687) 493 bp (139216–139708)
Table A.8: RT–PCR Programs for verifying hsp60s mRNA Alternative 3b
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RT–PCR step Program, Primer Program, Primer Program, Primer
RT4AV1A RT4AV2A RT4AV3A
3Start1v3 3Start1v3 3Start1v3
5Stop1v1 3Stop1v2 5Stop1v3
1.Reverse Transcription 30 min 50◦C 30 min 50◦C 30 min 50◦C
2.Initial PCR Activation 15 min 95◦C 15 min 95◦C 15 min 95◦C
3.Denaturation 1 min 94◦C 1 min 94◦C 1 min 94◦C
hline 4.Annealing 1 min 50◦C 1 min 55◦C 1 min 46◦C
hline 5.Extension 1 min 72◦C 1 min 72◦C 1 min 72◦C
6.Cycles Goto 3 30 times Goto 3 30 times Goto 3 31 times
7.Final Extension 10 min 72◦C 10 min 72◦C 10 min 72◦C
8.Hold Forever 4◦C Forever 4◦C Forever 4◦C
Expected Fragment Size 556 bp (138138–138693) 575 bp (138138–138712) 641 bp (138138–138778)
RT–PCR step Program, Primer Program, Primer Program, Primer
RT4AV4A RT4AV5A RT4AV6A
5Start1v4 5Start1v4 5Start1v4
5Stop1v1 3Stop1v2 5Stop1v3
1.Reverse Transcription 30 min 50◦C 30 min 50◦C 30 min 50◦C
2.Initial PCR Activation 15 min 95◦C 15 min 95◦C 15 min 95◦C
3.Denaturation 1 min 94◦C 1 min 94◦C 1 min 94◦C
4.Annealing 1 min 50◦C 1 min 53◦C 1 min 46◦C
5.Extension 1 min 72◦C 1 min 72◦C 1 min 72◦C
6.Cycles Goto 3 30 times Goto 3 31 times Goto 3 31 times
7.Final Extension 10 min 72◦C 10 min 72◦C 10 min 72◦C
8.Hold Forever 4◦C Forever 4◦C Forever 4◦C
Expected Fragment Size 538 bp (138156–138693) 557 bp (138156–138712) 623 bp (138156–138678)
RT–PCR step Program, Primer Program, Primer Program, Primer
RT4AV7A RT4AV8 RT4AV9A
53Start1v5 53Start1v5 53Start1v5
5Stop1v1 3Stop1v2 5Stop1v3
1.Reverse Transcription 30 min 50◦C 30 min 50◦C 30 min 50◦C
2.Initial PCR Activation 15 min 95◦C 15 min 95◦C 15 min 95◦C
3.Denaturation 1 min 94◦C 1 min 94◦C 1 min 94◦C
4.Annealing 1 min 49.5◦C 1 min 50◦C 1 min 46◦C
5.Extension 1 min 72◦C 1 min 72◦C 1 min 72◦C
6.Cycles Goto 3 31 times Goto 3 31 times Goto 3 31 times
7.Final Extension 10 min 72◦C 10 min 72◦C 10 min 72◦C
8.Hold Forever 4◦C Forever 4◦C Forever 4◦C
Expected Fragment Size 376 bp (138318–138693) 395 bp (138318–138712) 623 bp (138318–138678)
Table A.9: RT–PCR Programs for verifying hsp60s mRNA Alternative 4a
125
Persönliche Daten
Anja Teske
geboren am 31.05.1970
in Kiel
verheiratet
Lebenslauf
2005 Gebietsrepräsentantin Baden–Württemberg für den Bereich
Molekularbiologie/Verkauf Großgeräte bei der Firma
Applied Biosystems/Applera Deutschland GmbH.
2003–2004 Annotation der TRANSFAC Database (Transkriptionsfaktoren–
Datenbank) bei der Firma Biobase,
Biological Databases GmbH Wolfenbüttel.
1999–2004 Wissenschaftliche Mitarbeiterin am Institut für
Rechtsmedizin der Medizinischen Hochschule Hannover;
Dissertation: ”Variations in the Human hsp60 Gene between
Cases of Sudden Infant Death Syndrome and non–affected Children”.
1999 Analyse von Tierknochenfunden des Grundstücks Weberstr. 10
für die Bezirksregierung Braunschweig, Dezernat 406.
1998–1999 Auslandssemester an der University of California at Berkeley, USA.
1998 Analyse von Knochenfunden der arch"aologischen Ausgrabung
„Burg Wolfstein“ in Neumarkt/Oberpfalz.
1997–1998 Diplomarbeit im Lehrgebiet Anthropologie, Institut für Zoologie.
„Anthropologische Bearbeitung des slawischen, mittelalterlichen Gräberfeldes
Tulln, Ländgasse“.
1989–1998 Studium der Biologie an der Gesamthochschule Kassel
und Technischen Universität Braunschweig mit Abschluß Sehr Gut.
1989 Zeugnis der allgemeinen Hochschulreife.
1986–1989 Besuch der Albert–Schweitzer–Schule (Gymnasium) in Kassel.
1980–1986 Besuch des Wolfgang–Ernst–Gymnasiums in Büdingen/Wetterau.
1976–1980 Besuch der Grundschule in Bergheim/Erft.
126
Personal Data
Anja Teske
Born 31.05.1970
in Kiel
married
Curriculum Vitae
2005 Sales Representative Molecular Biology/Instruments
in Baden–Württemberg at
Applied Biosystems/Applera Deutschland GmbH.
2003–2004 Annotation of the TRANSFAC Database (Transcription factor database)
at the Biobase Biological Databases Company Wolfenbüttel.
1999–2004 Graduate student at the Institute of
Legal Medicine at the Medical School Hannover;
doctoral thesis: ”Variations in the Human hsp60 Gene
between Cases of Sudden Infant Death Syndrome and non–affected Children”.
1999 Freelance Work:
Analysis of animal skeletal remains of the archaeological excavation
Weberstr. 10 for the Department of City Archaeology, Braunschweig.
1998–1999 Semester abroad at the University of California at Berkeley, USA.
1997–1998 Field Work: Analysis of skeletal remains at the archaeological excavation
”Burg Wolfstein” in Neumarkt/Oberpfalz.
1997–1998 Diploma thesis at the Department of Anthropology, Institute for Zoology,
Technical University (TU) Braunschweig: ”Anthropological Analysis
of the Medieval, Slavonian Burial Ground of Tulln, Ländgasse (Austria)”.
1989–1998 Undergraduate studies of Biology at the University of Kassel
and the Technical University of Braunschweig.
1989 Final secondary-school examinations (University-entrance degree).
1986–1989 Secondary School Albert–Schweitzer–Schule (Gymnasium) in Kassel.
1980–1986 Secondary School Wolfgang–Ernst–Gymnasiums in Büdingen/Wetterau.
1976–1980 Elementary School in Bergheim/Erft.
127
